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Abstract 
Burkholderia cenocepacia is an opportunistic pathogen causing life-threatening 
infections in cystic fibrosis and other immunocompromised patients.  The 
bacterium survives within macrophages by interfering with typical endocytic 
trafficking, resulting in delayed maturation of a B. cenocepacia-containing 
phagosome.  We hypothesize that B. cenocepacia alters gene expression after 
internalization by macrophages, inducing genes involved in intracellular survival 
and host adaptation.  Furthermore, we hypothesize that specialized bacterial 
secretion systems are involved in the interactions between intracellular bacteria 
and macrophages.  In this work, we characterize later-stage infection of 
macrophages by B. cenocepacia, showing replication within an acidified 
endosomal compartment suggestive of a phagolysosome.  We examine 
differential gene expression by intracellular B. cenocepacia using selective 
capture of transcribed sequences (SCOTS) with both competitive enrichment and 
microarray analysis.  We identified 766 genes differentially regulated in 
intracellular bacteria, of which 329 were induced and 437 repressed.  Affected 
genes are involved in all aspects of cellular life, including information storage and 
processing, cellular processes and signalling, and metabolism; in general, 
intracellular gene expression demonstrates a pattern of environmental sensing, 
bacterial response, and metabolic adaptation to the phagosomal environment.  
Deletion of various SCOTS-identified genes affects B. cenocepacia entry into 
macrophages and intracellular replication, as well as host-directed cytotoxicity 
and spread to neighbouring cells.  Expression of secretion system genes is 
 iii
  
differentially-regulated by intracellular B. cenocepacia.  Although none of the five 
major secretion systems are essential for growth in culture, we show that 
bacterial secretion systems are involved in macrophage entry, intracellular 
replication, and host-directed cytotoxicity.  Type IV secretion systems play a role 
in early interactions with macrophages, while type II and VI secretion systems 
contribute to post-internalization intracellular replication and host-directed 
cytotoxicity.  As a whole, secretion systems appear to increase pathogenicity in 
macrophages while limiting the spread of B. cenocepacia infection. 
Together, these studies advance our understanding of the intracellular behaviour 
of B. cenocepacia in macrophages.  Further investigation into the remaining 
SCOTS-identified genes, as well as putative secreted effectors, will provide a 
better understanding of the adaptive responses of intracellular B. cenocepacia, 
leading to life in a phagosomal niche and host cell cytotoxicity. 
 
Keywords 
Burkholderia cenocepacia, macrophage, intracellular gene expression, 
microarray, SCOTS, secretion systems 
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Chapter 1 – Introduction 
 
1.1 Burkholderia cenocepacia and the Burkholderia cepacia 
complex 
 
1.1.1 The Burkholderia cepacia complex 
The Burkholderia cepacia complex, or Bcc, is a group of at least 17 closely 
related organisms which are phenotypically similar but genetically distinct (493, 
495).  Originally identified in the 1940’s as the causative agent of soft onion rot, 
or “sour skin”, discoverer Walter Burkholder designated the organism 
Pseudomonas cepacia, from the Latin cepia for onion (63).  Later studies showed 
P. multivorans, a metabolically diverse environmental isolate, and P. kingii, 
isolated from both clinical specimens and disinfectants, to be synonymous strains 
(442).  In 1992, the genus Burkholderia was created, and seven Pseudomonas 
spp., including P. cepacia were transferred into the new genus (529).  Two of the 
original seven species were later reclassified as Ralstonia spp. (530), and over 
sixty new species have since been described in the Burkholderia genus 
(http://www.bacterio.cict.fr).  Marked heterogeneity among species designated as 
B. cepacia led to division into genomovars, genetically distinct organisms 
awaiting official species designation based on phenotypic distinction (493).  
Eventually, as the sensitivity and specificity of tests improved, each genomovar 
received a binomial species designation.  Biochemical differentiation among 
members of the Bcc is difficult, thus genetic techniques are most often used for 
species determination (287).  Sequence polymorphisms in the recA gene, 
encoding a protein essential for DNA recombination and repair, are discriminatory 
for most species (288), but members of the Bcc are best distinguished based on 
multilocus sequence typing (MLST).  This strategy utilizes sequence 
polymorphisms in seven housekeeping genes located on the first two 
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chromosomes (atpD, gltB, gyrB, recA, lepA, phaC, and trpB); amplification of 
300-400 base pair (bp) fragments of each gene creates an allelic profile which 
can be used to assign a clonal sequence type (ST) (31).  Currently, the complex 
consists of B. cepacia, B. multivorans, B. cenocepacia, B. stabilis, B. 
vietnamiensis, B. dolosa, B. ambifaria, B. anthina, B. pyrrocinia, B. ubonensis, B. 
latens, B. diffusa, B. arboris, B. seminalis, B. metallica, B. contaminans, and B. 
lata (495).  Isolates of all 17 species have been found in a clinical setting, with all 
but B. ubonensis isolated from cystic fibrosis patients; additionally, with the 
exception of B. latens and B. metallica, all species have also been isolated from 
the natural environment (505).  Pre-classification literature from 1950 through 
mid-1990 refers to only P. cepacia or B. cepacia; current re-analysis has 
demonstrated that Burkholder’s original onion pathogens were true B. cepacia 
species, P. kingii clinical isolates were B. cenocepacia, and P. multivorans 
environmental isolates were mainly B. lata and B. cepacia (491).  Due to the 
complexity of taxonomic classification within the B. cepacia complex, many 
studies, particularly environmental surveys, in which Bcc bacteria are a 
serendipitous identification choose to identify the bacteria only as B. cepacia-like.  
Thus, current species designations will be utilized where possible, but when 
referring to literature where members of the Bcc were not distinguished, 
designations “P. cepacia”, or “B. cepacia” will be used. 
 
1.1.2 Burkholderia cenocepacia 
Burkholderia cenocepacia, literally meaning “new cepacia”, is an aerobic, Gram 
negative, non-spore-forming, motile, bacillus-shaped, β-proteobacterium (178, 
492).  The bacterium ranges in size from 1.0 to 2.0 µm long and from 0.6 to 0.9 
µm wide, and grows at 37oC and room temperature but not at 5oC; growth at 
42oC is strain-dependent (492).  B. cenocepacia is metabolically diverse; many 
functions are strain-specific (492), as are the production of pigment (231, 492), 
and lipopolysaccharide O antigen (356).  The species B. cenocepacia may be 
further subdivided into four phylogenetic clusters based on recA gene sequence, 
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IIIA to IIID, with most clinically relevant isolates represented in the first two 
groups (134).  B. cenocepacia is an opportunistic pathogen of cystic fibrosis (CF) 
patients (380) - the type strain for the species, LMG 16656, or J2315, was 
isolated from the sputum of a cystic fibrosis patient in Edinburgh in 1989 (492) - 
but B. cenocepacia infections are also found in non-CF patients (380).  The 
bacterium is also frequently isolated from environmental reservoirs; in some 
instances, the same strain can be found in both clinical and environmental niches 
(30). 
 
1.1.3 B. cenocepacia in the environment 
B. cenocepacia and other members of the Bcc have been isolated from many 
different environmental sources, ranging from urban (327), woodland (495), and 
agricultural (268) soils, to European rivers (503), Chinese lakes (146), and the 
sediments of American streams (353), to Mexican radishes (30), Indian sugar 
cane (496), Brazilian flowers (495), and raw milk (346).  B. cenocepacia engages 
in both pathogenic and beneficial interactions with plants, and can act as an 
endosymbiont for both fungi and insects.  Though non-Bcc Burkholderia spp. are 
able to cause serious disease in higher mammals - most notably equine glanders 
resulting from B. mallei infection – there is only a single example of natural Bcc 
infection in animals, where B. cenocepacia caused an outbreak of subclinical 
mastitis in sheep (49).   
 
1.1.3.1 Phytopathogens 
“B. cepacia” was first discovered as a phytopathogen in onion crops (63).  
Though recent classification of Burkholder’s original strains has identified true B. 
cepacia species, B. cenocepacia has also been isolated directly from the lesions 
of field-grown onion bulbs which naturally developed bacterial rot (452).   In a 
field study in Michigan, B. cenocepacia was isolated from both the bulk soil and 
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the onion rhizosphere, with presence in the rhizosphere increasing with onion 
root development; 90% of the 480 B. cenocepacia isolates were highly virulent 
when assayed for pathogenicity on detached onion bulb scales (213).   
In a natural setting, bacteria present in the surrounding soil and rhizosphere can 
be transferred to plant leaves and bulbs by splashing water from irrigation or rain 
(213).  Pathogenicity in onion tissue requires an existent tissue wound for 
bacterial ingress, and moisture for effective spreading (228).  Plant damage 
occurs by two separate mechanisms.  Plant tissue watersoaking (ptw) is an 
accumulation of fluids in the intracellular spaces of plant tissues caused by a loss 
of cell membrane integrity (141); accumulation of fluids contributes to the spread 
of the bacteria through the tissues.  Early studies in “P. cepacia” showed 
production of a pectic enzyme called polygalacturonase (486).  
Polygalacturonase is a secreted enzyme that hydrolyzes pectin, one of the 
principal macromolecular components in primary plant cell walls (313, 314).  
Bacterial infection lowered the pH of onion tissue from 5.5 to 4.0, conducive to 
polygalacturonase activity, and resulted in tissue maceration (486).  “B. cepacia” 
has also been shown to cause disease in tomatoes, mushrooms, and orchids 
(399); B. cenocepacia, specifically, is the causal agent of banana finger-tip rot 
(262). 
 
1.1.3.2 Beneficial interactions with plants 
Although B. cenocepacia is pathogenic in several types of plant, many bacteria-
plant interactions exist which are neutral or mutually beneficial.  Early research in 
“B. cepacia” showed antagonism and repression of soil-borne plant pathogens, 
including the fungi Alternaria which affects canola and ginseng (200), 
Aphanomyces in peas, alfalfa, and snap beans (57), Sclerotinia in sunflowers 
(323), and Pythium in cucumbers and peas (57, 200).  “B. cepacia” can also 
suppress damaging fungal growth in nursery seedlings (200).  Field studies 
showed presence of “P. cepacia” in the rhizosphere – soil on root surfaces – of 
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maize; through production of pyrrolnitrin and a second unidentified antifungal 
agent, “P. cepacia” was antagonistic to five major fungal pathogens of maize 
(249).  Paradoxically, endosymbiotic bacteria and fungi within the rhizosphere are 
able to promote plant resistance to stress and disease; “B. cepacia” is an 
endosymbiont of several species of the fungus Glomus, which establishes an 
endophytic relationship with sorghum (20).  Plant-associated Bcc bacteria also 
promote growth by the fixation of N2.  B. vietnamiensis, shown to promote growth 
of sugar cane, is the only currently identified diazotroph in the complex (179), 
though an unclassified member of the Bcc is able to induce nitrogen-fixing root 
nodules in the wild rose wood tree legume Dalbergia spp. (375). 
B. cenocepacia has been identified in the rhizosphere of onions (213) and maize 
(113).  From the rhizosphere, bacteria may enter the root tissue and establish an 
endophytic relationship with a plant.  B. cenocepacia has been isolated from the 
stem and roots of sugar cane (324), as well as wheat and lupine shoots (29).  In 
sugarcane, endophytic B. cenocepacia produces the plant growth hormone IAA, 
and strongly inhibits hyphal growth of Fusarium moniliforme, causative agent of 
Pokkah boeng disease (324).   
 
1.1.3.3 Endosymbiosis with insects 
Unidentified Burkholderia spp. have been found as endosymbiotic gut bacteria in 
plant-associated insects, including Japanese broad-headed bugs Leptocorisa 
chinensis and Riptortus clavatus (235), and the ant Tetraponera binghami (488); 
no purpose for this relationship has been experimentally established.  B. 
cenocepacia participates in a tri-symbiotic relationship with the leaf-cutting ant 
Atta sexdens rubropilosa and the fungus Leucoagaricus gongylophorus (96).  
Leaf-cutting ants maintain a fungus garden, protecting and providing leaf 
substrates to the obligate mutualistic fungus, which in turn supplies the ant with 
nutrients (416).  Bcc bacteria isolated from ant nests inhibit several species of 
entomopathogenic and general saprophytic fungi, as well as the specialized 
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garden parasite Escovopsis weberi, but not the mutualist L. gongylophorus (416); 
thus, in such a complex relationship, Bcc bacteria maintain the integrity of the 
fungus garden while protecting the ant from fungal infection.   
 
1.1.3.4 Bioremediation 
Bcc bacteria possess extraordinary metabolic diversity, to the extent that the 
bacteria can survive in simple tap water (279) and can utilize antibiotics such as 
penicillin as a sole carbon source (41).  As a consequence of this metabolic 
diversity, Bcc bacteria have shown promise in bioremedial applications.  2,4,5-
trichlorophenoxyacetic acid (2,4,5-T) is a herbicide to defoliate broad-leaf plants 
which is persistent in the environment, poorly biodegradable, and a major 
component of Agent Orange; 2,4,5-T can be broken down by “P. cepacia”  (74).  
Insecticide and anti-parasitic abamectin, an environmental pollutant affecting 
non-target soil vertebrates and aquatic systems, can be used as a carbon source 
by “B. cepacia” (12).  Bcc bacteria are also able to degrade the fungicide 
carbendazim (223), insect repellent and plasticizer dimethyl phthalate (511), 
solvent trichloroethylene (158), and pesticide endosulfan (208), among others.  
Endophytic and rhizospheric strains of Bcc bacteria have shown degradation of 
phenol (510).  In a biofilm with cyanobacteria, Bcc bacteria were able to degrade 
diesel in hydrocarbon-rich industrial wastewater (75); indeed, a strain of B. 
cenocepacia isolated from oil-contaminated soil produces a biosurfactant that 
enhances the solubilization of multiple pesticides (514).   
 
1.1.3.5 Commercial potential 
Bcc bacteria have the ability to degrade serious environmental pollutants, 
antagonize soil-borne pathogens, and promote plant growth, and as such, could 
be of great benefit to agriculture and industry.  As a biocontrol agent, Bcc 
bacteria have the potential to replace, at least in part, such common chemical 
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biocides as captan, thiram, benomyl, and chloropicrin, all of which have toxicity or 
carcinogenic issues (360).  Several strains of B. ambifaria and a strain of B. 
cenocepacia were registered as biopesticides in the mid-1990s and used 
commercially until withdrawn from use a decade later (79).  Field trials with B. 
vietnamiensis efficiently removed trichloroethylene, one of the most abundant 
organic aquifer contaminants, from groundwater (244), and a US patent was 
obtained (79).  Industrial applications continue to be explored, with development 
of a Bcc-containing microalgae-bacteria consortium to degrade crude oil (474), 
and a bioreactor utilizing Bcc to remove petroleum hydrocarbons from refinery 
wastewater (75).  An engineered endophytic strain of B. cepacia was used to 
improve lupine phytoremediation of soil co-contaminated with the organic 
pollutant trichloroethylene and toxic nickel (520).  However, commercial 
applications must be weighed against capacity for opportunistic infection, as 
identical strains have been isolated from both clinical and environmental sources 
(30); until Bcc infections can be successfully addressed, the biotechnological 
potential present among members of the complex cannot ethically be developed. 
 
1.1.4 B. cenocepacia as an industrial contaminant 
Outside the natural environmental, Bcc bacteria are also able to survive in a wide 
variety of man-made products.  “P. cepacia” contamination was found in serum 
albumin (461), the anaesthetic fentanyl (53, 439), and commercial iodine and 
benzalkonium chloride antiseptics (18, 161); in one study, “P. cepacia” survived 
for 14 years in an inorganic salt solution containing benzalkonium chloride as an 
antimicrobial (173).   “B. cepacia” contamination of oxymetazoline nasal spray 
resulted in an infection outbreak in the United States and recall of the product 
(132).  Bcc bacterial contamination has also been identified in prefabricated moist 
washcloths (310), ultrasound echocardiographic gel (304), multiple catheter 
disinfectants (183, 190), the antiemetic bromopride (312), trypan blue ophthalmic 
solution (470), heparin (531), alcohol-free mouthwash (245), Albuterol 
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nebulization solution (34), and moisturizing body milk (14), among others.  
Product contamination can be compounded, as “B. cepacia” contamination of 
trypan blue, a dye used to examine tissues, led to contamination of a cornea 
tissue bank, though no post-graft infection was reported for any of the 169 
contaminated grafts (331).   
In an 8 year study of 327 US Food and Drug Administration (FDA) non-sterile and 
sterile product recalls, “B. cepacia” was the most frequently isolated microbe in 
22% and 2.5% of the recalls, respectively (216).  Among Bcc bacteria, B. 
cenocepacia is one of the most common industrial contaminants (287).  However, 
Bcc contamination may arise from other sources, including water.  An outbreak in 
a haemodialysis unit in Brazil was linked to “B. cepacia” contamination of reverse 
osmosis tubing in the water reservoir (454).  Hospital tap water has also been 
linked to multiple infection outbreaks (279, 391).  Bcc-contaminated water is not 
unique to a hospital environment, as “B. cepacia” is also the primary contaminant 
of the Space Shuttle water system both pre- and post-flight (237).  The presence 
of B. cenocepacia within a hospital setting may contribute to opportunistic 
infection.  While recall of contaminated products is fairly straightforward, 
eradication of B. cenocepacia from an infected hospital unit water source is more 
complex (243).   
 
1.1.5 B. cenocepacia as an opportunistic human pathogen 
The first clinical isolate of “P. cepacia” was found in urine in 1951; over the next 
14 years, isolates were identified in a vast number of clinical sources, including 
blood, eye, stool, throat, myocardial abscess, spinal fluid, sputum, knee joint, and 
many others  (220).  Contaminated medical products led to frequent nosocomial 
infection outbreaks, including endocarditis, respiratory infection, and septicemia 
(39, 325, 420, 459).  Infections were seen in patients with conditions including 
cancer, congenital heart disease, fistulae, quadriplegia, diabetes, and surgically-
repaired major trauma (138).  Today, Bcc bacteria are generally considered 
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opportunistic pathogens, or bacteria which do not typically cause disease in a 
healthy host, but exploit a niche created in the absence of a functional immune 
system.  Bcc infection is most commonly seen in individuals with cystic fibrosis, 
although infections are also seen in immunocompromised patients, including 
those with chronic granulomatous disease, and, more rarely, in 
immunocompetent individuals (described in detail below).  With the exception of 
contaminated medical products and direct patient-to-patient transmission, the 
source of an infection is not always clear.  Unlike P. aeruginosa, which is carried 
by approximately 10% of the population, B. cenocepacia is not typically 
recovered from human sources other than sites of infection, and is thus likely 
acquired from the environment (287). 
 
1.1.5.1 Cystic fibrosis 
Cystic fibrosis is one of the most common genetic diseases in Caucasians, 
affecting approximately 1 in 3000 live births (301).  The disease is caused by 
mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene 
encoding a cyclic adenosine 5'- monophosphate (cAMP) regulated chloride 
channel (77, 384).  Although the disease affects many organs, the most important 
site for morbidity and mortality is the lungs.  In the lungs, CFTR defect results in 
thick mucus secretions which impair mucociliary clearance (81, 316), as well as 
an accumulation of salt in the airway surface liquid covering the epithelia, 
interfering with the bactericidal activity of defensins and lysozyme (175, 301).  
Bacteria like P. aeruginosa, the eventual predominant pathogen in CF patients, 
easily and sequentially colonize the CF lung causing chronic infection leading to 
bronchiectasis, respiratory failure, and death (116).   
 “P. cepacia” was recognized as an important pathogen in CF patients in 1984; 
throughout a ten year study, though the prevalence of P. aeruginosa remained 
stable at 70-80%, carriage of “P. cepacia” increased from 10% to 18%, with the 
latter infections associated with greater impairment in lung function  (212).  
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Currently, approximately 3.5% of CF patients are infected with Bcc by age 18 
(171), though regions of significantly higher prevalence exist (342); such patients 
exhibit a more rapid decline in lung function compared to those infected with 
other CF-related pathogens (100), with mean survival decreasing by between 12 
and 25 years following Bcc infection (79, 455).  Though many Bcc-infected 
individuals show asymptomatic carriage or chronic lung infection, one in five 
develop a condition known as ‘cepacia syndrome’, a generally fatal condition 
characterized by high fever, severe progressive respiratory failure, acute 
necrotizing pneumonia, and septicaemia (212).  Resistance to almost all clinically 
relevant antibiotics (264) complicates treatment and creates great difficulties in 
eradicating infection.  Though nosocomial acquisition is possible, patient-to-
patient transmission has been demonstrated (177, 457), resulting in segregation 
of the CF community and discouragement of CF social opportunities such as 
summer camps; such isolation negatively affects psychological well-being (137).   
Although nearly all species of the Bcc have been identified in the sputum of CF 
patients, B. cenocepacia and B. multivorans are the most prevalent species, 
accounting for 85-97% of all Bcc-CF infections (380, 495, 496).  However, B. 
cenocepacia infection has far more severe clinical consequences than B. 
multivorans.  B. cenocepacia is highly transmissible, containing the majority of 
epidemic strains identified thus far (134); indeed, two distinct sequence types of 
B. cenocepacia have shown intercontinental spread among CF patients (134, 
218).  B. cenocepacia is also associated with more severe infection, reduced 
survival, and increased risk of developing cepacia syndrome (102, 219, 292, 
457), and can replace other Bcc species in the CF lung (293).  Though lung 
transplantation is the only viable treatment for end-stage CF patients, infection 
with B. cenocepacia is a relative or absolute contraindication to transplantation in 
almost every centre outside of Toronto, where the prevalence of infection is over 
15% (22, 342).  Patients infected pre-operation with B. cenocepacia have 
significantly increased morbidity and mortality post-transplant, while those 
infected with other Bcc species fare no differently than P. aeruginosa-infected CF 
patients (22, 120).  B. cenocepacia post-transplant death is generally due to 
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development of sepsis, or cepacia syndrome (120); there are only five reported 
cases in the literature of survival in septic patients with cepacia syndrome, all 
after extremely aggressive antibiotic therapy (342).   
Aggressive CF management has increased the life expectancy of CF patients to 
mid-forties, revealing CF-related non-pulmonary conditions, including 
osteoporosis, diabetes, and liver disease (87, 137).  Chronic colonization with 
Bcc, but not with P. aeruginosa, is associated with risk of developing CF liver 
disease, which itself is associated with requirement for lung transplantation, and 
death (87).   
 
1.1.5.2 Chronic granulomatous disease 
Chronic granulomatous disease (CGD) is a much less common genetic disease, 
conferring immunodeficiency in approximately one in 250 000 individuals with 
presentation varying from fatal septicaemia in infancy to mild symptoms late in 
life (489).  CGD is genetically heterogeneous, caused by mutation to any of the 
five structural elements of the nicotinamide dinucleotide phosphate (NADPH) 
oxidase complex:  membrane-bound cytochrome components gp91phox and 
p22phox, and cytoplasmic components p47phox , p40phox and p67phox  (433).  Defect 
to the NADPH oxidase leaves phagocytes unable to generate an oxidative burst, 
causing susceptibility to recurrent infection; CGD patients also suffer from a 
dysregulated Th-17-lymphocyte-controlled inflammatory response resulting in 
granuloma formation, and poor wound healing and dehiscence (387, 431).  In a 
normally functioning oxidative burst, the NADPH oxidase generates superoxide 
anion, which is metabolized by superoxide dismutase to hydrogen peroxide, 
which is further metabolized by myeloperoxidase to hypohalous acid and 
hydroxyl anion; such reactive oxygen species (ROS) can function directly as 
antimicrobials (371).  Activation of the NADPH oxidase is also necessary for the 
activation of microbicidal granule proteases and formation of neutrophil 
extracellular traps (NETs) (433).  In the absence of a fully functional immune 
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response, CGD patients suffer from recurrent infections, most commonly with 
Nocardia and Aspergillus spp., Staphylococcus aureus, Serratia marcescens, 
and Bcc (433, 489, 523).  Large cohort studies in Europe and North America 
have shown Aspergillus spp. to be the most common infectious agents and cause 
of death in CGD patients; however, the latter is a function of the former, as 
Aspergillus-mediated death occurs in only 8% (15/181) and 19% (23/120) of 
European and North American infections, respectively (489, 523).  Less common, 
but far more serious, Bcc infections caused death in at least 43% (3/7) and 50% 
(12/24) of European and North American Bcc-infected CGD patients (489, 523).   
Serious “P. cepacia” infection in CGD patients has frequently been linked with 
pneumonia, septicaemia and death in smaller studies (9, 56, 247, 456).  It has 
been shown that CGD neutrophils, which can kill P. aeruginosa effectively, are 
unable to kill “P. cepacia” (456).  B. cenocepacia is able to promote apoptosis in 
both normal and CGD human neutrophils; however, engulfed B. cenocepacia is 
also able to induce necrosis in CGD neutrophils lacking ROS (67).  Among Bcc 
species, B. cenocepacia is most virulent in a gp91phox -/- murine model of CGD, 
causing septic death 3 days post-infection (p.i.) (453).  In a p47phox -/- murine 
model of CGD, restoration of p47phox through ex vivo gene transfer lowered “B. 
cepacia” bacteremia levels and conferred a survival advantage to the mouse 
(302), again linking the NADPH oxidase and Bcc infection.  Interestingly, B. 
cenocepacia is also able to delay assembly of the NADPH oxidase complex in 
murine macrophages (230).   
 
1.1.5.3 Nosocomial infection 
Hospitalized patients are susceptible to nosocomial “B. cepacia” infection, 
especially in light of contaminated medical products.  Nosocomial infections most 
commonly arise in the intensive care unit (ICU), and can result in pneumonia, 
bacteremia, surgical site infection, urinary tract infection, and skin-soft tissue 
infection (131).  Typically, non-CF-related “B. cepacia” bacteremia occurs in 
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severely ill patients who require frequent health care interventions and invasive 
procedures, and thus have multiple exposures to antibiotic resistant nosocomial 
pathogens; specific risk factors include greater than two bronchoscopic 
procedures, tracheostomy, abdominal surgery, dialysis-requiring renal failure, 
and the presence of an indwelling vascular catheter (60).  B. cenocepacia 
bacteremia has been seen in oncology patients (300, 311), haemodialysis 
patients (222, 271), and intensive care neonates (260), generally related to 
central venous catheter use.  In patients who have undergone mitral valve 
replacement, “B. cepacia” infections lead to endocarditis, or inflammation of the 
inside lining of the heart chambers or valves; such infections can be fatal (8).  “P. 
cepacia”-induced endocarditis has also been seen in heroin addicts both with and 
without histories of heart disease (345); in rare cases, these infections can 
exacerbate into skin and soft tissue involvement via ecthyma gangrenosum 
(299).  “B. cepacia” has also caused postoperative bacterial endophthalmitis and 
keratitis leading to poor visual outcome (354, 398, 470).  Bcc bacteria can also be 
transmitted between CF and non-CF patients, as seen in a large hospital 
outbreak where a single strain of “B. cepacia” infected 23 CF patients and 245 
non-CF ICU patients; non-CF patients that survived the infection generally 
cleared the bacteria following discharge from the ICU, while CF patients 
remained persistently infected (201). 
 
1.1.5.4 Immunocompetent individuals 
Bcc infections in immunocompetent patients are rare.  Community-acquired “P. 
cepacia” pneumonia and bacteremia have been reported on several occasions in 
previously-healthy adults (42, 111, 512), and children (368, 524).  Hospital-
acquired bacteremia has also been seen in immunocompetent children (174, 
524).  An individual with chronic suppurative otitis media developed intracranial 
infection and brain abscesses requiring multiple surgeries and resulting in loss of 
inner ear function in one ear (194).  Less serious infection has presented in 
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individuals with sinonasal polyposis (59, 305), while “B. cepacia” infection in an 
immunocompetent individual resulted in infective endocarditis with subsequent 
cerebral involvement (234).  “P. cepacia” was also found to cause ‘trench foot’, or 
macerated hyperkeratotic lesions of the feet, in soldiers working in swamp 
conditions (475).  A single case showed evidence of Bcc transmission from an 
infected CF child to a healthy, non-CF mother, resulting in chronic colonization 
and acquired bronchiectasis (257). 
 
1.1.6 Model systems to study B. cenocepacia pathogenesis 
Various in vivo and in vitro systems have been developed to study B. 
cenocepacia pathogenesis.  Though traditional murine models arguably provide 
the most relevant context for investigation relative to human disease, researchers 
have sought simpler, swifter, more economical models better suited to genetic 
manipulation (347).  Several different models have since been developed, 
including plants, animals, and in vitro cell culture, which fit some or all of the 
criteria, allowing investigation into virulence factors, host response, and treatment 
options. 
 
1.1.6.1 Murine models 
CF patients infected with Bcc have three potential clinical presentations, including 
asymptomatic carriage, chronic infection with slow lung function decline, and 
acute infection leading to bacteremia and death.  The latter two situations may be 
investigated by means of murine models.  A chronic, nonlethal, pulmonary 
infection in rats established for CF pathogen P. aeruginosa (72) can also be 
applied to Bcc (446, 450).  In this model, chronic infection is initiated by 
intratracheal insertion of agar beads containing the bacteria of interest; at 7 and 
28 days p.i., the lungs are removed for bacterial enumeration and 
histopathological analysis (446).  Lung inflammation in the model approximates 
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that seen in non-bacteremic pneumonia with mixed inflammatory cell infiltrate and 
foci of necrosis (72).  An agar bead model of Bcc lung infection has also been 
utilized to examine systemic infection in C57/BL6 mice (91, 458).  A second 
murine model of acute infection approximating bacteremia involves aerosol 
inoculation of neutropenic mice (106, 446).  On days 0, 3, and 7 p.i., the mice are 
sacrificed and bacterial load in the lungs enumerated; though the bacteria are 
generally cleared, factors involved in colonization and short-term infection can be 
explored (446).  Disease-specific murine models have been used with Bcc, 
including a cystic fibrosis Cftr-/- murine model of chronic pneumonia (407), and 
two murine models of chronic granulomatous disease:  gp91phox -/- (453), and 
p47phox -/- (302).  Aside from investigating pathogen virulence factors and host 
response, murine models are also useful in the development of B. cenocepacia 
vaccines (50, 294).    
 
1.1.6.2 Other animal models 
Simpler, less expensive animal models applied to Bcc infection include the 
zebrafish Danio rerio (502), the nematode Caenorhabditis elegans (241), the fruit 
fly Drosophila melanogaster (73), and larvae of the wax moth Galleria mellonella, 
or wax worms (429).  For each of the models, members of the Bcc, as well as 
strains of the same species, often have different outcomes; however, the results 
do not always agree between models (485). 
C. elegans is a simple, genetically-tractable model in which bacterial virulence in 
worms often parallels clinical data; C. elegans lacks adaptive immunity, but 
mounts an innate immune response to bacterial pathogens (347).  B. 
cenocepacia is able to effectively kill C. elegans via two separate killing modes, 
termed slow killing and fast killing (241).  In fast killing, B. cenocepacia grown on 
a high-osmolarity medium produces an extracellular toxin which paralyzes, then 
kills the nematodes within 24 h (241).  When B. cenocepacia is grown on 
nematode growth medium, slow killing of C. elegans occurs over 2-3 days as the 
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bacteria accumulate in the intestinal lumen; the more pathogenic the bacteria, the 
more rapid the killing (241).  To facilitate large scale analyses, a rapid screening 
method called the 48-well plate mortality assay was developed which correlates 
well with the standard slow killing assay (69).  Additionally, lumenal infection can 
be visualized microscopically (241). 
The innate immune system of D. melanogaster is similar to the mammalian 
version (152), and the genome has been fully sequenced (6), enabling a 
dissection of host-pathogen interactions.  Infection can be induced naturally by 
feeding, or artificially by nicking; ingested Bcc colonize the fly without injury, while 
nicked flies are killed by internally-replicating Bcc, at strain-specific rates, with 
results comparable to those seen in murine models  (73).   
Virulence assays with B. cenocepacia have used zebrafish at different stages of 
the life cycle.  Mortality assays and quantitation of bacterial survival have utilized 
6-month-old zebrafish following intraperitoneal inoculation of bacteria (122).  
However, at the embryonic stage (28-32 h post-fertilization), zebrafish have a 
developed innate immune system resembling the mammalian equivalent, but are 
transparent, allowing infection to be visualized in real-time (502).  Infection is 
more complicated than the previous models, requiring dechorionation – removal 
of the membrane surrounding the developing embryo – and anaesthetization of 
the embryo prior to microinjection of bacteria into blood circulation (502).  B. 
cenocepacia are taken up by macrophages, replicate intracellularly, then 
disseminate throughout the embryo, leading to systemic infection and embryo 
death; however, virulence is species and strain dependent (502).  While the 
ability to visualize infection in real-time is of great interest, D. rerio is temperature 
sensitive, a limitation common to D. melanogaster and C. elegans; none survive 
long at optimal temperatures for bacterial growth (73, 502).   
G. mellonella possesses a fairly complex innate immune system (429), but differs 
from the three previous models in two key ways:  Although it survives at 30oC – 
amenable to bacterial growth – it lacks genetic tractability thus far (73).  Similar to 
D. melanogaster and C. elegans, the model can be predictive of mammalian 
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response to pathogens;  Bcc infection in G. mellonella corresponds well with 
results in murine models (429).  The model itself is exceedingly simple, scoring 
larvae as alive or dead up to 72 h post-Bcc injection; dead larvae turn black as a 
result of melanization (429). 
 
1.1.6.3 Plant models 
Research with P. aeruginosa has demonstrated a conservation of virulence 
factors in the infection of plant and animal hosts (374), meaning preliminary work 
can be done in a simple, inexpensive model with no ethical considerations.  
Because “B. cepacia” was first identified as a phytopathogen in onions, Allium 
cepa remains a useful model for investigation of pathogenicity; tissue maceration, 
water soaking, and necrosis are quantified in wounded onion scales inoculated 
with Bcc (213).  Alfalfa, or Medicago sativa, was the first non-murine model 
proposed for Bcc.  Seedling leaves are wounded and inoculated with Bcc, then 
maintained at 37oC under normal light/dark conditions; 7 days p.i., disease 
symptoms – yellow leaves, stunted roots, and brown necrotic regions – are 
assessed (48).  Common plant model Arabidopsis thaliana has been little applied 
to Bcc work, though Bcc lipopolysaccharide (LPS) activates the innate immune 
response of the plant (286), and Bcc-produced volatiles promote its growth (504).  
 
1.1.6.4 In vitro cell culture models 
Although Bcc are predominantly extracellular bacteria, they have been isolated 
from intracellular environments in infected patients and in vivo models (80).  “B. 
cepacia” has been isolated from the tracheal epithelial cells of a septicaemic CF 
patient (80).  B. cenocepacia has also been found in the respiratory epithelium, 
alveolar septae, inflammatory cell infiltrates, and luminal and parenchymal 
macrophages of CF patients (406).  “B. cepacia” invades respiratory epithelial 
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cells and macrophages in a murine model of infection (80), while B. cenocepacia 
is preferentially taken up by macrophages in a zebrafish embryo model (502).   
Numerous cells and cell lines have been used to investigate interactions between 
Bcc and host cells (412).  In vitro, B. cenocepacia has been shown to survive 
within free-living amoebae (253, 308), phagocytes (252), and epithelial cells 
(409).  In Acanthamoeba polyphaga, B. cenocepacia survives without replication 
in an acidic vacuole distinct from the lysosomal compartment (253).  The 
interactions between B. cenocepacia, and macrophages and epithelial cells have 
been much more closely studied.   
It is not known whether B. cenocepacia is able to actively invade macrophages or 
whether the bacteria are taken up by phagocytosis, though internalization at a 
higher rate than P. aeruginosa or S. aureus has been demonstrated (321).  Once 
internalized, B. cenocepacia is able to delay phagosomal maturation (252) and 
assembly of the NADPH oxidase complex (230), and induce interleukin (IL)-1β 
production (242); each of these phenotypes requires viable bacteria, and is 
exacerbated in the absence of a functional CFTR (230, 242, 254).  B. 
cenocepacia is able to inactivate the Rab7 GTPase, a marker found on the 
cytosolic face of the phagosome which is important for phagolysosomal fusion 
(210).  B. cenocepacia is also able to alter the actin cytoskeleton of the 
macrophage in a process requiring a functional Type VI secretion system (T6SS) 
(25, 390).  Despite the delay in phagosomal maturation, the bacteria-containing 
vacuole (BCV) has been shown to fuse with lysosomes and become acidified by 
6h p.i.  (252), and replication of intracellular bacteria by 24h p.i. has been 
demonstrated (185), suggesting B. cenocepacia may be able to replicate within 
an acidic environment.   
B. cenocepacia invasion of pulmonary epithelial cells is mediated by binding to 
glycosphingolipid receptors (335), and involves bacterial lipase (336), and host 
microfilaments and microtubules, but not CFTR (477).  In CF-derived epithelial 
cells, F-actin polymerization into stress fibres is seen upon bacterial uptake into 
the endocytic pathway; live bacteria escape the classical endocytic pathway to 
 
 19
non-acidified autophagosomes and eventual replication in the endoplasmic 
reticulum (ER) (409).  Infection of epithelial cells with B. cenocepacia upregulates 
expression of matrix metalloprotease-9, which inhibits wound repair (525), and 
proinflammatory cytokine IL-8, which enhances growth of intracellular bacteria 
(229).  B. cenocepacia is able to access lung capillaries to initiate septicaemia by 
traversing the respiratory epithelium via disruption of tight junctions (236) or 
induction of epithelial cell death (107). 
The sputum of Bcc-infected CF patients has less viable granulocytes, and a 
higher proportion of secondary necrotic granulocytes, typically seen when 
phagocytic clearance of apoptotic cells is ineffective (513).  In cell culture models, 
B. cenocepacia interacts with neutrophils, promoting apoptosis post-
internalization (67).  B. cenocepacia is also able to interfere with normal 
maturation and induce necrosis in dendritic cells (285).   
 
1.1.7 Genetics of B. cenocepacia 
B. cenocepacia is a remarkably adaptable bacterium exhibiting nutritional 
versatility and inhabiting a wide variety of niches ranging from the CF lung to 
agricultural soil; the same sequence type has been isolated from clinical, 
industrial & natural sources (287).  It is thought that the adaptability of Bcc 
bacteria is due to both larger than average coding potential arranged in a 
multireplicon structure, and the presence of many insertion sequences yielding 
genomic plasticity & adaptability (265).   
 
1.1.7.1 Genetic organization 
The genome of the type strain of B. cenocepacia, J2315, encodes 7261 putative 
coding sequences (CDS) in 8 Mbp of genetic material with an average G+C 
content of 66.9% (195).  The genome is divided into three circular chromosomes 
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and a plasmid, with sizes of approximately 3.9 Mbp, 3.2 Mbp, 0.9 Mbp, and 92 
kbp, respectively; genes are designated with a replicon-specific prefix – BCAL, 
BCAM, BCAS, or pBCA – and a number.  The genome contains a perfect gene 
duplication of 57 putative CDSs on chromosome 1, as well as 79 insertion 
sequences, and 126 partial or pseudogenes; fourteen putative genomic islands – 
likely a result of horizontal gene transfer – account for 9.3% of chromosomal DNA 
and may contain mobile genetic elements including bacteriophage and 
transposons (195).   
 
1.1.7.2 Genetic manipulation 
B. cenocepacia is not readily tractable genetically, and until recently, genetic 
manipulation was greatly hindered by few tools and limited selection markers, 
mainly trimethoprim and tetracycline; while the latter has not changed, 
development of the homing endonuclease pGPI-SceI system enables sequential, 
non-polar, unmarked gene deletions in B. cenocepacia (156).  The system uses 
two separate plasmids, suicide plasmid pGPI-SceI, and replicative but unstable 
plasmid pDAI-SceI, each sequentially transferred via tri-parental mating.  Two 
small – 200 bp is sufficient – regions of homology flanking the sequence to be 
deleted are cloned into mutagenesis plasmid pGPI-SceI, which contains a unique 
I-SceI recognition site in the plasmid backbone.  Because B. cenocepacia does 
not produce Pir, required for maintenance of pGP plasmids with a Pir-dependent 
oriR6K (154), the mutagenesis plasmid is incorporated into the genome by 
homologous recombination, producing an intermediate mutant.  Introduction of 
the second plasmid, pDAI-SceI, constitutively expressing the I-SceI nuclease, 
creates a double strand break in the integrated plasmid backbone, which must be 
repaired for survival of the bacterium.  Recombination within the first region of 
homology restores the wild-type chromosome, but recombination within the 
second region of homology results in a deletion of all chromosomal DNA between 
the two regions of homology (156).  Deletion mutants are confirmed by 
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polymerase chain reaction (PCR) with primers external to the deletion, and/or 
Southern blot hybridization.  The plasmid expressing the I-SceI nuclease also 
contains a sacB site, allowing it to be cured by growth on sucrose (185).  
Because the resultant deletion is unmarked, application of the pGPI-SceI strategy 
allows continued re-use of the same two antibiotic selection markers to create 
sequential deletions in the same strain. 
 
1.1.7.3 Strain differences 
B. cenocepacia as a species designation takes in four different recA lineages, IIIA 
to D; thus far, all IIIC are environmental, while there are no environmental strains 
of IIID and few for IIIA, suggesting possible niche-specific adaptations (287).  
Though most CF epidemic strains in the United States, including PHDC – so 
designated based on the two American cities in which the strain was first isolated 
from CF patients (92) – and Midwest, belong to the IIIB group, Canada and 
Europe are dominated by IIIA strains; sequenced strain J2315 belongs to a 
recIIIA lineage known as Edinburgh Toronto (ET )-12, or ST-28 (134).  There are 
significant genetic differences between lineages, as comparison of the IIIA J2315 
sequence with IIIB lineage PHDC strains AU1054 and HI2424 showed regions of 
difference encompassing 21% of the total genome, including lack of all fourteen 
genomic islands in PHDC (195).  There are also genetic differences within the 
same lineage:  ST-28 and ST-32 are closely related IIIA strains with 
intercontinental distribution, but differing pathogenicity; the less-virulent ST-32 
undergoes extensive genomic rearrangement and transposition events when 
exposed to ROS, while the genome of the more-virulent ST-28 appears stable 
under the same conditions (134).   
The work described in this thesis uses B. cenocepacia K56-2, or ST-30, isolated 
from the lungs of a Canadian CF patient.  K56-2 belongs to the ET-12 lineage, 
and is assigned to the same clonal complex as J2315 (290).  Because K56-2 has 
yet to be sequenced, the published sequence of J2315 was applied to K56-2 for 
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the purposes of this work.  However, there are differences between K56-2 and 
J2315 both genetically (195), and phenotypically, including LPS structure (356), 
ability to infect macrophages (411), and virulence in G. mellonella (429), D. 
melanogaster (73), C. elegans (69), and D. rerio (502).  Because K56-2 has 
lower resistance to useful antimicrobial selection agents than does J2315, the 
former is more amenable to genetic manipulation, and was thus the strain of 
choice for this work.   
Recently, MH1K, an aminoglycoside-sensitive strain of K56-2, was developed; 
though sensitive to concentrations of gentamicin as low as 10 µg/mL, MH1K 
behaves as wild-type when internalized by murine macrophages (185).  This 
strain is a very useful tool for in vitro studies of B. cenocepacia.  Prior to MH1K, 
classical studies of the interaction between bacteria and eukaryotic cells were 
hampered by the extreme resistance of B. cenocepacia to antibiotics, requiring 
researchers to use high concentrations of gentamicin and ceftazidime to kill 
extracellular bacteria; the presence of such high levels of aminoglycosides had 
the potential to affect intracellular bacteria, as well as the eukaryotic cells.  With 
the use of MH1K, extracellular bacteria can now be killed, facilitating more 
accurate and longer-term investigation of the internalization and intracellular 
behaviour of B. cenocepacia.   
 
1.1.8 Virulence factors in B. cenocepacia 
B. cenocepacia possesses a wide range of virulence factors putatively involved in 
the ability of the bacterium to cause disease [reviewed in (278)].  Previous work 
employed a signature-tagged transposon mutagenesis (STM) to identify 84 
unique genes essential for in vivo survival in a rat model of chronic lung infection; 
these genes were spread across all four genetic elements of B. cenocepacia and 
included metabolic, regulatory, transport, cell surface-associated, and information 
processing genes, as well as conserved genes of unknown function (207).  
Transposon mutation screens have also been done in a C. elegans model, 
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identifying several genes involved in virulence (451).  Recently, the metabolic 
network was modelled for J2315, demonstrating biosynthesis pathways for 
virulence factors including lipopolysaccharide, quorum sensing molecules, and 
putatively, rhamnolipids (145).  Comparative transcriptomics has also been 
applied to the identification of virulence factors; global expression studies have 
examined the response of clinical and environmental isolates of B. cenocepacia, 
to synthetic CF sputum (133, 535, 536), although only four genes are common to 
all three studies.  Many putative virulence factors have been specifically targeted 
for investigation through a mutation-based approach; other studies have utilized 
these mutants to test the contribution of putative virulence factors in multiple 
models of infection.   
 
1.1.8.1 Genomic islands 
B. cenocepacia IIIA strain J2315 contains fourteen genomic islands, comprising 
9.3% of the total genome, which are not found in sequenced IIIB strains; because 
most IIIA strains are clinical isolates, it is possible that the genomic islands 
contain genes promoting adaptation to the CF lung (195).  Many of the islands 
are prophages, or are of phage or plasmid origin, while others contain metabolic 
genes; genomic island 11, formerly referred to as the B. cenocepacia island (cci), 
encodes 43 CDS involved in a wide variety of functions, including quorum 
sensing, stress response, antibiotic and arsenic resistance, and ion and amino 
acid transport (195).  The cci also includes the “B. cepacia epidemic strain 
marker” (BCESM), unique to strains capable of epidemic spread among CF 
patients (291); genes within the cci are linked with persistence and virulence in a 
murine model of chronic lung infection (32). 
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1.1.8.2 Antimicrobial resistance 
Pan-resistant B. cenocepacia strains – that is, resistant to most, if not all, 
clinically useful antibiotics – are common; where treatment is possible, it often 
requires the concurrent use of multiple antibiotics (1).  Isolates from CF patients 
suffering from pulmonary exacerbation are generally more resistant to antibiotics 
than those isolated from stable, chronically-infected patients (460).  Antibiotic 
resistance in B. cenocepacia is undoubtedly multifactorial, as the bacteria 
possess mechanisms for alteration of cell wall permeability, alteration of drug 
targets, enzymatic inactivation, and active efflux (134).  Transcriptomic studies 
have suggested a role for efflux pumps in antimicrobial resistance (417), which 
has been borne out in the increased antibiotic susceptibility of deletion mutants 
(40, 64, 185).  Surface structure lipopolysaccharide also plays a role in resistance 
to antimicrobial peptides (277).  Genomic analysis has also demonstrated the 
presence of beta-lactamases, fosmidomycin resistance protein, and trimethoprim 
resistance factor dihydrofolate reductase, among others (195). 
 
1.1.8.3 Quorum sensing 
Quorum sensing (QS) is a form of interbacterial communication that regulates 
gene expression relative to cell density; a signalling molecule – typically N-acyl-
homoserine-lactone (AHL) – is produced by a synthase and detected by a 
transcriptional regulator (167).  B. cenocepacia is able to synthesize at least three 
different types of signalling molecules, including putative intergenus signal 2-
heptyl-4(1H)-quinolone (HHQ), which can be processed into a QS signal by P. 
aeruginosa (129).  Epidemic strains of B. cenocepacia carry two copies of the 
AHL-mediated quorum sensing system:  The first, with AHL-synthase CepI and 
regulator CepR, is common to all B. cenocepacia strains and produces primarily 
N-octanoyl-L-homoserine lactone (C8-HSL) (266); the second, designated CciIR, 
is located within the cci and synthesizes mainly N-hexanoyl-L-homoserine 
lactone (C6-HSL) (32, 297).  Though both systems function as global regulators 
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of quorum sensing gene expression, the two participate in reciprocal regulation of 
many genes, including motility- and iron transport-associated genes, synthesis of 
exoenzymes, and the nematocidal protein AidA (349).  Accordingly, mutation of 
cepI reduces virulence in C. elegans, but mutation to cciI has no effect (485).  
CepIR QS-deficient mutants were less virulent in both the rat agar bead model of 
chronic lung infection, and intranasal infections in wild-type and Cftr-/- mice (449); 
CciIR mutants were also attenuated for virulence in the rat model (32).  A third 
CepR homolog exists in B. cenocepacia which lacks an associated AHL 
synthase; CepR2 participates in QS regulation, but can function in the absence of 
AHL signals (298). 
A third quorum sensing system in B. cenocepacia uses cis-2-dodecenoic acid 
(BDSF), a non-homoserine lactone diffusible signal factor detected by a histidine 
kinase encoded by BCAM0227; mutation of the sensor decreases virulence in 
both G. mellonella larvae and the mouse agar-bead model of chronic lung 
infection (318).  Mutation of a gene involved in the synthesis of BDSF results in 
decreased virulence in a D. rerio model of infection (122). 
 
1.1.8.4 Iron acquisition 
Though an essential nutrient, free iron is limited in a host environment, and must 
thus be scavenged by the infecting pathogen.  B. cenocepacia produces iron-
chelating siderophores salicylic acid (SA), ornibactin, and pyochelin (446, 506).  
In a survey of “P. cepacia” isolates from CF patients, pyochelin-producing strains 
were associated with more severe pulmonary disease and death, while 
pyochelin-negative strains were associated with more mild infections (444).  
Though the pyochelin biosynthesis genes in J2315 contain a frameshift mutation, 
the transport and utilization genes are intact (195); in a rat model of chronic lung 
infection, exogenously supplied pyochelin increased the virulence of pyochelin-
negative “B. cepacia” strains (450), though pyochelin alone is insufficient for iron 
acquisition in vivo (506).  SA, originally referred to as azurechelin, is also 
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produced by clinical isolates of “P. cepacia”; similar to pyochelin, SA is able to 
promote growth of “B. cepacia” under iron-limiting conditions, and compete with 
transferrin for iron in vitro (444, 447). Though SA and ornibactin are the 
predominant siderophores produced by clinical isolates of “B. cepacia” (114), SA 
does not appear to be able to compete with host iron binding proteins and 
promote iron acquisition in vivo (445), but may instead play a role in inducing 
antibiotic resistance (339).  Ornibactin contributes to colonization, bacterial 
persistence, and lung pathology in murine models of acute and chronic lung 
infection (446); ornibactin-deficient mutants also display decreased virulence in 
C. elegans, and are avirulent in G. mellonella (485).  B. cenocepacia is also able 
to utilize some xenosiderophores, including ferrichrome and ferrioxamine B (478). 
Iron sequestration in the lung typically involves molecules of transferrin, 
lactoferrin, and ferritin (484).  Compared to a normal lung, the CF lung contains 
elevated levels of ferritin, which are elevated further in the presence of an 
inflammatory response (379, 465).  B. cenocepacia is able to acquire iron from 
ferritin in a serine-protease-dependent manner (521), and also capable of utilizing 
oxidized haem as an iron source (478, 521). 
 
1.1.8.5 Secretion systems 
Many pathogens interfere with eukaryotic host cell processes by employing large, 
specialized secretion systems to translocate effector molecules into the host 
(168).  In particular, types III, IV, and VI secretion systems – all of which are 
present in B. cenocepacia – have been implicated in interactions between 
prokaryotic and eukaryotic cells. The pathogenic potential of the type III secretion 
system (T3SS) of B. cenocepacia has been examined in several models:  
Previous studies have shown that a mutant bearing a polar insertion in the T3SS 
gene cluster delays phagosomal maturation similar to wild type (252), but an 
insertionally-activated T3SS mutant was cleared more rapidly from the lungs of 
infected mice (480), and displayed reduced virulence in C. elegans (306, 485).  
 
 27
B. cenocepacia encodes two type IV secretion systems (T4SS), the first a 
chimera of VirB/D4 and F-specific subunits on the plasmid (T4SS-1), and the 
second a VirB/D4 homolog on chromosome two (T4SS-2) (86, 195).  B. 
cenocepacia T4SS-1 has been previously examined for in vivo relevance; 
insertional inactivation of a putative T4SS coupling protein affected intracellular 
persistence in macrophages (403).  T4SS-1 is also required to induce plant tissue 
water soaking (141).  The only known role for T4SS-2 is in plasmid mobilization 
(539). Mutations in the type VI secretion system (T6SS) of B. cenocepacia render 
the bacteria deficient in survival in a murine model of chronic lung infection (207) 
and susceptible to predation by the amoeba Dictyostelium discoideum (25).  An 
active T6SS mediates actin rearrangement in B. cenocepacia-infected 
macrophages (25).   
B. cenocepacia also encodes a type II secretion system (T2SS) (195), generally 
responsible for movement of toxins, proteases, cellulases and lipases across the 
bacterial membrane [reviewed in (217)].  A type II secretion pseudopilin was 
found to be involved in the pathogenesis of B. cenocepacia in C. elegans (451).  
Finally, B. cenocepacia possesses four type V secretion systems (T5SS); all four 
autotransporters appear to be involved in adhesion, two containing pertactin 
domains and two containing hemagglutinin repeat domains (195). 
 
1.1.8.6 Exoenzymes 
B. cenocepacia produces various exoenzymes which may be involved in host-
pathogen interactions.  Early studies of “P. cepacia” clinical isolates revealed 
production of lipase, protease, lecithinase, phospholipase C, and, in a small 
proportion of isolates, hemolysin (340, 497).  More recent genomic studies have 
shown that the B. cenocepacia J2315 genome encodes five phospholipase C 
homologs with putative functional specificity, and a phosphatidylinositol-specific 
phospholipase C, which, in gram-positive pathogens, is involved in virulence; 
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J2315 also encodes pectin degradation enzymes, involved in the breakdown of 
plant tissue (195).   
Functional studies with B. cenocepacia have revealed a wide variety of 
exoenzymes.  B. cenocepacia J2315 produces a haemolytic protein with strong 
biosurfactant properties that is able to induce apoptosis and degranulation in 
phagocytic cells; the toxin is capable of inhibiting S. aureus and, at high 
concentrations, P. aeruginosa, but does not inhibit B. cenocepacia (209).  B. 
cenocepacia also secretes a homologue of the redox enzyme azurin which is 
capable of inducing caspase-dependent apoptosis in macrophages (370), and a 
purple alkaline phosphatase highly active against phosphorylated proteins, and, 
to a lesser extent, phosphoenolpyruvate and ATP (533).  The invasion of 
epithelial cells by B. cenocepacia involves a secreted lipase that does not affect 
the eukaryotic plasma membrane or tight junction integrity (336).  The best 
studied exoenzymes of B. cenocepacia are the QS-regulated ZmpA and ZmpB 
zinc metalloproteases (99, 240).  Both enzymes can degrade casein, gelatin, 
tissue components type IV collagen and human fibronectin, protease inhibitors 
2-microglobulin and -1 proteinase inhibitor, and a variety of antimicrobial 
peptides, though the manner of cleavage is generally enzyme-specific (238-240, 
322); ZmpA also cleaves gamma interferon (238), and ZmpB degrades 
lactoferrin, transferrin, and immunoglobulins IgA, IgG, and IgM (240).  Though 
both enzymes contribute to lung pathology in a murine model of chronic lung 
infection (99, 240), ZmpA also contributes to persistence in the lung (99) and, 
when instilled in a purified form, induces bronchopneumonia in rats (322). 
 
1.1.8.7 Cell surface structures 
Structures present on the bacterial cell envelope are frequently involved in the 
interactions between the bacterium and host cells, modulating adherence, 
invasion, and cytotoxicity, as well as bacterial motility.  Alterations to the cell 
surface can affect persistence in murine models of infection (89).  B. cenocepacia 
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possesses polar flagella, which have been implicated in pathogenesis.  Non-
motile flagellar mutants are deficient in invasion of, but not in adherence to, 
respiratory epithelial cells, a phenotype dependent on flagellar-mediated motility 
(481).  Flagellar mutants are also non-lethal in a murine model of chronic lung 
infection, and do not stimulate a strong immune response, whereas wild type B. 
cenocepacia elicits a strong immune response, partially by initiating a signalling 
cascade through the interaction of bacterial flagellin with Toll-like receptor (TLR) 
5 (487).  There has been speculation that the flagella are important in 
establishment of an infection, while adaptation to chronic lung infection involves a 
loss of motility (417), as is seen for P. aeruginosa isolates from chronically-
infected CF patients (289).   
One of the two hallmarks of the highly transmissible ET-12 lineage of B. 
cenocepacia is the presence of the cblA gene encoding the major subunit of 
surface cable (Cbl) pili (469).  A 22-kDa Cbl pilin-associated adhesin mediates 
bacterial binding to cytokeratin 13 (CK13) and mucin, both of which are abundant 
in the CF airway epithelia (404, 408); binding of B. cenocepacia to CK13 
promotes bacterial invasion into epithelial cells and cell damage (405).  Cbl pili 
are cytotoxic, able to activate caspases and induce apoptosis in epithelial cells 
(78).  J2315 also encodes components of a type IVa pilus, and two clusters of 
Flp-type pili (195).   
Other proteins are also involved in mediating bacterial adherence to host cells.  A 
trimeric autotransporter adhesin is involved in in vitro adherence to extracellular 
matrix proteins and virulence against G. mellonella larvae (326).  Genomic 
studies have shown that J2315 encodes eight BuHA family proteins, 
autotransporting membrane proteins with homology to hemagglutinin and invasin 
proteins (195). 
In contrast, bacterial adherence to epithelial cells is inhibited by the presence of 
O-antigen, the outermost portion of lipopolysaccharide (LPS) (411).  LPS, which 
forms the major surface component of gram negative bacteria, is a complex 
glycolipid composed of lipid A, a core oligosaccharide, and, in some strains, O-
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antigen (373).  Unlike other bacteria, B. cenocepacia constitutively incorporates 
4-amino-4-deoxy-L-arabinose (Ara4N) residues into the lipid A and core 
oligosaccharide, resulting in a reduction in the net negative charge of the LPS 
molecule (358).  Lipid A anchors the LPS molecule in the membrane, maintaining 
membrane integrity while serving as an endotoxin (373).  B. cenocepacia LPS 
induces cytokine production by human monocytes in a TLR4- and CD-14-
dependent manner (35, 119); the immune response to “B. cepacia” LPS is over 
nine-fold greater than that elicited by P. aeruginosa LPS (434).  The O-antigen 
also prevents phagocytosis by macrophages (411) and serum-mediated killing 
(356).  Mutations to the O-antigen synthesis cluster result in attenuated survival 
in a rat model of chronic lung infection (207), as do mutant strains unable to 
synthesize the complete LPS core oligosaccharide (277).  The latter also show 
impaired virulence in C. elegans and G. mellonella models, fail to traffic properly 
in murine macrophages, and are more sensitive to antimicrobial peptides (357, 
485).   
The production of exopolysaccharide (EPS), leading to a mucoid phenotype, has 
been noted in some strains of B. cenocepacia; typically, EPS production appears 
more common in environmental isolates and strains belonging to the recA IIIB 
lineage (541).  In clinical isolates, there is speculation that EPS masks bacterial 
surface ligands, reducing the virulence of mucoid isolates and increasing 
bacterial persistence in the murine lung (97); however, EPS-deficient mutants 
show reduced virulence in a CGD mouse model of infection (453).  The most 
common EPS produced by Bcc species is designated cepacian (443).  Though 
the ET-12 lineage cannot produce cepacian due to a deletion in the biosynthesis 
cluster, other B. cenocepacia strains can produce EPS in response to 
carbohydrates in onion tissue and alcohol sugars (38).    B. cenocepacia is 
capable of producing mucoid material consisting of multiple polysaccharides, 
including polysaccharide-1 (PS-1), cepacian (formerly PS-2), and dextran; EPS 
produced by B. cenocepacia can inhibit neutrophil chemotaxis and the production 
of reactive oxygen species (66). 
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1.1.8.8 Resistance to oxidative stress 
In the course of a respiratory infection, B. cenocepacia is exposed to a toxic array 
of reactive oxygen species; intracellular bacteria are subject to the oxidative burst 
of phagocytic cells, while extracellular bacteria are exposed to the highly 
oxidative environment of the CF lung, characterized by persistent neutrophil 
infiltration and a sustained inflammatory response.  B. cenocepacia possesses 
numerous mechanisms to resist damage due to ROS.  Two separate 
catalase/peroxidase enzymes have been identified in B. cenocepacia, the first a 
classical enzyme participating in global resistance to oxidative stress, and the 
second a specialized enzyme employed in the metabolism of carbon sources 
through the tricarboxylic acid cycle, and in hydrogen peroxide resistance under 
conditions of iron limitation (263).  Intracellular B. cenocepacia is able to delay 
assembly of the NADPH oxidase complex, responsible for producing ROS (230); 
a periplasmic superoxide dismutase SodC is required for resistance to 
extracellular superoxide, mutations to which result in rapid NADPH oxidase-
dependent killing by murine macrophages (232).   
Some strains of B. cenocepacia produce a melanin-like pigment which also 
contributes to resistance to oxidative stress in vitro and intracellular survival 
within murine macrophages (231), while EPS produced by B. cenocepacia is able 
to scavenge ROS from activated phagocytes (66).  Genes involved in resistance 
to oxidative stress are upregulated when B. cenocepacia is grown in cystic 
fibrosis sputum (133).  Transcriptomic analysis of the response of sessile B. 
cenocepacia to ROS shows upregulation of pathways involved in scavenging and 
neutralizing ROS, and repair of cellular damage resulting from ROS exposure 
(363). 
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1.1.8.9 Biofilm 
B. cenocepacia is capable of forming biofilms – complex multicellular 
communities protected from antibiotics and host defences – on both abiotic (98) 
and biotic (425) surfaces.  The invasion of the airway epithelium by B. 
cenocepacia is mediated by biofilm formation; biofilm-associated bacteria are 
able to degrade the glycocalyx barrier, rearrange the actin cytoskeleton of the 
underlying epithelial cells, and induce necrosis of the luminal cells (425).  Biofilm-
associated B. cenocepacia produces cyanide, which may participate in 
destruction of host tissue (397); accumulation of cyanide in the sputum of P. 
aeruginosa-infected CF patients is associated with a decline in lung function 
(396). 
Reported regulators of B. cenocepacia biofilm formation, structure, and stability 
include all three quorum sensing systems (123, 206, 482), RpoN (410), ShvR 
(47), and AtsR, a hybrid sensor kinase-response regulator that also regulates the 
T6SS (25); formation and structure are also affected by iron availability (46), and 
EPS production (108). 
During co-infection of the CF lung, B. cenocepacia and P. aeruginosa can form 
mixed-species biofilms, where interspecies communication occurs (383).  P. 
aeruginosa is able to enhance the binding of “P. cepacia” to epithelial cells (401), 
and produces QS molecules that can upregulate the production of virulence 
factors in B. cenocepacia (320, 383). 
Biofilm-associated bacteria are more resistant to disinfectants (362), and 
antibiotics, including double antibiotic combinations (112).  However, treating 
biofilms with a combination of antibiotic and quorum-sensing inhibitors (QSI) has 
proven effective in killing biofilm-associated B. cenocepacia; compared to 
treatment with antibiotic alone, the combination with QSI also increases survival 
of infected C. elegans and G. mellonella, and decreases bacterial burden in a 
murine model of lung infection (58). 
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1.1.8.10 Other virulence determinants 
Degradation of many aromatic compounds converges at the catabolic pathway 
for phenylacetic acid (PA) prior to entering the Krebs cycle (280).  The PA 
pathway is upregulated when B. cenocepacia is grown in synthetic CF medium 
(186); transposon mutants in the PA pathway are attenuated for survival in C. 
elegans (256), as well as a rat model of chronic lung infection (207), suggesting 
aromatic compounds may be an important nutrient source in host-pathogen 
interactions.   
MgtC is a protein of unknown function which is required for growth under 
magnesium-limiting conditions and for intramacrophage survival in intracellular 
pathogens such as Salmonella enterica (381) and Brucella suis (255).  MgtC 
fulfills the same role in B. cenocepacia (296), where it is also necessary for 
virulence in a rat model of chronic lung infection (207).  There are two additional 
homologs of MgtC in the B. cenocepacia genome that have not yet been 
investigated; since the original mutant was not susceptible to in vitro 
intramacrophage-like conditions such as reactive oxygen and nitrogen species, 
cationic antimicrobial peptides, or low pH (296), it is possible the two additional 
MgtC proteins can complement certain phenotypes or under certain conditions.   
ShvR, a LysR-type transcriptional regulator, is necessary for virulence in an 
alfalfa model, as well as full lung histopathology in a murine model of chronic lung 
infection (47).  ShvR also regulates colony morphotype, biofilm formation, 
exoenzyme production, type II secretion, and production of an anti-fungal agent 
(348). 
HtrA is a periplasmic protein involved in the extracytoplasmic stress response; 
necessary for growth under thermal and osmotic stress, HtrA is also essential for 
in vivo survival in a murine model of chronic lung infection (154).  HtrA-like 
proteases are regulated by the alternative sigma factor RpoE, which in B. 
cenocepacia, is also necessary for growth under thermal and osmotic stress, as 
well as proper trafficking in murine macropahges (157).  A second alternative 
 
 34
sigma factor, RpoN, also plays a role in intra-macrophage trafficking, as well as 
motility and biofilm formation (410). 
Rhamnolipids are amphiphilic molecules which can act as biosurfactants; in P. 
aeruginosa, rhamnolipids are involved in biofilm development (115) and 
swarming motility (483), and can inhibit macrophage phagocytosis (319), disrupt 
the respiratory epithelium (543), and interfere with normal functioning of the 
tracheal cilia (378).  Rhamnolipid production has been seen in non-Bcc 
Burkholderia spp. (19, 136, 187), where it functions as an endotoxin in 
pathogenic strains.  Orthologs to the rhamnolipid biosynthetic genes of B. 
thailandensis and P. aeruginosa have been identified in B. cenocepacia, 
suggesting a capacity to generate rhamnolipids (145). 
 
1.2 Secretion systems 
Secretion in gram-negative bacteria requires transport across two hydrophobic 
membranes separated by a peptidoglycan-containing aqueous periplasm.  The 
movement of large macromolecules across this cellular envelope poses 
challenges in terms of maintaining the integrity of the membrane, as well as 
regulation of cross-membrane movement.  Estimates place at least 25-30% of 
the typical gram-negative total protein content in the cell envelope or secretome; 
as such, gram negative bacteria have developed six known large multi-gene 
secretion systems – types I through VI – including both one-step “tunnels” and 
two-step processes separated by a periplasmic stage (198).  A type VII secretion 
system has also been identified in gram-positive bacteria (2).  Secretion is 
particularly important in intercellular signalling for cooperation or competition, and 
in virulence effector delivery to eukaryotic cells, and thus some secretion systems 
are contact-dependent (188). 
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1.2.1 The Sec and Tat systems 
The general secretory (Sec) pathway and the twin-arginine translocation (Tat) 
pathway both function to move proteins across the inner membrane (IM); the 
former transports unfolded proteins, while the latter translocates folded proteins 
(261).  Protein substrates are targeted for export via an amino (N)-terminal signal 
sequence called a signal peptide (SP), which is cleaved when the protein 
reaches the periplasm.  The composition of the Tat sytem is varied, minimally 
consisting of a TatABC substrate-binding receptor complex which associates with 
a separate TatA complex to form an active translocon, through which tranport is 
driven by the proton motive force (385).  Proteins targeted to the Sec system bind 
to cytosolic motor protein SecA, an ATPase that drives translocation through a 
SecYEG channel; in the periplasm, the SP is cleaved by signal peptidase, 
allowing folding of the mature protein (135). 
 
1.2.2 Type I 
The type I secretion system (T1SS) is a simple trimeric complex spanning the 
entire cell envelope (199).  The translocon consists of an IM ATP-binding 
cassette (ABC) transporter, with a nucleotide binding domain (NBD) fused to a 
transmembrane domain, and an outer membrane (OM) pore linked by an adaptor 
protein, or membrane fusion protein.  Unfolded substrates are targeted to the 
T1SS, where a non-cleavable carboxy (C)-terminal signal sequence binds to the 
NBD of the ABC transporter to induce translocation. 
 
1.2.3 Type II 
The type II secretion system (T2SS), often referred to as the general secretory 
pathway, mediates a two-step process.  First, exoproteins with an N-terminal SP 
are transported to the periplasm by either the Sec or Tat systems; following 
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cleavage of the SP, fully folded proteins are translocated across the OM by the 
secreton (217).  The secreton is a large complex composed of an OM pore called 
a secretin, and an IM pilus-like structure postulated to act as a piston to force 
substrates through the secretin (90).  The T2SS is closely related to the type IV 
pili (217), and secretes a wide variety of exoenzymes (90). 
 
1.2.4 Type III 
The type III secretion system (T3SS) is a generally contact-dependent system 
found in pathogenic bacteria for the delivery of effectors to the cytosol of 
eukaryotic cells.  It is characterized by an injectisome, or needle-like structure 
capable of injecting substrates directly into a eukaryotic cell through a cell-
envelope-spanning channel; outside the bacterial OM, the T3SS is capped with a 
needle, a tip complex, and a translocation pore forming a channel in the 
eukaryotic membrane (188).  In structure and assembly, the T3SS is homologous 
to the flagellar export system (143), though secreted effectors are varied. 
 
1.2.5 Type IV 
The type IV secretion system (T4SS) is a mostly contact-dependent system able 
to transport substrates directly into both prokaryotic and eukaryotic cells. 
Homologous to bacterial conjugation machinery, T4SSs are able to translocate 
both DNA and protein substrates; the former contribute to rapid inter-bacterial 
spread of resistance genes and fitness traits, while the latter contribute to 
virulence against eukaryotic cells (86).  The main structures of the T4SS 
comprise a cell surface adhesin or pili for intercellular contact, a transenvelope 
channel, and a Type IV coupling protein (T4CP), which mediates substrate 
entrance into the channel (188).  There are two general lineages of T4SS, one 
homologous to the VirB/D4 system of Agrobacterium tumefaciens, and one 
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homologous to the Dot/Icm system of L. pneumophila, although there are T4SSs 
that fit well into neither lineage (86). 
 
1.2.6 Type V 
The simplest of the secretion systems, Type V secretion systems (T5SS) also 
use a two-step secretion mechanism with a periplasmic intermediate for the 
secretion of very large proteins.  Unfolded proteins are transported to the 
periplasm through the Sec system, where a -barrel translocator domain is 
needed for transport across the OM (189).  T5SS can be divided into 
autotransporters (AT) and two-partner secretion systems (TPS).  ATs consist of a 
signal domain and a -barrel domain linked by a passenger domain; the signal 
domain directs the protein to the periplasm where the -barrel domain forms a 
pore in the OM for secretion of the passenger domain.  The passenger domain 
may remain associated with the OM or be released into the extracellular milieu by 
proteolysis.  AT proteins often contribute to cellular adhesion, aggregation, biofilm 
formation, invasion, and toxicity (519).  TPSs are very similar to ATs, but the 
passenger domain, or exoprotein, and the pore-forming -barrel domain, or 
transporter, are translated as two separate proteins (189).  TPSs are implicated 
in contact-dependent growth inhibition (188). 
 
1.2.7 Type VI 
The type VI secretion system (T6SS) is the most recently discovered of the large 
multi-gene secretion systems, and as such, has not been as well characterized.  
Some proteins of the T6SS are homologous to bacteriophage proteins, including 
tube-like hexameric ring protein Hcp, and tailspike-like protein VgrG, and the 
T6SS can participate in contact-dependent effector delivery (215).  However, the 
purpose of the T6SS is a hotly debated topic, with phenotypes ranging from 
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restriction of H. hepaticus colonization and downregulation of the host immune 
response in infected epithelial cells (83), to P. aeruginosa toxin-mediated killing of 
neighbouring prokaryotic cells (204), B. thailandensis resistance to cell contact-
induced growth inhibition (427), B. mallei virulence in hamsters (421), and 
translocation of an actin cross-linking effector into host cells by intracellular Vibrio 
cholerae (284). 
 
1.3 Prokaryotic interactions with macrophages 
As professional phagocytic cells, macrophages are key elements of the innate 
immune response uniquely suited to engulf large particles, including 
microorganisms.  Particles are generally taken up by a receptor-mediated 
process into plasma-membrane derived vacuoles; these phagosomes mature 
through successive interactions with the endosomal pathway, a series of 
membrane bound organelles responsible for the degradation, recycling, and 
sorting of molecules from both the cellular membrane and the extracellular milieu.  
As the phagosome matures, both the membrane composition and the internal 
contents are altered through interaction with a multitude of cellular and 
membrane proteins, changing the phagosome from a relatively innocuous 
environment to a highly acidic and oxidative environment rich in degradative 
enzymes suitable for microbe destruction (55).  While most bacteria are 
successfully eliminated by the macrophage, some pathogens have developed 
strategies for preventing internalization or interfering with normal host cell 
processes.  Still others have adapted to the intracellular environment, which has 
advantages for pathogens able to overcome host defenses.  Macrophages are 
fairly long-lived cells, and thus provide a competition-free, nutrient-rich niche 
protected from extracellular host defenses for microbes able to subvert normal 
macrophage degradative processes. 
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1.3.1 Bacterial internalization 
The most common means of bacterial uptake into macrophages is via receptor-
mediated, actin-driven, zipper-like phagocytosis.  Macrophages express a wide 
range of receptors recognizing both pathogen-associated molecules and host 
serum opsonins coating the bacterial surface.  Opsonins such as complement 
protein C3b and immunoglobulin G (IgG) are recognized by complement receptor 
3 and Fc receptors, respectively; because Fc receptors are relatively low 
affinity, activation of phagocytosis requires simultaneous binding of multiple 
receptor-ligand complexes (55).  While opsonization is a non-specific process 
enabling detection of a vast array of microbes (490), phagocytes also express a 
wide variety of pattern recognition receptors (PRRs) which recognize pathogen-
associated molecular patterns (PAMPs) (479).  Plasma membrane-localized 
PRRs, including those belonging to the scavenger receptor, C-type lectin, and 
Toll-like receptor (TLR) families, are able to recognize diverse bacterial PAMPs, 
including simple and complex lipids, carbohydrates, proteins and peptides, and 
nucleic acids (364).  There is evidence of synergy between both opsonic and 
non-opsonic receptors.  Binding of microbial ligands to phagocytic receptors 
activates complex signalling cascades, cytoskeletal remodelling, and membrane 
delivery from intracellular compartments, leading to engulfment of the pathogen 
into a vacuole composed of the plasma membrane (55).  Receptor ligation and 
actin polymerization are linked by the action of Rho family small G proteins, 
including Rac1, RhoA, and Cdc42, which function as molecular switches (71).  
Inactive Rho proteins are bounding to guanine dissociation inhibitors (GDIs); 
guanine nucleotide exchange factors (GEFs) activate Rho proteins by 
exchanging GDP for GTP,  while GTPase-activating proteins (GAPs) mediate 
GTP hydrolysis and inactivation (71).  Rho-family GTPases recruit and activate 
downstream effectors, which in turn activate the actin-nucleating Arp2/3 complex 
to mediate actin remodelling (181). 
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1.3.1.1 Preventing bacterial internalization 
Bacteria unequipped to survive within phagocytic cells have developed methods 
to avoid internalization.  S. aureus, E. coli, and P. aeruginosa can all prevent 
opsonic phagocytosis; S. aureus interferes with the activation of complement via 
a secreted inhibitor (389), E. coli produces an outer membrane protein which 
binds to a regulator of complement (367), and P. aeruginosa secretes enzymes 
able to directly degrade complement proteins (203).  Group B streptococci 
prevent scavenger receptor-mediated non-opsonic phagocytosis by producing a 
polysaccharide capsule which masks a surface lipoprotein ligand (21).  
Pathogenic Yersinia spp. employ a T3SS to translocate multiple Yop effector 
proteins into phagocytic cells; YopO acts as a GDI, while YopE functions as a 
GAP, both of which modulate the activity of Rho GTPases to prevent bacterial 
uptake (7).  Other bacteria, including Clostridium spp., produce binary toxins 
capable of self-mediated delivery to the cytosol and ADP-ribosylation of actin, 
which inhibits actin polymerization and destroys the actin cytoskeleton, 
preventing uptake of bacteria (11).  Clostridium spp. also produce toxins capable 
of covalent modification and inactivation of Rho (37).  P. aeruginosa and 
Aeromonas salmonicida produce bifunctional T3-secreted effectors with both 
RhoGAP and ADP-ribosyltransferase activity (269, 303), while the T6SS effector 
VgrG1 from Aeromonas hydrophila is also able to ADP-ribosylate actin, leading to 
depolymerization of actin and apoptosis (467).   
 
1.3.1.2 Promoting bacterial internalization 
Bacteria have also developed methods to enter non-phagocytic cells, either by 
direct invasion – the zipper mechanism – or by promoting phagocytosis through 
manipulation of host signalling – the trigger mechanism.  Listeria monocytogenes 
employs the zipper mechanism, mimicking natural phagocytosis through the 
binding of bacterial surface proteins to cell-adhesion-associated receptors; the 
clustering of ligand-receptor complexes induces actin polymerization and 
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membrane extension, leading to engulfment of the pathogen (101).  While the 
zipper mechanism is dependent on adhesion, bacteria utilizing the trigger 
mechanism rely on translocation of effectors which directly activate the actin 
cytoskeleton remodelling necessary for phagocytic uptake. Salmonella mediates 
internalization into non-professional phagocytes via T3-secreted effector SopB, 
which mediates actin remodelling by activating SGEF, an exchange factor for 
RhoG (361).  Similarly, B. pseudomallei, Shigella flexneri, and E. coli (both EHEC 
and EPEC) secrete effectors capable of acting as GEFs for the Rho family 
GTPases, while Bordetella spp., E. coli, and Y. pseudotuberculosis produce 
toxins that covalently modify Rho proteins such that they are constitutively active 
(10). 
 
1.3.2 Phagosomal maturation 
Following internalization of a bacterium into a plasma-membrane-derived 
vacuole, the nascent phagosome matures from early phagosome to late 
phagosome to phagolysosome; the progression is mediated by sequential 
interactions with subcompartments of the endosomal pathway (155).  Interaction 
between the nascent phagosome and the early, or sorting, endosome creates the 
early phagosome, characterized by a mildly acidic pH (6.1 – 6.5) and an active 
form of the Rab5 GTPase.  Rab5 recruits effector proteins, including tethering 
protein early endosome antigen 1 (EEA1), which facilitates the fusion of 
phagosome and early endosome, and Vps34, a kinase that generates 
phosphatidylinositol-3-phosphate (PI(3)P); PI(3)P anchors EEA1 to the cytosolic 
face of the phagosomal membrane (155).  Active Rab5 also recruits Mon1, which 
in turn recruits Ccz1; the Mon1-Ccz1 complex displaces the Rab7 GDI, recruiting 
Rab7 to the phagosomal membrane and marking the transition to the late 
phagosome.  As markers of the early phagosome are lost, the late phagosome 
becomes characterized by a lower pH (5.5 - 6.0) due to the acquisition of V-
ATPases, as well as enrichment in hydrolytic enzymes, lysobisphosphatidic acid 
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(LBPA), mannose-6-phosphate receptors (M6PR), and lysosomal-associated 
membrane proteins (LAMPs).  Active Rab7 recruits Rab-interacting lysosomal 
protein (RILP), an adaptor for microtubule-associated motor protein dynein, which 
can bring together late phagosomes and lysosomes.  Late endosomal markers 
such as LBPA and M6PR are removed during the transition to a fully formed 
phagolysosome, a highly acidic (pH < 5.5) vacuole characterized by LAMPs and 
V-ATPases which employs both oxidative and non-oxidative killing mechanisms.  
The phagolysosome is rich in antimicrobial peptides and active hydrolases, 
including lipases, proteases, nucleases, and glycosidases; recruited NADPH 
oxidase and inducible nitric oxide synthase generate reactive oxygen and 
nitrogen species, and nutrients are scavenged by molecules such as lactoferrin, 
creating an environment hostile to continued microbial presence (55).   
 
1.3.3 Bacterial strategies for intracellular survival 
Pathogens have developed unique strategies for surviving within phagocytic 
cells.  True intracellular pathogens survive and replicate either in the cytosol or 
within a membrane-bound organelle, in most cases attempting to avoid the harsh 
lysosomal environment.  Bacteria remaining within a membrane-bound vacuole 
utilize several different survival strategies to evade or adapt to the lysosome. 
 
1.3.3.1 Escape to the cytosol 
Bacteria such as B. pseudomallei (464), S. flexneri (359), L. monocytogenes 
(372), and Rickettsia prowazekii (509) rapidly escape the nascent phagosome 
and invade the cytosol, where the pH is relatively neutral, nutrients are plenteous, 
and host cell defenses are less effective (428).  Generally, this exit strategy is 
environmentally triggered, but bacterially driven, caused by destabilization of the 
phagosome membrane by bacterial gene products and/or permeabilization via 
pores and enzymes (377).  Once in the cytosol, these bacteria can replicate, and, 
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by polymerizing eukaryotic actin, form comet tails to aid in intracellular and 
intercellular locomotion (377).  Bacterial actin-based motility (ABM) can force 
membrane protrusions into neighbouring cells, leading to the engulfment of the 
bacteria into a double-membrane vacuole in a process termed paracytophagy; 
rapid ABM facilitates evasion of host immune responses within the cell, as well as 
facilitating intercellular spread without exposure to the extracellular milieu (463). 
 
1.3.3.2 Arrest of phagosomal maturation 
Some bacteria, such as Mycobacterium tuberculosis (162), and S. enterica 
serovar Typhimurium (28), arrest the maturation of the phagosome, rendering the 
environment more hospitable for bacterial growth.  M. tuberculosis-containing 
vacuoles maintain an early-endosome-like environment, preventing the transition 
to late phagosome by retaining the Rab5 GTPase while excluding EEA1 and 
Rab7 (162).  The lipoglycan mannose-capped lipoarabinomannan can also affect 
vacuole dynamics (438).  In contrast, S. Typhimurium halts phagosome 
maturation at a later stage through the action of T3-secreted effectors; though the 
lumen acidifies and acquires late endosomal markers Rab7 and LAMP1, the 
Salmonella-containing vacuole (SCV) does not accumulate mature hydrolases, 
nor does it fuse with lysosomes (27).  Although a multiplicity of effectors are likely 
involved in SCV trafficking, a T3-secreted phosphoinositide phosphatase reduces 
the negative charge on the phagosomal membrane, which affects the trafficking 
of endocytic proteins and prevents lysosomal fusion (28).  Thus, by arresting 
phagosomal maturation, Mycobacterium  spp. and Salmonella spp. are spared 
the full microbicidal effects of the lysosome. 
 
1.3.3.3 Diversion from the endosomal pathway 
While some bacteria modify the phagocytic vacuole such that it is no longer 
recognized as part of the endosomal pathway, others manipulate the host cell 
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and take up residence in an existing organelle such as the endoplasmic reticulum 
(ER). Following phagocytosis, Legionella pneumophila persists within a vacuole 
that transiently recruits mitochondria, followed by ER exit vesicles; eventually, the 
Legionella-containing vacuole (LCV) takes on the character of the rough ER, 
suitable for bacterial replication (211).  Successful remodeling of the LCV 
requires T4-mediated secretion of a multitude of effectors affecting host signaling, 
membrane trafficking, and protein synthesis (182).  The Brucella abortus-
containing vacuole (BCV) acquires early endosomal markers EEA1 and Rab5, 
acidifies, and acquires LAMP1, but not Rab7, thus avoiding lysosomal fusion; 
similar to the LCV, the BCV interacts with ER exit vesicles in a T4SS-dependent 
manner, acquiring characteristics of the ER permissive to bacterial replication 
(364).  Chlamydia trachomatis produces proteins that insert into the nascent 
phagosomal membrane, interacting with Rab proteins to direct intracellular 
trafficking (68); C. trachomatis induces Golgi fragmentation, forming Golgi 
ministacks that accumulate around the vacuole to promote sphingolipid 
acquisition and bacterial replication (192). 
 
1.3.3.4 Delay of phagosomal maturation for adaptation to the 
phagolysosome 
Finally, some organisms, including Coxiella burnetti (507) and Leishmania 
donovani (273), delay the maturation of the phagosome while evolving to a form 
suitable for survival and replication within an acidic environment.  Previous work 
in our laboratory has examined the maturation of the B. cenocepacia-containing 
vacuole (BcCV) in the presence of metabolically-active bacteria, demonstrating 
rapid association with the early endosome, followed by prolonged absence of 
phagosomal markers, then eventual fusion with the late endosome and lysosome 
(252); bacterial replication has been noted 24h p.i. (185).  In other organisms, 
mechanisms of delay are thought to include regulation of surface 
glycoconjugants, release of effectors through a secretion system, and blebbing of 
outer membrane vesicles (OMV).  Though not a bacterium, L. donovani delay of 
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phagosomal maturation has been well characterized.  L. donovani employs 
lipophosphoglycan (LPG) to alter lipid microdomains in the phagosomal 
membrane, inhibiting fusion with late endocytic organelles (124, 125); LPG also 
prevents assembly of a functional NADPH oxidase complex on the phagosomal 
surface (274). In the presence of LPG, the L. donovani-containing vacuole retains 
RhoGTPase Cdc42, causing an accumulation of periphagosomal F-actin (272).  
Assembly of an F-actin coat delays phagosomal maturation by physically 
preventing vesicle docking; this association is transient, as F-actin is not found on 
mature phagolysosomes (267).  C. burnetii is the only true bacterium known to 
delay phagolysosomal fusion as a prelude to replication in an acidified, 
proteolytically-active environment (205).  Early, transient interactions with the 
autophagy pathway have been postulated to contribute to C. burnetii delay of 
phagosomal maturation (388).  During early stages of infection, C. burnetii 
upregulates expression of a T4SS (332) capable of translocating effectors into 
the host (76); many effectors contain eukaryotic-like domains capable of 
modifying host proteins and modulating signalling pathways (76).  Although L. 
pneumophila employs multiple strategies for intracellular survival, the bacterium 
has been shown to delay autophagosomal maturation (221); it is thought that this 
delay involves developmental regulation and shedding of LPS (430) and the 
release of OMV (151), though modulation of phagosomal membrane composition 
(436) and host trafficking via T4-secreted effectors (142, 528) are also likely. 
 
1.3.4 The immune response 
Ligand binding to PRRs initiates the immune response by activating a signalling 
cascade, leading to gene expression, biosynthesis, and secretion of inflammatory 
mediators, including cytokines and chemokines.  In particular, bacterial ligands 
binding to TLRs activate type I interferons (IFN) and/or transcription factor NF-B 
(165), which controls expression of a wide variety of genes involved in the 
immune response, including cytokines TNF-, IL-6, IL-8, and IL-2 (33).  
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Membrane-associated receptors, both surface and endosomal, are 
complemented by a family of cytosolic PRRs, deemed NOD-like (NLRs), which 
detect microbial products present in the cytosol following effector injection or 
escape from the phagosome (127).  NLRs form a critical component of the 
inflammasome, a complex containing a NOD-like receptor linked to pro-caspase-
1 by an adaptor protein; signalling through the NLR results in cleavage of pro-
caspase-1 to the active form (127).  Cross-talk between membrane-associated 
and cytosolic signalling systems is seen in the activation of IL-1; TLR-mediated 
NF-B activation produces pro-IL-1, which is cleaved to form active IL-1 by 
NLR-activated caspase-1 (226).  Caspase-1 also promotes maturation of other 
cytokines, including IL-18, and IL-33, an inducer of IL-4, IL-5, and IL-13 (165); 
caspase 1 also contributes to unconventional protein secretion and pyroptosis 
(251).  Since potential host responses to infection include oxidative stress, 
inflammasome activation, autophagy, apoptosis, pyroptosis, and necrosis, host 
survival depends on both control of the infection and activation of a protective 
response, including downregulation of sensory receptors and induction of stress 
response mechanisms (364).   
 
1.3.4.1 Pathogen response to inflammation 
Controlling or evading the host immune response is essential to the survival of 
intracellular pathogens.  Some bacteria have modified forms of TLR ligands, 
thereby preventing activation of the immune response; Campylobacter jejuni, 
Helicobacter pylori, and Bartonella bacilliformus all produce flagellin that is not 
recognized by TLR5 (17).  Other bacteria exploit TLR2 signalling to induce 
immunosuppression:  M. tuberculosis produces a lipoprotein that persistently 
activates TLR2, thus inhibiting IFN- production (160), whereas Yersinia spp. 
secrete V antigen to stimulate production of IL-10, and resultant suppression of 
IFN- and TNF (441).  Inflammasome activation can be inhibited by microbial 
products, including M. tuberculosis zinc metalloprotease Zmp1 (315), and P. 
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aeruginosa T3-secreted exoenzymes ExoU (471) and ExoS (169).  Yersinia spp. 
also produce a range of T3-secreted effectors that can interfere with the immune 
response; YopP and YopJ prevent activation of NF-B (394, 540), while YopE 
and YopT inactivate Rac1, causing inhibition of caspase-1 activation and IL-1 
secretion (424), and YopK prevents NLR recognition of the T3SS, thus 
preventing inflammasome activation (61).  L. pneumophila manipulates 
expression of the inflammasome adaptor ASC (3), thereby downregulating 
inflammasome activation; ASC is also able to modulate expression of NF-B 
(462).  L. pneumophila also inhibits host protein synthesis via T4-secreted 
effectors, causing prolonged activation of NF-B due to decreased synthesis of 
inhibitor IB (159).  Chlamydia spp. produce a protease which degrades a 
subunit of NF-B (248), thereby reducing host sensitivity to proinflammatory 
stimuli (85). 
 
1.3.5 Cell death 
The three principal mechanisms of host cell death are apoptosis, necrosis, and 
pyroptosis, which differ in initiation and outcome; under certain conditions, 
autophagy can also lead to cell death.  Apoptosis is an immunologically silent 
form of programmed cell death characterized by chromosome fragmentation and 
nuclear condensation, cytoplasmic shrinkage, plasma membrane blebbing, and 
eventual cell dispersion in membrane-bound fragments known as apoptotic 
bodies with exposed phosphatidylserine residues (355).  Apoptosis may be 
induced by both intrinsic and extrinsic pathways, the former caused by the 
release of pro-apoptotic proteins from the mitochondria, and the latter involving 
ligand binding to cell surface-associated death receptors; both pathways activate 
a caspase-signalling cascade, ultimately leading to the activation of executioner 
caspase 3, which cleaves cellular substrates and induces apoptosis (250).  
Release of pro-apoptotic proteins through the mitochondrial outer membrane 
occurs through the Mitochondrial Apoptosis-induced Channel, and is regulated by 
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the Bcl-2 family of proteins; the Bcl-2 family includes anti-apoptotic effectors such 
as Bcl-2, pro-apoptotic effectors such as Bax, Bak, and Bim, and pro-apoptotic 
BH3-only sentinels such as Bad (121).   
Necrosis is a caspase-independent mode of cell death characterized by 
increased cell volume and permeability, but uncondensed DNA content; necrosis 
is also characterized by an oxidative burst, mitochondrial hyperpolarization, and 
lysosomal membrane permeabilization, releasing hydrolytic enzymes (44).  Due 
to membrane permeabilization, necrotic cells spill intracellular contents into the 
extracellular milieu, triggering a significant inflammatory response and tissue 
damage (250).  Though originally considered an accidental form of death due to 
severe cellular insult, necrosis can be regulated by ligand-bound death receptors 
in the absence of caspase activation; such a mechanism, employing the RIP1 
kinase, is termed necroptosis (494).   
Pyroptosis is a form of programmed cell death initiated by excessive 
inflammasome activation, and thus typically induced by infection (54).  Pyroptosis 
is characterized by cellular DNA damage, cell lysis, and inflammatory cytokine 
release; activation of caspase-1 causes membrane perturbations and an influx of 
extracellular calcium, leading to lysosome exocytosis (45).  Pyroptosis is highly 
inflammatory, due to the release of inflammatory cytokines, antimicrobial 
lysosomal contents, and potentially degraded microbial products suitable for 
presentation as antigens by neighbouring cells (45).   
Though autophagy is typically a protective response to cellular starvation and 
stress, when excessive, the process can result in cell death.  The kinase mTOR 
and ATG/Beclin proteins regulate autophagosome formation, resulting in the 
engulfment of a portion of the cytoplasm into a double membrane-bound 
organelle. The autophagosome, characterized by marker LC3-II, fuses with 
lysosomes to degrade phagosomal contents, including damaged organelles or 
intracellular bacteria (54).  Autophagy can be induced by TLR ligands, and can 
thus be used to control bacterial infections, including those that can alter the 
classical phagosomal pathway (54).  In comparison to necrosis and pyroptosis, 
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by very nature, autophagy is an immunologically silent death process, similar to 
apoptosis.   
 
1.3.5.1 Bacterial influence on host cell death 
Bacterial modulation of host cell death is common; intracellular pathogens seek 
to inhibit host death to promote bacterial survival and replication, while other 
pathogens evade macrophage-mediated killing by rapidly inducing host cell 
death.  Bacterial targetting of caspases, Bcl-2 family proteins, and survival 
pathways (52) can inhibit cell death.  Intracellular C. burnetii blocks apoptosis via 
T4-secreted effector AnkG, which prevents cytochrome c release from 
mitochondria (281, 282).  C. burnetii also recruits anti-apoptotic Bcl-2 (498) and 
activates prosurvival kinases Akt and Erk1/2 (508).  T4SS effectors of L. 
pneumophila are capable of specific interaction with and neutralization of 
proapoptotic Bcl-2 family proteins (36), induction of NF-B nuclear translocation 
(5), and upregulation of antiapoptotic genes (276).  C. trachomatis prevents 
apoptosis by degrading multiple pro-apoptotic BH3-only proteins (534), and 
activating Akt, leading to sequestration of proapoptotic Bad (501).  
Some pathogens may induce host cell death to eliminate host cells required to 
mount an immune response.  Clostridium septicum produces a pore-forming -
toxin which induces programmed necrosis (233), while H. pylori secretes a 
protein which induces apoptosis by binding to the death receptor Fas (15).  
Yersinia and Salmonella promote apoptosis in naïve macrophages by T3-
secreted effector inhibition of NF-B activation (422) (94); however, infection of 
activated macrophages with the same bacteria results in pore formation in the 
host membrane, calcium influx, and lysosome exocytosis in a caspase-1 
dependent manner (45).  Following escape from the phagosome, intracellular S. 
flexneri induces pyroptosis in macrophages (544, 545) via a T3SS-secreted 
effector IpaB that activates caspase-1 (193).  L. monocytogenes induces 
pyroptosis through the activation of multiple inflammasomes by bacterial ligands, 
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including DNA (526); oddly, L. monocytogenes infection also causes metabolic 
signalling which inhibits activation of caspase-1 (542), potentially balancing pro- 
and anti-pyroptotic effects in macrophage infection.  L. pneumophila induces 
apoptosis in a T4SS-dependent manner at late stages of infection (414); 
however, Legionnaire’s disease is typically characterized by extensive 
inflammation, and L. pneumophila can also induce pyroptosis (440), and necrotic 
macrophage death, especially with high bacterial load (333).  Intracellular 
pathogens may induce cell death at the end of their replication cycle to facilitate 
escape from the macrophage. In M. tuberculosis, induction of caspase-
independent necrosis occurs in response to a high bacterial burden (259, 518).  
Similarly, Francisella tularensis, which escapes to the cytosol, prevents 
inflammasome activation and modulates caspase-3 activity to inhibit apoptosis 
until late stage infection (23, 415). 
Bacteria have also developed strategies to counteract autophagy.  M. 
tuberculosis is able to non-specifically inhibit autophagy, which also inhibits 
necrotic-like host cell death (437).  VirG, an intracellular ABM protein produced 
by S. flexneri binds Atg5 to induce autophagy; S. flexneri prevents induction of 
the autophagy signalling cascade by T3-secretion of an effector to competitively 
bind VirG (351).  L. monocytogenes evades autophagy by recruiting host 
cytoskeleton proteins to the bacterial surface via ABM protein ActA (537).  
Conversely, Y. pseudotuberculosis activates autophagy, but prevents 
acidification to survive and replicate within an autophagosome (330). 
 
1.4 Identification of intracellular gene expression by 
prokaryotic cells 
While many studies have examined the transcriptional response of bacteria to in 
vitro host-like conditions, true understanding of bacterial response to 
internalization by macrophages requires analysis of global transcription by 
intracellular bacteria.  Such studies are inherently challenging, being hampered 
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by the quality and quantity of microbial mRNA compared to host RNA, especially 
at a lower multiplicity of infection (MOI) and early time points p.i..  However, a 
lower MOI is desirable for physiological relevance, and though pathogen 
numbers are low and transcriptional changes often subtle, early time points p.i. 
represent the greatest potential for therapeutic intervention (466).  Typical 
bacteria contain 0.05-0.10 pg of RNA, of which mRNA comprises only 4% and 
has a half-life of mere minutes (246, 376).  Because bacterial gene expression 
can change rapidly, chemical disruption of the host cell and/or bacterial 
purification from the cell is impractical; thus, total RNA from both host and 
pathogen is extracted, from which bacterial mRNAs must be purified. 
 
1.4.1 Bacterial mRNA purification and enrichment 
In the last decade, a wide variety of strategies have been employed to separate 
mixed populations of prokaryotic and eukaryotic transcripts in an infectious 
context (246).  Some enrichment strategies employ commercial kits to selectively 
remove host ribosomal transcripts and polyadenylated eukaryotic mRNA; though 
simple and relatively swift, such practices risk loss of pathogen RNA, particularly 
small transcripts (466).  Other strategies, including differential expression using 
customized amplification libraries (DECAL) (13), coincidence cloning (CC) (26), 
and selective capture of transcribed sequences (SCOTS) (180), rely on 
purification of bacterial sequences from a pool of mixed eukaryotic and 
prokaryotic cDNAs.   
DECAL first requires construction of a customized amplification library (CAL) 
containing size-fractionated genomic DNA lacking ribosomal sequences; each 
library fragment is ligated to PCR adaptors, allowing total library amplification.  
Total RNA from the infection system of interest is reverse-transcribed with 
biotinylated primers; CAL fragments that hybridize to cDNA are retained with 
streptavidin-coated magnetic beads, and can be PCR amplified for infection-
proportional representation of prokaryotic-specific cDNA sequences (13).  
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DECAL has been applied to analysis of the Borrelia burgdoferi transcriptome in 
the central nervous system of infected non-human primates (341). 
Coincidence cloning is a recent development wherein total cDNA from infected 
tissue is hybridized with a great excess of bacterial genomic DNA, followed by 
selective PCR amplification.  RNA from the system of interest is reverse-
transcribed using nonanucleotides linked to a 5’ 25-nucleotide constant region 
containing a restriction endonuclease site.  Both genomic DNA and cDNA are 
digested with the restriction endonuclease, and each pool is ligated to a separate 
suppression adaptor.  When the two pools are hybridized together, DNA 
fragments unique to one set – eukaryotic sequences – can only self-hybridize, 
forming homo-duplexes, while sequences common to both pools – presumably 
prokaryotic – form hybrid duplexes.  While hybrid duplexes can be PCR-
amplified, the matching 5’ adaptors in homo-duplexes cause PCR-selective 
suppression.  CC has been used with M. tuberculosis-infected murine lung tissue; 
random sequencing of CC-selected amplicons showed 30% murine sequences 
and 70% M. tuberculosis sequences, while pyrosequencing demonstrated greater 
than 1000-fold increase in bacterial  transcripts following a single round of CC 
(26). 
SCOTS shares features with both DECAL and CC.  Transcripts isolated from the 
system of interest are reverse-transcribed and double-stranded with random 
nonanucleotides linked to a 5’ 25-nucleotide linker sequence containing a 
restriction site.  Microbial cDNAs can be positively selected by hybridization to 
biotinylated bacterial genomic DNA fragments pre-blocked with ribosomal 
sequences; hybrids retained via streptavidin-coated magnetic beads can be PCR 
amplified with a linker-specific primer (180).  Successive rounds of SCOTS 
amplification can enrich low abundance transcripts.  SCOTS can also be used to 
create multiple libraries for a single species under different conditions or at 
different infection time points, each library bearing a unique linker sequence. This 
technique has been used to identify genes expressed by several intracellular 
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pathogens, including M. tuberculosis (180), S. enterica serovar Typhi (109, 149), 
E. coli O157:H7 (365), Ehrlichia ruminantium (140), and L. pneumophila (148). 
 
1.4.2 Analysis of intracellular transcription 
Following purification and amplification of the infectious prokaryotic 
transcriptome, there are different methods available for transcript identification.  
Several techniques, including SCOTS competitive enrichment (SCOTS-CE) (180) 
and suppressive subtractive hybridization (128), allow isolation and enrichment of 
sequences preferentially transcribed in vivo; this requires creation of a second 
cDNA pool representing sequences transcribed in vitro.  For SCOTS-CE, the 
capturing chromosome is pre-blocked with both rDNA and an excess of cDNA 
from non-macrophage-exposed bacteria, such that only infection-specific cDNAs 
will be captured.  By using different linkers for each cDNA pool, infection-specific 
cDNAs can be selectively PCR-amplified.  Restriction sites present in the linker 
allow cDNA cloning into a vector for single-transcript analysis. 
Practical global transcriptome analysis requires a high-throughput method.  
Bacterial DNA microarrays hybridized to initial macrophage-infected cDNA show 
few and faint signals; however, purification and amplification of prokaryotic-
specific transcripts through one of the above methods produces cDNA probes 
suitable for microarray analysis (149, 341).  Recently, B. cenocepacia J2315 
genomic microarrays have been developed, leading to an explosion in B. 
cenocepacia transcriptomic research (133).  More recently, high-throughput 
massively parallel sequencing technologies have led to direct sequencing of 
prokaryotic cDNA pools in a technique known as RNA-seq (43, 105), which has 
been used to examine the intra-amoebae transcriptome of L. pneumophila (517); 
despite removal of ribosomal sequences, of the total sequences from two broth 
cultures and two infection time points, nearly half represented amoebae 
transcripts.  RNA-seq has been applied to in vitro investigation of B. cenocepacia 
niche-specific gene expression (535).  High-throughput pryosequencing has also 
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been applied to the downstream analysis of the CC amplicon derived from M. 
tuberculosis infecting murine lung tissue (26).  Both DNA hybridization-based 
microarrays and massively parallel next-generation sequencing present 
advantages in the analysis of cDNA pools:  Microarrays are low cost, and have 
rapid multiple-sample throughput, low requirements for initial starting material, 
and a well-established bioinformatic infrastructure (466); sequence-based 
analyses are less subject to experimental design artefacts, and have digital rather 
than analog signal quantitation, offering greater sensitivity and inter-platform 
reproducibility (435). 
 
1.5 Hypothesis and research objectives 
The overall hypothesis of this work is that B. cenocepacia adapts to persist within 
murine macrophages; this adaptation is a result of changing gene expression, 
and may involve classical multi-gene secretion systems.  The first hypothesis was 
addressed by surveying intracellular transcription at a global level, and the 
second by a reductionist approach involving the deletion of secretion systems to 
examine individual and combined contributions to the intracellular behaviour of B. 
cenocepacia.   
The results of this work are divided into two separate sections.  The first section 
details the optimization of the SCOTS technique for B. cenocepacia, and its 
subsequent application to B. cenocepacia-infected murine macrophages.  Global 
gene expression is described at an early post-infection stage in an attempt to 
identify gene products involved in avoidance of macrophage microbicidal activity 
and adaptive response to the phagosomal environment.  The second section 
describes the contribution of the T2SS, T3SS, T4SS-1, T4SS-2, and T6SS both 
individually and collectively, in internalization by macrophages, intracellular 
replication, and host-directed cytotoxicity. 
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Chapter 2  
2 Materials and Methods 
2.1 Bacterial strains, plasmids, media, and growth 
conditions 
Bacterial strains and plasmids used in this study are listed in Tables 1 and 2, 
respectively.  Bacteria were grown at 37oC in Luria-Bertani (LB; Difco) broth with 
agitation or on LB plates with 1.6% Bacto agar.  Escherichia coli cultures were 
supplemented as required with 20 μg/ml tetracycline, 50 μg/ml trimethoprim, and 
40 μg/ml kanamycin; B. cenocepacia cultures were supplemented as required 
with 100 μg/ml tetracycline and 100 μg/ml trimethoprim.  Plasmids were 
conjugated into B. cenocepacia by triparental mating at 37oC using E. coli DH5α 
carrying helper plasmid pRK2013 (153).  E. coli donor and helper strains were 
selected against with 50 μg/ml gentamicin or 100 μg/ml ampicillin and 25 μg/ml 
polymyxin B.  To determine growth rates of parental and mutant strains of B. 
cenocepacia, overnight cultures were inoculated into fresh medium at a starting 
optical density at 600 nm (OD600) of 0.01.  Growth rates with high-amplitude 
shaking were determined in 100-well microtiter plates via Bioscreen C automated 
microbiology growth curve analysis system (MTX Lab Systems). 
 
2.2 General molecular techniques 
DNA manipulations were performed as in (413).  DNA was amplified by PCR 
using a PTC-221 DNA engine (MJ Research) with Taq DNA polymerase or 
HotStar DNA polymerase (Qiagen).  Amplification of B. cenocepacia DNA was 
aided by the inclusion of Qiagen Q solution.  DNA sequencing was performed at 
the York University Core Molecular Biology and DNA Sequencing Facility in 
Toronto, Ontario, Canada.  Sequence analysis was done by BLAST.  Restriction 
enzymes, T4 DNA ligase (Roche Diagnostics) and Antarctic alkaline  
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Table 1:  Bacterial strains and cell lines 
Strain or 
cell line Relevant characteristics
 Source or 
reference 
Escherichia coli 
DH5α 
F-, f80 lacZ DM15 D(lacZYA-argF) U169  endA1 
recA1 hsdR17 (rK- mK+) supE44 thi-1 DgyrA96 
relA1 
Laboratory 
stock 
SY327 araD D(lac pro) argE(Am) recA56 rifr nalA, l pir (328) 
   
Burkholderia cenocepacia 
J2315 epidemic strain ET12 clone, CF clinical isolate P.A. Sokol 
K56-2 epidemic strain ET12 clone, CF clinical isolate BCRRCa 
MH1K K56-2 ∆BCAL1674-6 (185) 
JST19 MH1K ∆BCAL0124 This study 
JST71 MH1K ∆BCAS0186 This study 
JST75 MH1K ∆BCAM2837 This study 
JST128 MH1K ∆BCAL1726 This study 
JST130 MH1K ∆BCAM0276 This study 
JST132 MH1K ∆BCAM0411 This study 
JST134 MH1K ∆BCAM2446 This study 
JST136 MH1K ∆BCAM0434-5 This study 
JST190 MH1K ∆BCAL0340 This study 
JST194 MH1K ∆BCAM1679 This study 
JST89 K56-2 ∆T2SS ∆BCAL1674-6 This study 
JST40 MH1K ∆T3SS This study 
JST17 K56-2 ∆T4SS-1 ∆BCAL1674-6 This study 
JST39 MH1K ∆T4SS-2 This study 
JST53 K56-2 ∆T6SS ∆BCAL1674-6 This study 
JST112 K56-2 ∆T2SS ∆T3SS ∆T4SS-1 ∆T4SS-2 ∆T6SS 
∆BCAL1674-6 
This study 
JST178 MH1K ∆BCAL3516 This study 
JST182 MH1K ∆pBCA025 This study 
JST184 MH1K ∆BCAM0333 This study 
JST162 K56-2 ∆BCAL0343 ∆BCAL1674-6 This study 
   
Macrophage cell lines 
ANA-1 C57BL/6 murine bone marrow-derived macrophage cell line (103) 
RAW 264.7 BALB/c murine macrophage cell line ATCCb 
   
a B. cepacia complex Research and Referral Repository for Canadian CF Clinics 
b American Type Culture Collection 
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Table 2:  Plasmids 
Source or 
reference Plasmid Relevant characteristics
 
RK2 derivative, KanR, mob+, tra+, oricolE1 pRK2013 (153) 
oripMB1, ApR, mob+, Plac (532) pUC19 
pUC19 with K56-2 rDNA (23S, 16S, 5S), ApR pJT25 This study 
oriR6K, TpR, mob+, carries I-SceI cut site pGPI-SceI (156) 
oripBBR1, TetR, mob+, Pdhfr, sacB, encodes I-SceI 
endonuclease 
pDAI-SceI 
-SacBN 
(185) 
oripBBR1, TetR, mob+, Pdhfr pDA12 (25) 
pDA42 pDA12, eGFP (25) 
pJT31 pGPI-SceI with regions flanking BCAL0124 This study 
pJT41 pGPI-SceI with regions flanking BCAS0186 This study 
pJT42 pGPI-SceI with regions flanking BCAM2837 This study 
pJT45 pGPI-SceI with regions flanking BCAL1726 This study 
pJT46 pGPI-SceI with regions flanking BCAM0276 This study 
pJT47 pGPI-SceI with regions flanking BCAM0411 This study 
pJT48 pGPI-SceI with regions flanking BCAM2446 This study 
pJT49 pGPI-SceI with regions flanking BCAM0434-5 This study 
pDelbcsM pGPI-SceI with regions flanking BCAL0340 (24) 
pJT72 pGPI-SceI with regions flanking BCAM1679 This study 
pMH306 pGPI-SceI with regions flanking gspDEF (T2SS) M. Hamad
pJT43 pGPI-SceI with regions flanking T3SS (BCAM2040-57) This study 
pJT30 pGPI-SceI with regions flanking T4SS-1 (pBCA017-59) This study 
pGPI-SceI with regions flanking T4SS-2 (BCAM0324-
35) pJT44 This study 
pDelT6SS pGPI-SceI with regions flanking T6SS (BCAL0333-52) (24) 
pJT59 pGPI-SceI with regions flanking BCAL3516 This study 
pJT61 pGPI-SceI with regions flanking pBCAL025 This study 
pJT62 pGPI-SceI with regions flanking BCAM0333 This study 
pMH304 pGPI-SceI with regions flanking BCAL1674-6 (185) 
pJT57 pDA12, BCAL0124 This study 
pJT71 pDA12, BCAL0340 This study 
pJT52 pDA12, BCAL1726 This study 
pJT54 pDA12, BCAM0411 This study 
pJT62 pDA12, BCAL3516 This study 
pJT67 pDA12, BCAM0333 This study 
pJT69 pDA12, pBCA025 This study 
pHcp pDA12, BCAL0343 (25) 
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phosphatase (New England Biolabs) were used as recommended by 
manufacturers.  Transformation of E. coli SY327 and DH5α was done by the 
calcium chloride protocol (93). 
 
2.3 Cell culture and infection 
Macrophage cell lines listed in Table 1 were maintained in Dulbecco's modified 
Eagle medium (DMEM; Wisent) supplemented with 10% fetal bovine serum 
(FBS; Wisent) at 37oC in a 95% humidified atmosphere with 5% CO2.  For 
macrophage infection, cells were seeded in a 12-well plate at 1.25 x 105 cells per 
well or a 6-well plate at 2.5 x 105 cells per well and grown 15 h.  Bacterial cultures 
grown at 37oC for 16 h were washed twice and resuspended in DMEM-10% FBS.  
Macrophage monolayers were washed with phosphate-buffered saline (PBS; 
Wisent).  Bacteria were added at a multiplicity of infection (MOI) of 50:1 or 10:1 in 
1-2 ml DMEM-10% FBS.  Plates were centrifuged 1 min at 300 x g and incubated 
at 37oC, 95% humidity and 5% CO2.   
 
2.4 RNA extraction, cDNA synthesis, and amplification 
RNA was extracted from two 6-well plates containing equal numbers of B. 
cenocepacia, differing only in the presence (intracellular (I) RNA) or absence 
(non-macrophage-exposed (NME) RNA) of macrophages.  At 4 h post-infection, 
macrophage monolayers were washed three times with PBS and lysed in 1 ml 
cold deionized H2O.  NME cells were resuspended and collected.  For each 
condition, cells from 6 wells were resuspended in 1 mg/ml lysozyme (Roche).  
Total RNA was extracted using TRIzol (Invitrogen) and treated with RNase-free 
DNase (Roche) according to the manufacturer's instructions.  RNA purity, 
integrity, and concentration were determined by PCR, agarose gel 
electrophoresis, and A260/A280 spectrophotometer readings, respectively.  A 5 μg 
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RNA sample from each condition (“intracellular” and “NME”) was converted to 
first-strand cDNA by random priming with Transcriptor reverse transcriptase 
(Roche) according to the manufacturer's specifications.  Primers had a defined 5' 
terminal sequence and a 3' random nonamer; different terminal sequences were 
used for intracellular (I-3025) and NME RNA (N-3017) (Table 3).  cDNAs were 
double-stranded using Klenow fragment (Roche) as described in (164); cDNA 
libraries were amplified for 25 cycles using defined primers I-3032 (intracellular) 
or N-3033 (NME).   
 
2.5 Selective capture of transcribed sequences 
The SCOTS protocol was carried out as described (110).  In brief, 0.3 μg of 
denatured, sonicated, biotinylated B. cenocepacia K56-2 chromosome were 
mixed with 5 μg denatured ribosomal DNA fragments (sonicated pJT25; Table 2) 
and hybridized 30 min at 68oC to pre-block rRNA-encoding DNA regions.  3 μg of 
cDNA were denatured and re-annealed 30 min at 68oC to remove abundant 
transcripts.  cDNA and chromosomal DNA were combined and hybridized 24 h at 
68oC.  Chromosome-cDNA hybrids were removed from solution with streptavidin-
coated magnetic beads (Invitrogen).  Captured cDNA was eluted, precipitated, 
and amplified using library-specific defined primers (Table 3).  For each condition, 
10 parallel first-round reactions were done to maximize the cDNA sample 
diversity; the resultant cDNA was pooled for each condition and two subsequent 
rounds of SCOTS carried out.  The final cDNA libraries were used both for 
competitive enrichment hybridization and as probes for B. cenocepacia 
microarrays.  A detailed protocol may be found in Appendix 2. 
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Table 3:  Oligonucleotide primers 
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a Restriction endonuclease sites incorporated into the oligonucleotide sequences 
are underlined  
b N/A indicates the absence of a restriction site 
c native ClaI site in chromosome 
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2.6 Competitive enrichment 
To preferentially enrich for phagosomally-expressed or -upregulated transcripts, 
0.3 μg of B. cenocepacia K56-2 chromosome was pre-blocked with both 5 μg 
rDNA and 10 μg of denatured triple-SCOTS enriched NME cDNA (above).  3 μg 
of triple-SCOTS enriched intracellular cDNA (above) was denatured and re-
annealed 30 min at 68oC to remove abundant transcripts.  cDNA and blocked 
chromosomal DNA were combined and hybridized 18 h at 68oC.  Chromosome-
cDNA hybrids were removed from solution with streptavidin-coated magnetic 
beads.  Captured cDNA was eluted, precipitated, and amplified using intracellular 
library-specific defined primer I-3032.  Following three rounds of enrichment, 
cDNA were digested with restriction enzyme XbaI, cloned into XbaI-digested, 
dephosphorylated pUC19, and transformed into E. coli DH5α.  Individual cDNA 
inserts were screened by Southern blot for hybridization to DIG-labelled cDNA 
libraries.  cDNA which hybridized to intracellular cDNA, but not to NME cDNA, 
were sequenced and identified by BLAST analysis. 
 
2.7 Microarray experimental design and analysis 
SCOTS cDNA or B. cenocepacia J2315 genomic DNA was labelled with 
CyScribe™ Array CGH Labeling Kit (GE Healthcare) according to the 
manufacturer's protocols.  SCOTS cDNA was labelled with Cy5 and genomic 
DNA with Cy3; cDNA samples were mixed, hybridized to custom B. cenocepacia 
microarrays (Agilent) according to the Agilent 60-mer oligonucleotide microarray 
processing protocol, and scanned.  Labelling of cDNA, hybridization, and 
scanning of arrays were performed by the Mahenthiralingam Laboratory, Cardiff 
University, Wales.   
Microarray data analysis was done using GeneSpring GX 7.3.1 (Agilent).  Raw 
data was preprocessed via the enhanced Agilent FE import prior to per-spot and 
per-chip normalizations for each array.  Feature intensity varied across the six 
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arrays.  Genes were selected as “expressed” at a threshold of 1.0 relative to 
genomic DNA.  Statistical analysis between intracellular and non-macrophage-
exposed conditions was performed using a paired Student’s t-test; genes were 
considered differentially expressed at an I:NME ratio of 2-fold with a p < 0.05. 
The microarray dataset has been deposited in the ArrayExpress database 
(http://www.ebi.ac.uk/arrayexpress/) under accession number E-MEXP-3408. 
 
2.8 Quantitative reverse transcriptase PCR (qRT-PCR) 
To validate microarray data, five genes with altered expression (4 upregulated:  
BCAM0314, BCAM2141, BCAM0276, and BCAS0186; and 1 downregulated:  
BCAM1928) were examined individually using qPCR.  Sigma factor gene rpoD 
(BCAM0918) was used as a reference gene.  Oligonucleotide primers for each 
gene (Table 3) were designed with Primer3 (393).  Total RNA was isolated as 
described above.  cDNA was synthesized using random hexamers (Invitrogen) 
and Transcriptor reverse transcriptase.  Quantitation and melting curve analyses 
for qPCR were performed using the Rotor Gene 6000 (Corbett Life Science) with 
FastStart SYBR Green (Roche) according to the manufacturer's instructions.  
Expression of the target gene was normalized to the reference gene for each 
condition, allowing inter-condition comparison.  Data shown are representative of 
at least two independent experiments. 
 
2.9 Mutagenesis of B. cenocepacia K56-2 
The I-SceI homing endonuclease system was used for all deletions of genes or 
gene clusters in B. cenocepacia K56-2 (156, 185).  In brief, regions flanking the 
gene or region to be deleted were amplified with gene-specific primers containing 
restriction sites (Table 3).  Upstream amplicons were digested with restriction 
enzymes XbaI-ClaI; downstream amplicons were digested with ClaI-EcoRI.  Both 
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upstream and downstream amplicons were cloned into XbaI-EcoRI digested, de-
phosphorylated pGPI-SceI, giving rise to mutagenesis plasmids (Table 2).  
Mutagenesis plasmids were introduced to either B. cenocepacia K56-2 or MH1K 
by triparental mating.  A plasmid - pDAI-SceI-SacBN – carrying the homing 
endonuclease was conjugated into single crossover mutants, causing a double-
strand break resolved by either a second crossover, yielding mutant genotype, or 
by reversion to wild-type.  Exconjugants were screened by PCR, and confirmed 
mutants were plated on LB with 5% sucrose to cure pDAI-SceI-SacBN.  For the 
T2SS, T4SS-1, and T6SS, deletions were made in K56-2, followed by deletion of 
BCAL1674-6 to confer gentamicin sensitivity.  For the T3SS and T4SS-2, 
deletions were made directly in MH1K.  For JST112 (Table 1), lacking all 
secretion systems, deletions were performed sequentially.  PCR and Southern 
blot hybridization confirmed that the deletion had occurred, yielding gentamicin-
sensitive mutants (Table 1).  In the same manner, single gene deletions in MH1K 
were made in the T2SS (BCAL3516), T4SS-1 (pBCA025), T4SS-2 (BCAM0333), 
and T6SS (BCAL0343), as well as SCOTS-identified genes BCAL0124, 
BCAL0340, BCAM1679, BCAS0186, BCAM2837, BCAL1726, BCAM0276, 
BCAM0411, BCAM2446, and BCAM0434-5. 
 
2.10 Complementation experiments 
To complement single gene deletions, wild-type genes were PCR amplified from 
B. cenocepacia K56-2 with gene-specific primers (Table 3) and the following 
thermal cycling conditions:  95oC for 5 minutes, 30 cycles of 95oC for 45s, 60oC 
for 45s, and 72oC for 90s, and a final extension at 72oC for 10 min.  The resulting 
amplicon was digested with restriction enzymes XbaI and NdeI, and ligated into 
similarly-digested, dephosphorylated pDA12, giving rise to a complementation 
plasmid (Table 2) which could be introduced to the mutant strain through 
conjugation.  pDA12 was used as a vector control in all experiments. 
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2.11 Motility plate assays 
Swimming and swarming motility were assessed by the appearance of rings of 
growth away from the site of inoculation on specialized agar plates; motility was 
quantified by measuring the diameter (in mm) of the bacterial growth.  Swimming 
motility was determined following stab inoculation of LB plates with 0.3% agar.  
Swarming motility was determined following drop inoculation onto nutrient broth 
plates with 0.2% glucose and 0.5% agar. 
 
2.12 Exoenzyme secretion assays 
Secretion of protease, lipase, and phospholipase C (PLC) was measured via 
plate assays.  Protease secretion was measured as a zone of clearing on 
dialyzed brain-heart infusion agar with 1.5% skim milk (448).  Lipase secretion 
was measured as the width of the insoluble precipitate halo formed upon 
inoculation of Tween 80 agar (82).  PLC activity was measured as the zone of 
clearing on LB plates containing one hen egg yolk per 100 mL (227); egg yolk 
plates also show activity of lipase and lecithinase, the former by the appearance 
of an iridescent sheen on the surface of the bacterial growth, and the latter by the 
production of an insoluble opaque precipitate surrounding bacterial growth. 
 
2.13 Lipopolysaccharide analysis 
LPS was extracted as described previously (307, 309).  Briefly, bacteria were 
resuspended in PBS, and boiled for 10 min in lysis buffer containing 2% sodium 
dodecyl sulfate (SDS), 4% -mercaptoethanol, 10% glycerol, and 1M Tris (pH 
6.8).  The lysate was treated with proteinase K at 60oC for 12h, and stored at -
20oC.  LPS was separated on a 14% polyacrylamide gel using Tricine-SDS buffer 
and silver-stained as described previously (309). 
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2.14 Gentamicin protection assays 
30 min post-infection, B. cenocepacia-infected cells were washed three times 
with PBS and DMEM-50 μg/ml gentamicin was added to kill extracellular bacteria.  
After 30 min, the media was replaced with DMEM-10 μg/ml gentamicin.  Infected 
monolayers were washed with PBS, and lysed with 0.1% Triton X-100 (Sigma) in 
PBS at 1 and 24 h post-infection.  Surviving bacteria were enumerated by 
bacterial plate count (CFU).  Bacterial entry was  calculated as a percentage of 
initial inoculum.  Intracellular replication was calculated as a percentage of 
bacterial entry for each strain.  To compare between experiments, percentage 
recovery was normalized against the parental control, set as 100% entry and 
replication. 
 
2.15 Flow cytometry 
B. cenocepacia expressing eGFP from the plasmid pDA42 (25) were infected as 
above in 12-well plates at a multiplicity of 50:1.  At 2 h post-infection cells were 
washed three times with PBS and DMEM-50 µg/ml gentamicin was added to kill 
extracellular bacteria.  After 30 min, the media was replaced with DMEM with and 
without 10 μg/ml gentamicin.  Infected monolayers were washed with PBS, and 
removed with cold 0.04% EDTA in PBS at 24 h post-infection.  Cells maintained 
in media with gentamicin represented initial infection, while cells maintained in 
antibiotic-free media represented uncontrolled infection.  Macrophages were 
collected by centrifugation for 5 min at 400 x g and 4oC .  Cells were resuspended 
in cold PBS with 2.5 µg/mL 7-aminoactinomycin D (7AAD; Invitrogen) and 
maintained on ice.  Samples were enumerated using a FACSCalibur with 
CellQuest Pro acquisition software (Becton Dickinson).  Data analysis was done 
via FlowJo (Tree Star, Inc.).  All results were normalized against uninfected 
controls.   
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2.16 Fluorescence microscopy 
The B. cenocepacia-containing vacuole (BcCV) in macrophages was 
characterized 24 h post-infection.  Macrophages were infected with B. 
cenocepacia MHK1 at a moi of 50:1; 2h post-infection, extracellular bacteria were 
killed as above, and the infection maintained in DMEM-10 μg/ml gentamicin.  
Labelling of the endocytic pathway, including lysosomes, was done using 250 
g/ml  tetramethylrhodamine-dextran (TMR-dextran; Invitrogen).  To label 
lysosomes, macrophages were pulsed with TMR-dextran for 2 h, followed by a 1 
h chase in dextran-free media prior to bacterial infection.  To label the endocytic 
pathway, 21 h post-infection, macrophages were pulsed with TMR-dextran for 2 
h, followed by a 1 h chase in dextran-free media.  Acidic compartments were 
labelled with 0.5 M Lysotracker Red (Invitrogen) for 30 s prior to visualization.  
Live images were acquired using a Qimaging cooled charged-coupled device 
camera (Burnaby) on an Axioscope 2 (Carl Zeiss) microscope with a 100x oil 
immersion objective and a 50W mercury arc lamp.  Images were digitally 
processed using Northern Eclipse imaging software (Empix Imaging). 
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Chapter 3  
3 Global changes in gene expression by the opportunistic 
pathogen B. cenocepacia in response to internalization 
by murine macrophages 
 
3.1 Construction of SCOTS components for B. cenocepacia 
Application of the SCOTS technique to any system requires the creation of two 
organism-specific elements:  The first is a library of biotinylated bacterial 
chromosome fragments with ribosomal blocking sequences; the second is a 
cDNA library containing the transcripts of interest, where both ends of each cDNA 
contain a 25-nt defined “linker” sequence not found within the bacterial 
chromosome.  
B. cenocepacia J2315 encodes four complete rRNA operons on the first 
chromosome, and one on each of the second and third chromosomes; all six 
operons are 99-100% identical (195).  The 16S rRNA gene, and 23S/5S rRNA 
genes were each amplified from the final operon on chromosome 1, which does 
not contain any tRNA sequences. All genes were cloned into pUC19, a high-copy 
number plasmid, to form pJT25 (Figure 1A), the source of ribosomal blocking 
sequences.  Chromosomal DNA extracted from B. cenocepacia K56-2 was 
biotinylated (Figure 1B) and sonicated together with an excess of pJT25 to form 
the chromosomal library (Figure 1E).   
Two linker primers were created, each containing a different restriction site (Table 
3).  When added to a random nonamer, the linker primer can be used for both 
single-strand cDNA synthesis and double-stranding to create a pool of cDNAs 
with the linker sequence at both ends; this allows the entire cDNA pool to be 
amplified with a single primer (Figure 1E).  Neither linker primer binds to the K56-
2 chromosome, as PCR amplification occurs only in the presence of linkered 
cDNA. 
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Figure 1.  SCOTS components for B. cenocepacia. 
(A) Ribosomal blocking plasmid pJT25. (B) Biotinylated B. cenocepacia 
chromosome.  Biotinylated (2) and unbiotinylated (1) K56-2 chromosome 
were electrophoresed, and the gel stained with IRDye800 streptavidin 
(right), labeling biotinylated DNA, followed by ethidium bromide (left), 
labeling all DNA. (C) RNA isolated from K56-2 shown pre- (1) and post- (2) 
DNase treatment. (D) DNase treatment is effective, as neither bacterial nor 
eukaryotic sequences can be PCR-amplified from RNA template.  1 – I-
RNA, 2 – NME-RNA, 3 – K56-2 DNA, 4 – macrophage cDNA. (E) 
Complete B. cenocepacia chromosomal library fragments (1) and cDNA 
libraries from intracellular (2) and NME (3) B. cenocepacia.  L – GeneRuler 
Ladder mix. 
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3.2 Optimization of the SCOTS protocol for B. cenocepacia 
The SCOTS protocol is complex, with no readout of functionality until the final 
screening step.  Thus, a simple artificial system was created to test the individual 
steps of the protocol, including capture of cDNA with biotinylated chromosomal 
fragments, cDNA amplification with a linker primer, and blocking the capture of 
duplicate sequences during competitive enrichment.  We created this artifical 
system using three test genes of different sizes:  500bp BCAL2831 (T1), 700bp 
mgtC (T2), and 900bp arnA1 (T3), all easily separated and visualized by simple 
gel electrophoresis.  All three genes were amplified with linker sequence 2 (N) at 
either end; the first two genes were also amplified with linker sequence 1 (I) at 
either end (Figure 2).  These artificial cDNA constructs enabled testing and 
optimization of every aspect of the B. cenocepacia-specific SCOTS protocol in 
five separate tests; cDNA captured from each test library was divided in half and 
amplified separately with each linker primer (I or N) (Table 3).  Sonicated herring 
sperm DNA was used to represent eukaryotic sequences, to which the test genes 
were added in known quantities to form the test cDNA libraries (L1-L5).  L1 
contained only genes I1 and I2, while L2 contained N1, N2, and N3; these two 
libraries tested the capture of bacterial sequences and the specificity of linker 
primer amplification.  L3 contained the five test genes, but capture was carried 
out in the absence of biotinylated library fragments to ascertain the necessity of 
hybridization for cDNA capture.  The fourth test pre-hybridized a ten-fold excess 
of L2 to the chromosome prior to the capture of L1 to examine the efficacy of 
blocking during competitive enrichment; in a successful test, pre-hybridization of 
L2 would prevent the capture of L1.  The fifth test pre-hybridized a ten-fold 
excess of T1-N and T3-N to the chromosome prior to capture of L1; in this case, 
successful competitive enrichment would prevent binding of T1-I while capturing 
T2-I.  
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Figure 2.  An artificial system to optimize SCOTS for B. cenocepacia 
Test genes (A) can be clearly distinguished by size via gel electrophoresis 
(B). (C-E) Optimization of SCOTS conditions. (C) Expected results. (D) 
Pre-hybridization effectively removes abundant sequences. (E) Genes can 
be effectively captured and amplified, but blocking sequences are 
insufficient. (F) 100x NME genes are required to effectively prevent 
capture of I genes. 
Legend:  L – GeneRuler Ladder mix 
PCR amplification with I linker primer (A) or N linker primer (B) 
1 – Capture of I2 and I3 ; 2 – Capture of N1, N2, and N3 
3 – Capture of all five genes in the absence of biotinylated chromosome 
4 – Capture of I2 and I3 following pre-hybridization with 10x N1, N2, and N3 
5 – Capture of I2 and I3 following pre-hybridization with 10x N1 and N3 
6 – Capture of I2 and I3 following pre-hybridization with 100x N1, N2, and N3 
7 – Capture of I2 and I3 following pre-hybridization with 100x N1 and N3 
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The initial experiment revealed the efficacy of the pre-hybridization step to 
remove abundant transcripts (Appendix 2), as only cDNA hybridized to the 
chromosome immediately following denaturation could be amplified (Figure 2D).  
After eliminating pre-hybridization of the cDNA pools, the second experiment 
demonstrated successful capture in the presence of biotinylated bacterial 
chromosome fragments and linker-specific amplification of cDNA; however, 
blocking for competitive enrichment was ineffective (Figure 2E).  Successive 
experiments demonstrated successful competitive enrichment by decreasing the 
hybridization temperature, and increasing both the duration of pre-hybridization 
with blocking sequences and the quantity of blocking sequences (Figure 2F).   
 
3.3 Preliminary applications of SCOTS:  Transcriptional 
changes during growth in sub-inhibitory concentrations 
of tetracycline 
Sub-inhibitory concentrations of tetracycline modulate outer membrane protein 
expression in B. cenocepacia J2315, implying changes in gene transcription 
(295); SCOTS and CE were applied to identify these transcriptional changes 
while optimizing later steps in the SCOTS-CE protocol.  cDNA from J2315 grown 
to log phase in LB with and without 25 g/mL Tet was subjected to three rounds 
of SCOTS, followed by three rounds of CE.  The resultant selectively captured 
sequences (scs) were cloned into pUC19 (Table 2) for individual screening by 
Southern blot hybridization; cDNAs were identified that hybridized to DIG-labelled 
cDNA from tetracycline-grown J2315 more strongly than to cDNA from broth-
grown J2315 (Figure 3).  Sequencing of tetracycline-enhanced transcripts 
identified an imidazole glycerol phosphate synthase, a putative exported protein 
with a coagulation factor domain, an extracellular solute-binding protein, a 
putative cell wall lysis peptidase, and several hypothetical proteins.  Previous 
studies in protein expression changes also identified an extracellular solute-
binding protein, as well as a peptidoglycan-associated lipoprotein, and multiple  
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Figure 3.  Modulation of bacterial transcript levels during growth in sub-
inhibitory concentrations of tetracycline. 
Each lane contains captured cDNAs amplified from a single recombinant 
plasmid, transferred to a membrane, and probed with SCOTS-amplified 
DIG-labelled cDNA from growth in tetracycline (A) or LB (B).  Arrows 
indicate genes upregulated during growth in tetracycline. 
 
 76
conserved hypothetical proteins (295). 
Originally, cDNA inserts were amplified with M13 vector primers (Table 3), such 
that empty vectors would show a small product.  However, PCR amplification with 
linker primers revealed the presence of multiple cDNAs within a single vector 
(Figure 4).  Such a situation could lead to false-negatives during Southern blot 
screening, should both probes detect one of several cDNAs in a single amplicon.  
Modification to the ligation procedure decreased the incidence of multiple cDNA 
inserts within a single vector. 
 
3.4 Intracellular gene expression by B. cenocepacia in 
murine macrophages 
SCOTS was used to examine gene expression by intracellular B. cenocepacia in 
murine macrophages at 4 h p.i..  We have previously demonstrated that at 4 h 
p.i., most intracellular bacteria reside in vacuoles that do not fuse with the 
lysosome (230, 252, 296).  In addition, by 4 h p.i., infected macrophages display 
observable alterations to the actin cytoskeleton caused by the bacterial T6SS, 
which is not well-expressed under normal culture conditions in LB medium (25).  
These observations suggest that at 4 h p.i., there are changes in bacterial gene 
expression reflecting response and adaptation to the intracellular environment.  
As a control, we used bacteria grown for 4 h under the same conditions in 
macrophage growth medium (DMEM-10% FBS), but without macrophages.  To 
isolate and enrich bacterial transcripts, three rounds of SCOTS were performed 
on both intracellular and non-macrophage-exposed (NME) bacterial cDNA 
samples.  The resultant cDNA pools were subjected to competitive enrichment for 
transcripts specific to the phagosome, and to microarray analysis with B. 
cenocepacia J2315 DNA arrays. 
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Figure 4.  Multiple cDNAs may be present in a single recombinant plasmid. 
PCR amplification with M13 vector primers shows a negative product from 
an empty vector (1), or a single product containing all cDNA inserts (2). 
PCR amplification with I linker primers reveals multiple cDNA inserts 
present in a single recombinant plasmid (3).  L – GeneRuler Ladder Mix 
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3.4.1 Low abundance transcripts identified by competitive 
enrichment 
Competitive enrichment is similar to the initial SCOTS technique, but pre-blocks 
the chromosome with both rDNA and control NME cDNA prior to capture of 
intracellular cDNA.  This encourages the capture of sequences specifically or 
more highly expressed within the phagosome.  Following three rounds of 
competitive enrichment, cDNA sequences were cloned into pUC19, a high-copy-
number vector, and introduced into E. coli DH5α by transformation.  DNA inserts 
from colonies were individually amplified by PCR and screened by Southern blot 
for differential hybridization to DIG-labelled cDNA libraries.  A number of 
recombinant plasmids contained multiple cDNA inserts; however, these could be 
differentiated during Southern blot analysis.  Following competitive enrichment, 
many scs clones were obtained which hybridized to labelled intracellular cDNA 
but not to NME cDNA (Figure 5).  One hundred eighteen unique scs sequences, 
encoding 124 proteins, were mapped to the B. cenocepacia genome (Table 4); of 
these sequences, four were secondary sequences in an already-identified gene, 
two were within a duplicated region on chromosome one, and one was a 
transposase with nine identical copies distributed throughout the genome.  
Identified sequences were proportionally represented in each of the three 
chromosomes and the plasmid:  57 scs mapped to chromosome one, 51 to 
chromosome two, 14 to chromosome three, and 2 to the plasmid.  For the latter 
three genetic elements, this represents approximately 2 percent of coding 
sequences, whereas for chromosome one, only 1.5 percent of the genes were 
identified.  While this is a small difference, it is interesting to note that the core 
functions of the cell, including cell division, central metabolism, and 
“housekeeping genes” are overrepresented on chromosome one, while the latter 
three genetic elements carry a higher proportion of accessory functions and 
unknown proteins (195).  Identified scs were classified into functional categories 
based on clusters of orthologous groups of proteins (COG) designations (Figure 
6).  The COGs database (http://www.ncbi.nlm.nih.gov/COG/) predicts the  
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Figure 5.  Modulation of bacterial transcript levels by intracellular B. 
cenocepacia 
Selectively captured sequences (scs) isolated from intracellular bacteria 
were hybridized with DIG-labelled SCOTS-derived B. cenocepacia cDNA 
pools from (A) intracellular bacteria or (B) non-macrophage-exposed 
bacteria.  Each lane represents cDNA amplified from a single recombinant 
plasmid.  L indicates equally loaded DIG-labelled ladder. 
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Table 4:  Intracellular-specific selectively captured sequences 
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a Genes are strongly upregulated (log2 > 2, p < 0.05) 
  Genes are in a transcriptional unit with strongly upregulated genes (log2 > 2, p 
< 0.05) 
  Genes are upregulated in intracellular bacteria 
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Figure 6.  Functional classification of selectively captured sequences. 
Profile of each COG functional class is shown as a percentage of all scs.  Also 
shown is the functional profile of the genome as a whole.  
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function of a protein based on orthology, or homology among species (476).  
Almost half (46%) of identified scs represented poorly characterized genes, of 
which two-thirds had no functional classification.  Several major COGs were not 
represented in the set, including nucleotide metabolism and transport, trafficking, 
secretion and transport, posttranslational modification and chaperones, and 
defense mechanisms; however, genes classified as cell motility were 
overrepresented relative to genome content.  This COG profile is representative 
of 115 genes; B. cenocepacia J2315, a sequenced clonal isolate of K56-2, has 
over 7000 identified genes (195). Therefore, to determine if these trends hold true 
across the entire cDNA library, SCOTS-derived cDNA pools were applied to B. 
cenocepacia-specific microarrays to gain a more complete overview of 
intracellular gene expression. 
 
3.4.2 Global intracellular gene expression identified by microarray 
analysis 
Each cDNA pool was hybridized against reference genomic DNA; expression 
was set as a value of 1.0 or greater versus the genomic control.  Using this 
threshold, 55 percent of all genes, or approximately 4000 genes, were expressed 
under each condition. Of the 115 unique genes identified by competitive 
enrichment, only 6 failed to meet the arbitrary level for expression by intracellular 
bacteria; of the remainder, more than half were upregulated by intracellular 
bacteria.  Twenty percent of sequences identified by competitive enrichment 
showed significant intracellular upregulation (> 4-fold, p < 0.05) of the gene itself 
or of a putative transcriptionally-associated gene.  Gene expression was 
compared between intracellular and non-macrophage-exposed bacteria; seven 
hundred sixty-six microarray genes or intergenic sequences showed significant 
changes in expression (-2 > log2 > 2, p < 0.05), of which 329 were induced and 
437 were repressed.  Distribution of these genes among and throughout the four 
genetic elements of B. cenocepacia was relatively proportionate to the size of the 
genetic element, regardless of G+C content (Figure 7), with the exception of the  
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Figure 7.  Genes differentially expressed by intracellular bacteria are 
distributed among the four genetic elements of B. cenocepacia 
The outer pair of concentric circles represents both coding strands of the 
B. cenocepacia genome.  The second pair of concentric circles represents 
gene induced (outer) and repressed (inner) by intracellular B. 
cenocepacia.  Percentage of G+C is also shown, with above average in 
yellow and below average in purple.  Chromosome 3 is 3x scale; the 
plasmid is 17.5x scale.   
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plasmid, where 20% of the plasmid-encoded genes were repressed in 
intracellular bacteria.  Among the differentially expressed genes, 145 were 
regulated greater than  10-fold (p < 0.05) (Figure 8); many of these genes are 
poorly characterized (Tables 5 & 6), suggesting a novel survival strategy.  
Differentially regulated genes were classified into functional categories based on 
COG designations (Figure 9).  Expression was altered in every COG designation 
represented in B. cenocepacia.  Metabolic adaptation accounts for one-third of 
differentially regulated genes in intracellular bacteria, though more metabolic 
genes were induced than were repressed.  Genes involved in amino acid, lipid, 
and carbohydrate transport and metabolism, and energy production and 
conversion account for 25% of all induced genes.  The large categories of 
information storage and processing, and cellular processes and signaling each 
accounted for one-sixth of differentially regulated genes; in particular, significant 
changes were seen in the expression of transcriptional regulators, accounting for 
9% of all differentially regulated genes.  Similar to the over-representation seen in 
the SCOTS-CE profile (Figure 6), cell motility (flagellar) genes were mainly 
induced.  Interestingly, genes involved in the synthesis and transport of 
phospholipid precursor sn-glycerol-3-phosphate were induced by intracellular 
bacteria, as were genes involved in the production and transport of cholesterol-
like hopanoids, exoenzymes, ion transporters, an osmolarity-dependent two-
component regulatory system, and catalase katB.  Unexpectedly, many genes 
involved in the acquisition of iron were repressed, including ornibactin receptor 
orbA, the transcriptional activator of the pyochelin receptor, and a putative 
pyochelin biosynthesis protein.  Other repressed genes of note include B. 
cenocepacia-specific quorum sensing regulator cciR, adhesin adhA, and many 
transport genes, including the Sec and Tat systems, and elements of the type II 
and both type IV secretion systems.  However, at least one-third of both induced 
and repressed genes fall into the poorly characterized classification; of these, 
greater than half lack a COG designation.  In total, 25% of all differentially 
regulated genes are annotated only as hypothetical proteins. 
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Figure 8.  Relative expression of genes strongly regulated by intracellular 
B. cenocepacia. 
Heat map of the I:NME expression ratio of  genes induced (A) or 
repressed (B) greater than 10-fold (p < 0.05).  Colour scale shows green 
as high expression, red as low expression, and yellow as intermediate. 
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Figure 9.  Functional classification of genes differentially expressed by 
intracellular B. cenocepacia 
Profiles of functional classes are shown as a percentage of all induced 
(green bar) or repressed (red bar) genes (-2 > log2 > 2, p < 0.05).  
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3.5 SCOTS-identified changes in gene expression validated 
by other means      
A previous study identified B. cenocepacia K56-2 signature-tagged transposon 
mutants (STM) attenuated for survival in a rat agar bead model of chronic lung 
infection (207); in total, the study mapped 84 unique insertions within genes 
essential for in vivo survival.  Four of these genes were identified directly by 
SCOTS competitive enrichment; another three SCOTS-identified genes were 
found in genes located within a putative transcriptional unit with an STM insertion 
(Table 7).  SCOTS microarray analysis identified 26 of the 84 STM genes as 
being expressed by intracellular bacteria (Table 7), a significant finding 
considering the lung environment exposes the bacteria to many factors other 
than macrophages.   
Quantitative RT-PCR was performed for a subset of genes to experimentally 
validate trends seen in the microarray data in the absence of any capture or 
enrichment.  Total RNA was extracted and DNase-treated as was done for 
SCOTS, and reverse transcribed to cDNA using random hexamers.  Microarray 
data indicates conserved hypothetical protein BCAM0314, ABC transporter ATP-
binding protein BCAM2141, putative universal stress protein BCAM0276, and 
putative acyl carrier protein phosphodiesterase BCAS0186 should be induced by 
intracellular bacteria, while putative transcription elongation factor BCAM1928 
should be repressed.  Sigma factor BCAM0918, or rpoD - also designated sigA 
(297) or sigE (297, 349) – was chosen as an internal control.  An internal 
reference gene allows comparison across samples; despite reverse transcribing 
equal amounts of RNA, expression of the reference gene averaged 60-fold less 
in intracellular samples as compared to NME samples due to eukaryotic content.  
Expression of the gene of interest was first related to the internal control; this 
ratio was compared between samples to give fold increase in expression in 
intracellular bacteria.  qRT-PCR confirmed the expected trends of higher  
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Table 7:  In vivo essential genes expressed by intracellular bacteria 
 
aTag assigned to mutant in STM in vivo study (207) 
bGene names in bold were strongly induced (>3.5-fold, p<0.05) 
cImmediately adjacent gene identified by SCOTS 
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expression of BCAM0314, BCAM2141, BCAM0276, and BCAS0186, and 
negligible expression of BCAM1928 in intracellular bacteria (Figure 10). 
 
3.6 SCOTS-identified genes are involved in bacterial entry 
and intracellular replication 
Because survival within macrophages may contribute to the pathogenesis of B. 
cenocepacia, the role of several SCOTS-identified genes in intracellular survival 
was examined.  Ten genes were deleted in the gentamicin-sensitive B. 
cenocepacia MH1K, allowing intracellular survival to be assessed via the 
gentamicin protection assay (185).  The ten deleted genes encoded the following 
proteins: a subunit of the flagellar regulon master regulator (BCAL0124), a 
putative acyl carrier protein phosphodiesterase (BCAS0186), a cation efflux 
system (BCAM0434-5), the response regulator component of a two-component 
regulatory system (BCAM2837), a putative oxidoreductase (BCAL1726), a 
putative universal stress protein (BCAM0276), an MgtC family protein 
(BCAM0411), a putative lipoprotein (BCAL0340), a putative 
lysylphosphatidylglycerol synthetase (BCAM1679), and a putative Gram-negative 
porin (BCAM2446).  These genes were chosen based on high intracellular 
expression by microarray data; the first three genes were also identified by 
competitive enrichment.  
The ability of mutant strains to enter and replicate within macrophages was 
assessed relative to the parental strain (Figure 11).  While six of the ten mutant 
strains showed a defect in macrophage entry, the defect was statistically 
significant only for BCAL0124 (p < 0.01) and BCAM0411 (p < 0.05).  In contrast, 
deletion of BCAL1726 resulted in a significant increase in macrophage entry (p < 
0.001).  While none of the deletions negatively affected intracellular survival, 
deletions in BCAL0340 and BCAM0411 increased the ability of the bacteria to 
replicate intracellularly.  Statistically significant differences could be 
complemented by introducing the deleted gene encoded in a plasmid under the 
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Figure 10. n-Fold changes in the intracellular expression of SCOTS-
identified B. cenocepacia genes as measured by qRT-PCR. 
 Fold change represents the induction of expression by intracellular 
bacteria over NME bacteria, each relative to a reference gene presumed 
to have stable transcriptional levels.   
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Figure 11. Comparative macrophage entry and intracellular replication of 
parental B. cenocepacia and scs mutants in murine macrophages. 
Entry (A) was calculated relative to initial inoculum, and replication (B) was 
calculated relative to entry; both were normalized relative to the parental 
control, set at 100% entry and 100% replication.  Standard error bars are 
indicated.  Significance was determined using one-way ANOVA and 
Dunnett’s Multiple Comparison Test.  Mutants demonstrating significant 
difference from the wild-type are indicated (*p<0.05, **p<0.01, ***p<0.001).   
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 control of a constitutive promoter (Figure 12).  Among the deletion strains, the 
only gene with an obvious phenotype is JST19, or ∆BCAL0124, which is 
defective in both swimming and swarming motility; complementation restored 
motility to the deletion strain (Figure 13).  JST75, or ∆BCAM2837, is impaired in 
swarming motility, but not in swimming motility (Figure 14). 
 
3.7 SCOTS-identified genes are involved in bacterial 
spread and macrophage cytotoxicity 
The gentamicin protection assay allows the enumeration of intracellular bacteria.  
However, the results may be misleading if the survival of the host cell is not 
considered, as bacterial toxicity associated with membrane damage of the host 
cell will allow entry of the antibiotic, which will in turn result in the killing of 
intracellular bacteria.  Analysis of toxicity of the host cell can be performed via 
flow cytometry.  The membrane impermeant fluorescent dye 7-AAD binds DNA 
only in macrophages with permeabilized membranes.  Macrophages were 
infected with GFP-expressing bacteria and assessed on three different 
parameters:  entry, cytotoxicity, and spread.  Parental B. cenocepacia was found 
in 3% of all macrophages, and was cytotoxic to macrophages at a 1:1 ratio, killing 
approximately 3% of all cells (Figure 15A).  Despite infecting nine-fold better than 
parental, ∆BCAM2837 was also cytotoxic at a 1:1 ratio, killing 27% of all 
macrophages.  Though ∆BCAL0340 infected two-fold better than the parental 
isolate, it was only half as cytotoxic, whereas ∆BCAL0124 demonstrated the 
opposite trend with two-fold less infection, but seven-fold greater cytotoxicity.  
Other mutants, including ∆BCAM0276 and ∆BCAM2446, appear to prevent 
permeabilization of the macrophage membrane, decreasing cytotoxicity below 
the level seen in uninfected macrophages (Figure 15).  In total, of the ten 
mutants, only four were cytotoxic, defined as permeabilization of the host cellular 
membrane greater than seen in uninfected cells.  However, a permeable 
membrane would permit gentamicin to enter the cell, thereby killing intracellular 
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Figure 12.  Comparative macrophage entry and intracellular replication of 
parental B. cenocepacia and complemented scs mutants in murine 
macrophages. 
Plasmid pDA12 is a vector control; pJTx is a constitutively active 
complementation plasmid (Table 2).  Entry (A) was calculated relative to 
initial inoculum, and replication (B) was calculated relative to entry; both 
were normalized relative to the parental control, set at 100% entry and 
100% replication.  Standard error bars are indicated.  Significance was 
determined using one-way ANOVA and Dunnett’s Multiple Comparison 
Test.  Mutants demonstrating significant difference from the wild-type are 
indicated (*p<0.05, **p<0.01, ***p<0.001).  
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Figure 13.  A mutation in the flagellar regulon master regulator results in a 
strain (JST19) defective in both swimming and swarming motility. 
This defect can be restored by complementation on a constitutively active 
plasmid pJT57.  pDA12 is a vector control.  Bacterial cultures were 
adjusted to an OD600 of 0.1; 2 L was stab-inoculated into LB 0.3% agar to 
observe swimming motility, and 2 L was drop-inoculated onto NB 0.2% 
glucose, 0.5% agar to observe swarming motility.   
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Figure 14. Deletion of a putative response regulator results in a strain 
(JST75) defective in swarming, but not in swimming motility. 
Bacterial cultures were adjusted to an OD600 of 1.0; 2 L was stab-
inoculated into LB 0.3% agar to observe swimming motility, and 2 L was 
drop-inoculated onto NB 0.2% glucose, 0.5% agar to observe swarming 
motility. 
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Figure 15. B. cenocepacia entry and host cytotoxicity in murine 
macrophages. 
Bacterial entry and cytotoxicity are shown as a percentage of total cells.  
Cytotoxicity was normalized against cell death in uninfected cells. 50 000 
cells were counted in each of three independent experiments.  Standard 
error bars are indicated.  Significance was determined using one-way 
ANOVA and Dunnett’s Multiple Comparison Test.  Mutants demonstrating 
significant difference from the wild-type are indicated (*p<0.05, **p<0.01, 
***p<0.001). 
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 bacteria and preventing quantification in the gentamicin protection assay.  Thus, 
intracellular replication was normalized for cytotoxicity (Figure 16), revealing 
significant intracellular replication by ∆BCAL0124.  In contrast, normalization 
revealed that ∆BCAL0340 replicates at a rate similar to the parental isolate, but is 
protected from gentamicin because it is less cytotoxic.  Mutants displaying a 
cytotoxic ratio (Figure 16A) less than zero were not normalized, as in the 
absence of membrane permeability, intracellular bacteria would not be affected 
by gentamicin.       
Flow cytometry also permits investigation of the spread of B. cenocepacia in an 
unchecked infection.  Following killing of extracellular bacteria, infected 
macrophages were maintained in antibiotic-free media; any bacteria able to 
escape the macrophage, whether through lysis or otherwise, were able to infect 
neighbouring macrophages.  Under such conditions, the number of macrophages 
infected with the parental strain increased six-fold (Figure 17), indicating that B. 
cenocepacia was able to escape the macrophage by some means.  With the 
exception of ∆BCAM2837, which spread with half the efficiency of parental, the 
scs mutants spread as well or better than parental.  ∆BCAL1726 and 
∆BCAM1679 spread efficiently, increasing macrophage infection by 15-fold in an 
uncontrolled environment. The ratio of dead:infected cells remained 
approximately 1:1 in an unchecked infection, suggesting that viable B. 
cenocepacia escaped from dead macrophages.  The two exceptions to this ratio 
were seen in ∆BCAL0124, which killed 2.5 cells for every cell infected at the time 
of analysis, and ∆BCAM2837, which killed only 30% of infected cells. 
 
3.8 B. cenocepacia remains in an acidic vacuole associated 
with the endocytic pathway 
Despite using 24 h as an endpoint in gentamicin protection assays, the BcCV has 
not been extensively characterized beyond 6 h p.i., where greater than 80%  
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Figure 16. Intracellular replication normalized for host cytotoxicity of B. 
cenocepacia parental strain and scs mutants. 
(A)  Cell death was normalized against infection, determined by flow 
cytometry.  (B)  Intracellular replication, determined by the gentamicin 
protection assay, was then multiplied by this ratio to give the total 
expected ratio of intracellular bacteria in the absence of cell death.  
Mutants with a ratio in (A) less than zero were unchanged in (B). 
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Figure 17.  B. cenocepacia spread of infection and host cytotoxicity in an 
unchecked infection of murine macrophages. 
Capacity to spread (A) is calculated as the fold increase in infected 
macrophages when maintained in antibiotic-free media rather than 10 
µg/mL gentamicin in the same experiment.  Host cytotoxicity (B) is 
calculated as the ratio of total dead cells to infected cells.  50 000 cells 
were counted in each of three independent experiments.  Standard error 
bars are indicated.  Significance was determined using one-way ANOVA 
and Dunnett’s Multiple Comparison Test.  Mutants demonstrating 
significant difference from the wild-type are indicated (*p<0.05, **p<0.01, 
***p<0.001). 
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of BcCVs remain associated with the endocytic pathway, and approximately 50% 
of BcCVs are acidic phagolysosomes (252).  At 24 h p.i., B. cenocepacia is still 
found within a vacuole, and a proportion of BcCVs contain numerous bacteria 
(Figure 18).  92% of BcCVs are acidic, indicated by colocalization with the 
acidotropic dye LysoTracker Red; in some vacuoles, rapidly-moving bacteria are 
strongly-labelled with Lysotracker Red, while the surrounding vacuole is only 
weakly-stained (Figure 18B).  The BcCV remains associated with the endocytic 
pathway, as TMR-dextran added 21 h p.i. is delivered to 90% of BcCVs during a 
2 h pulse followed by a 1 h chase (Figure 19).  A fluid phase marker internalized 
via endocytosis, dextran follows the typical endocytic pathway, ultimately and 
rapidly accumulating in the lysosome.  A dextran pulse-chase prior to bacterial 
infection is often used to pre-label lysosomes (252).  However, 24 h post-B. 
cenocepacia infection, the dextran signal is weak in infected macrophages 
(Figure 19B); while some BcCVs are labelled with dextran, the weakness of the 
signal precludes designation of non-labelled BcCVs as non-lysosomal. 
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Figure 18.  B. cenocepacia remains within a membrane-bound vacuole that 
accumulates acidotropic probe Lysotracker Red. 
RAW 264.7 macrophages infected with B. cenocepacia were observed at 
24 h p.i. after treatment with Lysotracker red. Panel A shows accumulation 
of Lysotracker in the BcCV, while panel B shows accumulation of 
Lysotracker by B. cenocepacia.  From left to right, panels show the phase 
contrast image, red fluorescence (Lysotracker red), and a merged image.  
Arrow indicates representative BcCVs. 
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Figure 19. The B. cenocepacia-containing vacuole remains associated with 
the endocytic pathway. 
Panel A shows RAW 264.7 macrophages infected with B. cenocepacia 
that were pulsed with dextran at 21 h p.i. and observed 3 h later. Panel B 
shows the opposite experiment, where RAW 264.7 macrophages were 
pulsed with dextran, then infected with B. cenocepacia and observed at 24 
h p.i. From left to right are the phase contrast image, red fluorescence, 
and a merged image. Arrows indicate representative BcCVs.   
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Chapter 4  
4 The role of secretion systems in the intracellular 
behaviour of B. cenocepacia in murine macrophages  
 
4.1 Identification and deletion of secretion systems in B. 
cenocepacia K56-2     
Large, specialized, multi-protein secretion systems are a common device 
employed by intracellular pathogens to interact with eukaryotic cells (188).  The 
specific contribution of secretion systems to the intracellular lifestyle of B. 
cenocepacia is not well understood.  The recent development of a system to 
create unmarked deletions in B. cenocepacia (156) permits construction of large, 
sequential deletions in the same strain.  For each of the various secretion 
systems in B. cenocepacia, we deleted the entire gene cluster; we also created 
combination mutant strains with deletions in multiple secretion systems.  This 
strategy served a dual purpose in preventing both any potential cross-
complementation from paralogous genes, as well as a potentially toxic build-up of 
inactive or partial secretion systems.  Because the clusters encode numerous 
proteins, deletion entailed removal of large segments of DNA:  28.7 kbp of 
chromosome 2 for the T3SS, 41.5 kbp of the plasmid for T4SS-1, 11.3 kbp of 
chromosome 2 for T4SS-2, and 22.3 kbp of chromosome 1 for the T6SS.  For the 
plasmid, in particular, deletion of all putative T4SS-1-associated genes – a stretch 
of DNA including 45 genes - represented 45% of the entire plasmid sequence.  
We also deleted multiple essential genes of the T2SS, totalling 5 kbp of 
chromosome 1.  In the strain JST112, lacking all secretion systems, this totals 
deletion of 108.7 kbp of genetic material.  Despite these large deletions, growth 
of all strains in culture was unaffected (Figure 20). 
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Figure 20.  Deletion of secretion system clusters does not affect growth in 
culture. 
Data represents the mean of two independent experiments, each 
performed in triplicate.  
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4.2 Characterization of secretion system deletion mutants 
Secretion system mutants were examined for in vitro phenotypes, including 
exoenzyme secretion and LPS production.  Among the secretion system mutants, 
∆T2SS and ∆allSS were defective in secretion of casein-degrading protease, and 
lipase; ∆T3SS was also attenuated for secretion of protease, but not lipase 
(Figure 21).  Results on the egg yolk agar were less clear; ∆T2SS and ∆allSS 
could not clear the media – characteristic of phospholipase A or protease 
secretion – nor form an opaque precipitate – characteristic of phospholipase C 
secretion (84, 275).  The ∆T3SS mutant cleared the media more slowly than the 
parental strain; however, bacterial growth resembled neither ∆T2SS nor the 
parental strain, appearing flat, rough, dry, and white (Figure 21).  None of the 
deletions had any effect on LPS production (Figure 22).  
 
4.3 Secretion systems are involved in bacterial entry and 
intracellular replication 
B. cenocepacia has previously been shown to enter (252, 402) and replicate 
within murine macrophages (185).  Early studies of intracellular B. cenocepacia 
either relied on microscopic techniques (252), or utilized high concentrations of 
ceftazidime and gentamicin to overcome high aminoglycoside resistance and kill 
extracellular bacteria (409).  Recent construction of an aminoglycoside-sensitive 
strain of B. cenocepacia with intramacrophage behaviour similar to the parental 
isolate (185) has enabled use of the gentamicin protection assay to reliably 
quantify intracellular survival using only low doses of antibiotic.  We utilized the 
gentamicin protection assay to examine whether any of the secretion systems 
play a role in the entry and intracellular replication of B. cenocepacia in murine 
macrophages (Figure 23).  After an initial infection period, extracellular bacteria 
were killed with gentamicin, allowing quantitation of intracellular bacteria at 1h 
(entry) and 24h (replication) post-infection.  Because the generation time of  
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Figure 21. Deletion of secretion system clusters affects exoenzyme activity. 
Protease secretion (A) was measured as the zone of clearing on skim milk 
agar.  Lipase secretion (B) was measured as the zone of precipitation on 
Tween 80 agar.  Phospholipase C secretion (C) was measured as the 
zone of clearing on egg yolk agar. 
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Figure 22.  Lipopolysaccharide production is unaffected in secretion 
system deletion mutants. 
Samples were separated on a 14% Tricine-SDS-PAGE gel, and stained 
with silver nitrate. 
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Figure 23. Secretion systems play a role in B. cenocepacia entry into 
murine macrophages and intracellular replication. 
Entry was calculated relative to initial inoculum, and replication was 
calculated relative to entry; both were normalized relative to the parental 
strain, set at 100% entry and 100% replication.  Standard error bars are 
indicated.  Significance was determined using one-way ANOVA and 
Dunnett’s Multiple Comparison Test.  Mutants demonstrating significant 
difference from the wild-type are indicated (*p<0.05, **p<0.01, ***p<0.001). 
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B. cenocepacia in growth medium is approximately 1 h, the quantitation data at 
this time point after macrophage infection were considered to reflect amount of 
bacteria engulfed by macrophages prior to significant intracellular replication.  
Deletion of the T3SS had no apparent effect on bacterial entry or intracellular 
replication.  Deletion of T4SS-1 resulted in slight, non-significant differences – a 
two-fold decrease in bacterial entry coupled with a two-fold increase in 
intracellular replication.  Deletion of T4SS-2 resulted in a significant increase in 
bacterial entry; however, once internalized, ∆T4SS-2 replicated at the same rate 
as the parental strain.  Deletion of the T2SS and the T6SS each showed the 
opposite trend with a significant increase in intracellular replication despite no 
effect on bacterial entry.  Deletion of all secretion systems together showed no 
demonstrable phenotype in terms of either bacterial entry or intracellular 
replication.   
Due to the large size of the cluster deletions, complementation of the original 
secretion system mutants was not practical.  Instead, we created 
complementable single gene deletions in key structural components of each 
secretion system demonstrating a role in bacterial internalization or intracellular 
replication.  To inactivate the T2SS, we deleted BCAL3516 (GspM), a key inner 
membrane protein component of the T2 apparatus (225, 283).  Successful 
complementation by expression of the gene from plasmid pJT62 was evidenced 
by restored secretion of lipase, protease, and phospholipase C (Figure 24).  
Overexpression of GspM did not affect internalization of the bacteria, but 
significantly reduced intracellular replication (Figure 25), thereby complementing 
the phenotype seen in deletion of the entire cluster.  To inactivate the T6SS, we 
deleted BCAL0343, or Hcp, a structural and secreted protein critical to the 
function of the T6SS in B. cenocepacia (25).  Complementation of the deletion 
reduced intracellular replication to parental strain levels (Figure 25B).  To 
inactivate the T4SS, we deleted pBCA025 (TraF) for T4SS-1, and BCAM0333 
(VirB10) for T4SS-2.  VirB10 is an essential inner membrane protein for the 
formation of the core complex of the T4SS-2 (86, 214); TraF is the homologous 
protein in the T4SS-1 (163).  Deletion of VirB10 affected neither internalization  
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Figure 24. Defects in exoenzyme release in a T2SS mutant can be 
complemented. 
Protease secretion was measured as the zone of clearing on skim milk 
agar.  Lipase secretion was measured as the zone of precipitation on 
Tween 80 agar.  Phospholipase C (PLC) secretion was measured as the 
zone of clearing on egg yolk agar.  pDA12 is a vector control. 
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Figure 25.  Defects in macrophage entry (A) and intracellular replication (B) 
of B. cenocepacia secretion system mutants can be complemented. 
Complementation plasmids are indicated as pJTx (Table 2); pDA12 is a 
vector control.  Entry was calculated relative to initial inoculum, and 
replication was calculated relative to entry; both were normalized relative 
to the parental strain, set at 100% entry and 100% replication.  Standard 
error bars are indicated.  Significance was determined using one-way 
ANOVA and Dunnett’s Multiple Comparison Test.  Mutants demonstrating 
significant difference from the wild-type are indicated (*p<0.05, **p<0.01, 
***p<0.001). 
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nor replication (Figure 25).  However, deletion of traF alone yielded marginal 
increases in bacterial entry into the macrophage and intracellular replication, 
phenotypes that could be complemented. 
 
4.4 Secretion systems are involved in bacterial spread and 
macrophage cytotoxicity 
The fate of the host cells is not usually investigated in cellular infection models.  
However, it is reasonable to assume that intracellular bacteria may exert various 
effects on the host cells that could alter the gentamicin protection assay. 
Therefore, we also utilized flow cytometry to examine bacterial infection and host 
cell viability.  Infected macrophages were identified by green fluorescence due to 
B. cenocepacia expression of GFP from a constitutively-active plasmid.  Host cell 
viability was determined based on the permeability of cellular membranes; dead 
macrophages were identified by red fluorescence from the marker 7-AAD, a 
DNA-binding compound which cannot cross membranes.  For initial infection, the 
data produced by the gentamicin protection assay (Figure 23) correlated well with 
the data produced by flow cytometry (Figure 26A).  The single exception to this 
correlation was seen with ∆T4SS-1.  The gentamicin protection assay showed 
two-fold less viable intracellular bacteria than the parental isolate, while flow 
cytometry showed two-fold more infected cells than the parental strain; however, 
neither difference was statistically significant from the parental isolate.  It is 
important to note that the two assays have different measures; whereas the 
gentamicin protection assay quantifies the total number of intracellular bacteria, 
flow cytometry quantifies the total number of infected eukaryotic cells.  This data, 
then, would suggest that, compared to infections with the parental strain, a 
greater number of macrophages internalize a lower number of bacterial cells in 
the absence of T4SS-1.  Deletion mutants in T2SS, T3SS, and T6SS all showed 
infection levels similar to those of the parental strain, whereas deletion of T4SS-2 
resulted in a statistically significant (p < 0.05) four-fold increase in infected cells.  
Deletion of all secretion systems caused a non-significant reduction in the 
 
 124
 
Figure 26.  Secretion systems are involved in B. cenocepacia entry and 
host cytotoxicity in murine macrophages. 
Bacterial entry (A) and cytotoxicity (B) are shown as a percentage of total 
cells.  Cytotoxicity was normalized against cell death in uninfected cells.  
50 000 cells were counted in each of three independent experiments.  
Standard error bars are indicated.  Significance was determined using 
one-way ANOVA and Dunnett’s Multiple Comparison Test.  Mutants 
demonstrating significant difference from the wild-type are indicated 
(*p<0.05, **p<0.01, ***p<0.001).  
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number of infected macrophages (Figure 26A).  However, deletion of all secretion 
systems also resulted in a significant decrease in cytotoxicity, equivalent to that 
seen with deletion of the T6SS.  In both these mutant strains, as well as the T2SS 
mutant, membrane permeability was lower than that seen in natural cell death in 
uninfected cells, one of the controls for flow cytometry experiments.  It is possible 
that these strains induce an alternate form of cell death in which the membrane is 
not permeabilized, which would prevent 7-AAD access to the host DNA.  The 
cytotoxicity of B. cenocepacia towards the host macrophage was relatively 
unaffected by deletion of the T3SS, nor by deletion of either of the T4SSs (Figure 
26B).  However, because permeabilization of the membrane in the presence of B. 
cenocepacia allows gentamicin into the host cell, a measure of host cytotoxicity 
could be used to correct intracellular replication.  When the ratio of dead cells to 
infected cells at 24 hours was taken into account (Figure 27A), intracellular 
replication was higher for both the parental isolate and for ∆T3SS, but lower for 
both T4SSs (Figure 27B); while ∆T4SS-1 appears to replicate at the same pace 
as the parental isolate, intracellular ∆T4SS-2 is three-fold less.  
In the gentamicin protection assay, extracellular bacteria are killed via 30 minute 
incubation with a higher dose of gentamicin.  In the classical assay, cells are then 
maintained in a low concentration of gentamicin such that bacteria that escape 
the macrophage cannot replicate in the media or re-infect neighbouring cells.  
However, by maintaining parallel cells in antibiotic-free media – an unchecked 
infection – bacteria which permeabilize the host membrane and escape from the 
macrophage are free to re-infect neighbouring cells, and the capacity of the 
bacteria to spread can be examined.  The number of cells infected with the 
parental strain increased eight-fold in an unchecked infection (Figure 28A), and 
two-thirds of all infected cells had permeabilized membranes, and were 
presumably dead (Figure 28B).  Deletion of the T3SS, which showed no 
discernable phenotype in gentamicin protection assays, appeared to facilitate the 
spread of infection at more than three times the speed of the parental isolate 
(27.4-fold increase for ∆T3SS versus 8.6-fold for parental).  Deletion of all  
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Figure 27. Intracellular replication normalized for cytotoxicity of B. 
cenocepacia parental strain and secretion mutants in murine 
macrophages. 
(A)  Cell death was normalized against infection, determined by flow 
cytometry.  (B)  Intracellular replication, determined by the gentamicin 
protection assay, was then multiplied by this ratio to give the total 
expected ratio of intracellular bacteria in the absence of cell death.  
Mutants with a ratio in (A) less than zero were unchanged in (B).  
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Figure 28.  Secretion systems are involved in B. cenocepacia spread of 
infection (A) and host cytotoxicity (B) in an unchecked infection of 
murine macrophages. 
Capacity to spread (A) is calculated as the fold increase in infected 
macrophages when maintained in antibiotic-free media rather than 10 
µg/mL gentamicin in the same experiment.  Host cytotoxicity (B) is 
calculated as the ratio of total dead cells to infected cells.  50 000 cells 
were counted in each of three independent experiments.  Standard error 
bars are indicated.  Significance was determined using one-way ANOVA 
and Dunnett’s Multiple Comparison Test.  Mutants demonstrating 
significant difference from the wild-type are indicated (*p<0.05, **p<0.01, 
***p<0.001). 
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secretion systems significantly increased the ability of the bacterium to spread to 
neighbouring macrophages, resulting in a 40-fold increase in infected cells 
(Figure 28A).  In the T3SS mutant, this increase in infected cells was 
accompanied with a proportionate increase in cell death, such that the ratio of 
dead:infected cells was equivalent to parental strain (Figure 28B).  However, 
∆T4SS-2, ∆T6SS, and ∆allSS all showed a significant decrease in cytotoxicity in 
an unchecked infection, killing only 28%, 14%, and 23% of infected 
macrophages, respectively. 
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Chapter 5  
5 Discussion 
 
5.1 Transcriptional changes by intracellular B. cenocepacia 
B. cenocepacia is a bacterium with a large genome and an ability to survive in 
diverse environments, including within macrophages and other eukaryotic cells.  
In this study, we sought to identify genes expressed by intracellular B. 
cenocepacia.  Microbial transcripts were initially isolated and amplified using the 
SCOTS technique, which removes eukaryotic cell transcripts and amplifies 
bacterial transcripts while discarding bacterial ribosomal RNA.  Previous studies 
in other bacteria have shown that application of SCOTS enriches microbial 
transcripts without introducing a significant bias in gene expression data (148).  
SCOTS-purified cDNA was subjected to both microarray analysis and a 
competitive enrichment approach to identify gene regulation by intracellular B. 
cenocepacia, producing a wealth of information towards understanding the 
behaviour of intracellular B. cenocepacia following internalization by 
macrophages.   
The distribution of upregulated classes of genes was similar between both 
analysis techniques, and 86% of the genes identified by SCOTS-CE also showed 
upregulation in the microarray data.  However, while competitive enrichment 
identified 115 genes putatively upregulated by intracellular bacteria, microarray 
analysis showed expression of over 4000 genes and significant upregulation of 
329 genes by intracellular bacteria.  In some instances, the analysis techniques 
provided complementary information.  For example, though CE-identified flagellar 
regulon master regulator BCAL0124 itself is not significantly upregulated by 
intracellular bacteria 4 h p.i., flagellar genes controlled by BCAL0124 show 
increased expression, and BCAL0124 clearly plays a role in the interaction of B. 
cenocepacia with macrophages (Figures 11-12, 15-17).  Combining the SCOTS 
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technique with microarray analysis yields global gene profiles of genes induced 
and repressed in intracellular bacteria.  
 
5.1.1 The gentamicin protection assay and flow cytometry:  
Complementary analyses for cell culture infection models  
The classical measure of bacterial intracellular survival in eukaryotic cells is the 
gentamicin protection assay (139, 185), which is based on intracellular bacterial 
colony forming unit (CFU) counts.  Extracellular bacteria are eliminated by 
treatment with gentamicin, which poorly permeates eukaryotic cells; 
subsequently, host cells are lysed to quantify intracellular bacteria. However, 
should the infecting bacterium be toxic to the host cell, resulting in a potentially 
compromised host cell membrane, antibiotics present in the cell culture medium 
would also kill intracellular bacteria, confounding plate counts.  In addition, total 
intracellular bacteria are quantified, rather than the actual number of host cells 
infected.  Population analysis by flow cytometry addresses some of these issues.  
Flow cytometry links macrophage infection with cell death on a per cell basis.  
Thus, combining the gentamicin protection assay with flow cytometry reveals 
trends in bacterial entry into macrophages, including the numbers of bacteria 
taken up per macrophage, as well as the capacity of bacteria to replicate within 
the cell and induce host cell death. 
 
5.1.2 The role of SCOTS-identified genes in interactions with 
macrophages  
The contribution of SCOTS-identified genes to macrophage entry, intracellular 
replication, and host-directed cytotoxicity was examined through deletion of 
genes upregulated by intracellular bacteria.  In comparing initial infection data 
between the gentamicin protection assay and flow cytometry assay, those scs 
mutants that showed a defect in entry with the former assay generally show the 
same trends with the latter.  However, while the gentamicin protection assay 
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shows a striking increase in infection by ∆BCAL1726, flow cytometry shows a 
more modest increase in infection, coupled with a higher level of cell death.  This 
suggests two potentially-complementary possibilities:  Either more mutant 
bacteria may be present per macrophage, or ∆BCAL1726 is more cytotoxic than 
the parental strain and, despite initially infecting at a higher level, has been killed 
by gentamicin entering dying host cells.  The enhanced ability of the mutant to 
spread to neighbouring cells in an unchecked infection could support either 
hypothesis; a greater number of bacteria per macrophage potentiates re-infection 
of a greater number of host cells, while increased cytotoxicity could lead to more 
rapid spread.  However, complementation of the BCAL1726-mediated increase in 
bacterial entry was unsuccessful (Figure 12).  While complementation in B. 
cenocepacia can prove generally difficult, it is possible that the lack of 
complementation for BCAL1726 may be due to a secondary mutation, or to a lack 
of regulation.  BCAL1726, annotated as a putative oxidoreductase, is located in a 
precorrin synthesis cluster, and is orthologous to precorrin-3B synthetase, 
involved in aerobic cobalamin biosynthesis (224, 225).  This gene is one of five in 
B. cenocepacia regulated by a cobalamin riboswitch (195), which modulates the 
expression of associated genes – all involved in cobalamin biosynthesis or 
transport - in response to changing concentrations of the cofactor (338).  
Although the complementing plasmid pJT52 encodes the complete sequence of 
BCAL1726, it does not include the riboswitch found immediately upstream, 
resulting in constitutive expression regardless of cobalamin concentration.  It is 
possible that overexpression of a single key enzyme in the biosynthetic pathway 
disrupts cellular homeostasis in a manner equivalent to absence of the enzyme.  
Cobalamin is an important cofactor, and has been shown to act as an intracellular 
antioxidant (51), to inhibit nitric oxide synthase (516), and to regulate cytokines 
IL-6 (419) and TNF-α (418), thus indirectly regulating transcription factor NFκB 
(499).  
A disparity between flow cytometry and gentamicin protection assays was also 
seen for ∆BCAM2837.  While the gentamicin protection assay shows a modest 
increase in initial infection, flow cytometry shows a dramatic increase in infection, 
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coupled with an equivalent increase in cell death; the failure of this particular 
mutant to spread effectively suggests that host cell death may be rapid – 
accounting for the more modest increase seen with the gentamicin protection 
assay – and that the bacterium may not be able to escape the dying macrophage 
as efficiently as parental strain, or may be killed during host cell death.  
BCAM2837 is annotated as the response regulator component of a two-
component regulatory system (TCS).  Though it is indicated as a pseudogene in 
the Artemis visualization of the J2315 genome (195, 395), it is evidently active in 
K56-2, as deletion of the gene demonstrates a clear phenotype in macrophage 
infection.  Bioinformatic analysis shows that the protein consists of two distinct 
domains, one homologous to the chemotaxis protein CheC, and the second 
homologous to the response regulator CheY.  Che proteins are typically involved 
in chemotaxis, where phosphorylated CheY (CheY-P) binds to the flagellar switch 
to alter rotation, affecting the ability of the bacterium to swim smoothly rather than 
tumbling (366).  CheC is a phosphatase for the dephosphorylation of CheY (473).  
CheYC proteins – having an N-terminal CheY domain and a C-terminal CheC 
domain – are also found in organisms such as Pseudomonas syringae (334), 
although the function is unclear; CheYC proteins may function as standard TCS 
phosphatases, as phosphate sinks, or as completely novel proteins (334).  Unlike 
the typical CheYC protein, BCAM2837 is likely cotranscribed with a putative 
diguanylate cyclase and is found together with a histidine kinase, suggesting a 
role in signal transduction.   B. cenocepacia carries three other genes annotated 
as CheY (224, 225), all of which show expression by intracellular bacteria.  The 
only recognized CheY-phosphatase gene within B. cenocepacia is a single CheZ 
– BCAL0136 – which does not show expression by intracellular bacteria.  If the 
CheYC gene encoded by BCAM2837 does indeed function as a phosphate sink, 
its inactivation will lead to increased levels of CheY-P and thus increased 
bacterial tumbling; as bacterial reorientation becomes more frequent, 
unidirectional smooth swimming decreases, slowing bacterial migration; 
∆BCAM2837 shows a defect in swarming motility, but not in swimming motility 
(Figure 14).  Such impaired motility may enhance bacterial uptake by simply 
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decreasing the ability to move away from the phagocytic cell, and may also make 
escape from a dying macrophage more difficult.   
The contribution of bacterial motility to interaction with macrophages can also be 
seen in ∆BCAL0124, which encodes FlhD, a subunit of the flagellar regulon 
master regulator necessary for expression of the flagellar structural components 
(270).  The regulator is essential for both swimming and swarming motility (Figure 
13), and appears to be required for efficient bacterial internalization (Figure 11).  
Loss of the bacterial flagella through deletion of fliCD also results in a severe 
defect in bacterial internalization by macrophages (data not shown).  Related 
strain B. pseudomallei requires flagellin for efficient invasion of macrophages 
(88), while in CF-pathogen P. aeruginosa, loss of swimming motility results in a 
resistance to phagocytosis (16).  Mouse studies demonstrate a requirement of B. 
cenocepacia flagella for lethality, but not for bacterial dissemination; survivors 
showed no differences in bacterial load between non-flagellated versus parental 
strain infection (487).  Deletion of BCAL0124 increases cytotoxicity and 
dissemination of the bacteria to neighbouring cells.  In the aforementioned mouse 
study, B. cenocepacia lacking flagellin was unable to activate NFκB or elicit 
secretion of IL-8 through TLR signalling (487).  ∆BCAL0124 may avoid activation 
of classical proinflammatory signaling cascades, allowing it to replicate 
undetected until it overwhelms the macrophage and escapes in large numbers to 
re-infect neighbouring cells.  
Modifications to membrane proteins of B. cenocepacia affect interactions with 
macrophages.  BCAM0411 is one of three genes in B. cenocepacia encoding an 
MgtC family protein.  Deletion of this gene, which has multiple transmembrane 
helices, resulted in a defect in bacterial internalization, but an increase in 
intracellular replication (Figure 11).  This phenotype was gene-specific, as it could 
be complemented (Figure 12).  A second MgtC family protein in B. cenocepacia 
was previously shown to be important for growth under magnesium-limiting 
conditions and for intramacrophage survival (296), phenotypes common to those 
identified for MgtC family proteins in intracellular pathogens such as Salmonella 
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enterica (381) and Brucella suis (255).  However, because B. cenocepacia 
encodes three MgtC family proteins, it is possible that each protein serves a 
different role within the bacterium.  BCAL0340 encodes a putative lipoprotein 
located within the Type VI secretion cluster of B. cenocepacia; deletion of this 
protein promotes replication of intracellular bacteria (Figure 11) but does not 
inactivate the secretion system itself, as actin protrusions are still seen in infected 
macrophages (data not shown).  Thus, the contribution of BCAL0340 to the 
intracellular persistence of B. cenocepacia remains unclear.  ∆BCAM1679, 
lacking a putative lysylphosphatidylglycerol (Lys-PG) synthetase, shows a minor 
decrease in host cell cytotoxicity, but paradoxically, also shows a significant 
increase in infected cells in an unchecked infection, demonstrating a capacity for 
rapid spread.  The addition of lysine to PG lowers the net negative charge of the 
cellular envelope, already lowered in B. cenocepacia by the constitutive 
expression of 4-amino-4-deoxy-L-arabinose linked to lipid A (358).  Lys-PG may 
also decrease permeability to cations and protons by raising the surface potential 
of the membrane, increase membrane fluidity, inhibit genomic DNA replication, 
and decrease activity of the host defense factor phospholipase A2 (PLA2) 
[reviewed in (392)].  Deletion of the Lys-PG synthetase may enhance intracellular 
replication – a small increase is seen in the gentamicin protection assay (Figure 
11B) – leading to more rapid host cell death, possibly potentiated by an increase 
in PLA2 activity.  Interestingly, secretory PLA2 is capable of hydrolyzing the 
membrane of cells undergoing early stages of apoptosis (343), possibly providing 
a more rapid exit for intracellular bacteria. 
 
5.1.3 Gene expression in intracellular B. cenocepacia 
Internalization of B. cenocepacia by macrophages causes changes in bacterial 
gene expression.  In particular, large changes are seen in the expression of 
genes associated with signal transduction mechanisms and transcription, 
showing that B. cenocepacia senses the phagosomal environment and activates 
mechanisms necessary for survival in a new niche.  Repression of many 
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transcriptional regulators may indicate downregulation of non-essential genes 
and a shifting of resources towards survival.  This hypothesis is supported by the 
repression of genes associated with invasion or entry, which would be no longer 
required by internalized bacteria. 
Though motility clearly plays a role in the intracellular behaviour of B. 
cenocepacia, based on the phenotypes seen for ∆BCAL0124 and ∆BCAM2837, it 
is possible that upregulation of flagellar genes may be a stress response.  
Escape is a logical response to exposure to a harsh environment, and indeed, 
similar upregulation of motility-associated genes has been found in microarray 
analyses of B. cenocepacia response to other stressors (data not shown).  Strong 
upregulation of flagellar genes may be a common response by intracellular 
bacteria, as it is also seen in intracellular L. pneumophila (148).   
The largest category of characterized genes affected by bacterial internalization 
is that of metabolism suggesting metabolic adaptation to the phagosomal 
environment is key to survival and replication of the bacterium.  Genes involved 
in carbohydrate transport and metabolism were prominently upregulated in 
intracellular bacteria, accounting for 6% of all differentially upregulated genes 
(Figure 9).  In species of the protozoan parasite Leishmania, which also delays 
phagosomal maturation and replicates in an acidified phagolysosome, metabolic 
pathways involved in carbohydrate metabolism are important for intracellular 
survival; studies with metabolic mutants of Leishmania have suggested that the 
phagolysosome contains a variety of carbon sources and essential nutrients, but 
is lacking in carbohydrates (337).  Some of the most strongly induced genes are 
involved in amino acid transport (Table 5); many pathogens upregulate amino 
acid transport during intracellular growth, including L. pneumophila (148), S. 
Typhi (149), and Y. pestis (166), suggesting amino acid acquisition from the host 
may be a general carbon and nitrogen acquisition strategy.     
B. cenocepacia is able to occupy a diverse array of niches, and more than one-
third of B. cenocepacia's 7261 genes are involved in metabolism (195). Thus, it is 
possible that there are redundant nutrient uptake systems to function under 
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different conditions and exploit multiple forms of the same metabolite.  The 
changes seen in expression of metabolic genes (Figure 9) may demonstrate the 
ability of B. cenocepacia to utilize phagosomal resources.  Production of 
cholesterol-like hopanoids is catalyzed by squalene-hopene cyclase Shc; B. 
cenocepacia encodes two shc genes. Of these, BCAS0167 is found alone on the 
third chromosome and, although contributing little to in vitro hopanoid production 
(423), was strongly upregulated by intracellular bacteria.  However, the theme of 
genetic redundancy and niche specialization carries beyond metabolism.  One of 
the most strongly repressed genes was cciR, the transcriptional regulator for the 
B. cenocepacia-specific second quorum sensing system.  A deletion mutant in 
cciR has lower protease activity than the parental isolate (297), suggesting that 
production or secretion of proteases is regulated by CciR, and is thus repressed 
by intracellular bacteria.  Interestingly, a number of genes involved in protein 
export are also strongly repressed, including the first gene of the Tat system, 
several genes in the Sec system, and the signal recognition particle RNA. 
Poorly characterized genes account for one-third of the B. cenocepacia genome.  
This trend holds true when examining differential regulation of genes by 
intracellular bacteria, where at least one-third of identified genes are poorly 
characterized.  
 
5.1.4 The BcCV at 24 hours post-infection 
During late-stage infection, B. cenocepacia appears to reside within acidic 
vacuoles (Figure 18) that remain associated with the endocytic pathway (Figure 
19), suggestive of acidified phagolysosomes.  Lysosomes loaded with TMR-
dextran pre-infection showed only a weak signal in infected macrophages 24 h 
p.i. (Figure 19), suggesting that B. cenocepacia can alter the dextran in some 
way.  Molecular Probes dextran conjugates are hydrophilic polysaccharides with 
an -1,6-poly-glucose linkage; of the three polysaccharides produced as EPS by 
B. cenocepacia, one is a dextran consisting of -1,6-glucans (66).  Since B. 
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cenocepacia can produce dextran, it may also possess mechanisms to degrade 
or alter dextran; thus, long-term co-infections of B. cenocepacia and fluorescent 
dextran are not feasible. 
During the delay of phagosomal maturation, B. cenocepacia alters transcription of 
many metabolic genes.  The low pH of the phagolysosome can be used to drive 
high-affinity uptake of metabolite:proton symporters to bring nutrients into the cell 
(62).  Such a mechanism could account for the labeling of intraphagosomal 
bacteria by the acidotropic dye Lysotracker red during late-stage infection (Figure 
18); as the bacteria take up nutrients from the phagosome, the corresponding 
increase in intracellular proton concentration would cause the bacteria to be more 
acidic than the surrounding vacuole, leading to Lysotracker labeling of the 
bacteria rather than the vacuole.  The SCOTS microarrays show intracellular 
upregulation of a putative sodium:solute symporter and a putative Na+/H+ 
antiporter.  This suggests a cyclic system whereby the low vacuolar pH drives 
sodium out of the cell through the antiporter, which returns with a metabolite 
through the symporter. 
 
5.1.5 Bacterial cytotoxicity towards murine macrophages  
Previous studies have demonstrated B. cenocepacia cytotoxicity in epithelial cells 
(78, 107); however, this study is the first to demonstrate B. cenocepacia 
cytotoxicity towards macrophages.  B. cenocepacia infection of macrophages 
results in secretion of proinflammatory cytokines IL-1β (242), IL-6, IL-8, and TNF-
α, (104).  Elevated levels of the inflammatory mediators IL-6, TNF-α, macrophage 
inflammatory protein MIP-2, and IL-8 homolog KC are also found in the 
bronchoalveolar lavage of mice infected with B. cenocepacia (487, 500).  
Production of proinflammatory cytokines, in particular TNF-α, can lead to both 
apoptosis and necrosis (4).  Pilin-mediated apoptosis of B. cenocepacia-infected 
epithelial cells depends on the bacterial load (78).   Similarly, macrophage cell 
death can be induced by M. tuberculosis when the intracellular bacillary load 
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exceeds a certain threshold (258); this atypical cell death freely releases viable 
bacteria to the extracellular space (259).  Non-apoptotic cell death in monocytes 
is associated with higher bacterial burden for infections with both E. coli and 
Klebsiella pneumoniae; in both instances, cell death results in membrane 
permeabilization (515).  The capacity of B. cenocepacia to spread in an 
unchecked infection suggests either pyroptosis or necrosis, both non-apoptotic 
forms of host cell death in which the macrophage membrane is permeabilized.  
Production of IL-1β by infected cells is indicative of inflammasome and caspase-1 
activation; excessive caspase-1 activation can lead to pyroptosis.  The 
inflammasome is activated by NLR-detection of bacterial ligands in the cytosol, 
and many bacterial elements – putative NLR-ligands – are dispersed throughout 
the macrophage by late stages of infection (Figure 39).  Pyroptosis also induces 
lysosome exocytosis, whereby any bacteria residing within a lysosome are freely 
delivered to the extracellular milieu as the lysosome fuses with the macrophage 
plasma membrane.  Thus, further investigation into bacterially-induced pyroptosis 
as the putative mechanism of macrophage cell death is warranted.  Where the 
mutant strain appeared to prevent cytotoxicity (Figure 15), it is possible that 
infected macrophages instead underwent non-membrane-permeabilizing 
apoptosis, which would not be detected with 7-AAD. 
 
5.2 Secretion systems and B. cenocepacia  
The objective of this study was to determine the role played by classical multi-
gene secretion systems in the interaction of B. cenocepacia with phagocytic cells.  
Because B. cenocepacia is a significant pathogen within cystic fibrosis patients, 
leading to chronic infection, and increased morbidity and mortality, an 
understanding of pathogenesis is critical.  Survival and replication within host 
cells may contribute to the establishment and persistence of chronic infection, 
while induction of host cell death and stimulation of a strong inflammatory 
response may lead to deterioration of the lung.  Studies have shown that B. 
cenocepacia is able to modulate the endocytic pathway of phagocytic cells, 
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delaying phagosomal maturation (210, 252).  Furthermore, the transcriptomic 
studies above suggest that B. cenocepacia utilizes the delay to metabolically 
adapt to the phagosomal environment for persistence and replication in the 
phagolysosome; differential regulation of a number of secretion-associated genes 
by intracellular bacteria emphasizes the involvement of bacterial secretion in 
interactions with macrophages.  
Classical multi-gene secretion systems have been shown to have many differing 
roles in the interaction of intracellular bacteria with host cells, ranging from 
inhibition of phagocytosis to alteration of phagosomal maturation, to induction of 
host cell death.  Thus, secretion systems may play a role in the internalization, 
intracellular replication, and host-directed cytotoxicity of B. cenocepacia.  The 
ability of B. cenocepacia to inactivate Rab7 (210), located on the cytosolic face of 
the phagosome, suggests that the bacterium must be able to secrete one or more 
effectors into the host cell cytosol.  Though direct translocation remains to be 
shown, a functional T6SS is required for intracellular B. cenocepacia to alter the 
actin cytoskeleton of macrophages (25); in Vibrio cholerae (369) and Aeromonas 
hydrophila (467), a T6SS has been shown to secrete effectors into the host cell 
capable of affecting actin.  Thus, it is likely that intra-vacuolar B. cenocepacia is 
able to secrete effectors from the phagosome into the host cell. 
 
5.2.1 Type II secretion 
B. cenocepacia employs a T2SS for secretion of a variety of enzymes, including 
protease, lipase, and phospholipase C (Figure 21).  Deletion of the major 
structural components of the T2SS did not affect internalization of B. 
cenocepacia, but increased intracellular replication. This phenotype could be 
complemented in a single-gene deletion (Figure 24).  Deletion of the T2SS also 
decreased host-directed cytotoxicity (Figure 26), and marginally increased 
bacterial spread (Figure 28); the latter is likely accounted for by higher 
intracellular replication yielding an increased number of bacteria available to re-
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infect.  It is also possible that less host-directed cytotoxicity could account for, at 
least in part, the increase seen in intracellular replication, as preservation of intact 
host cells protects intracellular bacteria from the antibiotic-containing cell culture 
media.  Lower host-directed cytotoxicity in ∆T2SS could indicate a role for type II-
secreted enzymes in interactions with eukaryotic cells.  Inactivation of the T2SS-
essential gene gspD in B. pseudomallei caused a small increase in LD50 in a 
hamster model of infection (126), but had no effect on nematode killing (350).  A 
B. cenocepacia AU1054 transposon mutant in gspJ, a pseudopilin of the T2SS, 
was less pathogenic in a nematode model of infection (451), whereas four 
different transposon mutants in the T2SS apparatus of B. cenocepacia H111 had 
no effect on nematode killing (241).  In B. vietnamiensis, the T2SS is not involved 
in the intracellular survival in Acanthamoeba polyphaga (150).  Thus, it seems 
probable that the membrane-compromising induction of cell death by the T2SS 
and T2-secreted effectors is specific to macrophages.  
 
5.2.2 Type III secretion 
Many intracellular pathogens utilize a T3SS in diverse interactions with eukaryotic 
cells.  In Yersinia spp., effectors secreted by the T3SS are able to prevent 
phagocytosis (144).  In Edwardsiella tarda, lack of a functional T3SS allows 
acidification of the bacteria-containing vacuole, which precludes intracellular 
replication (352).  Salmonella enterica also utilizes T3SS-secreted proteins to 
alter intracellular trafficking, directing the BCV away from the endosomal pathway 
to a compartment more suitable for replication (191).  An effector secreted 
through the T3SS of Shigella flexneri induces IL-8 secretion in epithelial cells 
(147).  In contrast, the T3SS of Y. pseudotuberculosis is responsible for 
restricting the intracellular survival of the bacterium while inducing apoptosis in 
host macrophages (539).  The gentamicin protection assay showed no real 
contribution of the B. cenocepacia T3SS to bacterial entry or intracellular 
replication (Figure 23), with 1.6- and 1.5-fold increases respectively, nor does it 
appear to contribute significantly to host-directed cytotoxicity.  However, deletion 
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of the T3SS significantly increases spread of B. cenocepacia in an unchecked 
infection, while maintaining a parental strain rate of host cell death, suggesting 
that a functional T3SS is necessary to restrict B. cenocepacia to the phagosome.  
Previous studies regarding the role of the T3SS in B. cenocepacia have had 
mixed results.  A polar insertion in the T3SS cluster did not impair intracellular 
trafficking of B. cenocepacia in macrophages (252).  Insertional inactivation of 
T3SS gene bcscN resulted in reduced lung tissue inflammation and more rapid 
bacterial clearance from the lung in a mouse model of lung infection, but did not 
affect invasion of epithelial cells (480).  Mutations in the T3SS also affect the rate 
of killing in C. elegans in a strain-dependent manner only seen at certain time 
points (306). 
 
5.2.3 Type IV secretion 
T4SSs are able to translocate both DNA and protein substrates, usually in a cell-
contact dependent manner [reviewed in (188)].  Together with the T3SS, T4SSs 
are the most common secretion systems involved in the interplay between 
prokaryotes and eukaryote hosts.  Many intracellular pathogens shown to delay 
or alter phagosomal maturation utilize T4SS to translocate effectors into the host.  
Legionella pneumophila requires a functional Dot/Icm T4SS for intracellular 
replication and evasion of BCV fusion with lysosomes (472).  Brucella spp. also 
utilize a T4SS to subvert the endosomal pathway (95), with recent work showing 
translocation of a Rab2-interacting effector into the host cytosol through the VirB-
type T4SS (117).  Coxiella burnetii, which is able to delay phagolysosomal fusion 
and subsequently replicate within an acidified compartment (317), possesses a 
functional T4SS capable of secreting effectors containing eukaryotic-like domains 
into the cytosol of the host cell (76).  Some bacteria utilize T4SSs to induce 
inflammation, including L. pneumophila (172), which, along with C. burnetii, also 
produces a T4-secreted effector capable of preventing host cell apoptosis (36, 
281); in Bartonella spp., T4SSs lead to host adaptability (400).   
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Previous research in B. cenocepacia has identified two T4SS which contain 
different subunits and carry out different functions (141, 538).  T4SS-1 consists of 
a combination of VirB/D4 and F-specific subunits, the genes for which are spread 
across half of the 92 kb plasmid of B. cenocepacia; also referred to as the Ptw 
T4SS, it secretes a cytotoxic effector protein responsible for plant tissue water 
soaking, thought to provide the bacteria with nutrients through the leakage of 
plant cell cytosol during soft rot (141).  T4SS-2, located on chromosome 2, is 
homologous to the VirB/D4 T4SS of Agrobacterium tumefaciens (141), and is 
involved in plasmid mobilization (538).  A single study linked T4SS-1 with 
intracellular survival in epithelial cells and macrophages, showing reduced 
intracellular replication and more rapid maturation through the endosomal 
pathway in the absence of a functional T4SS coupling protein (403).  We found 
that absence of the complete T4SS-1 cluster halved the number of total 
internalized bacteria in the gentamicin protection assay, but doubled the number 
of total infected cells with flow cytometry, suggesting internalization of fewer 
bacteria per cell. The intracellular replication of ∆T4SS-1 was increased relative 
to the parental strain, though correction for cytotoxicity lowered replication to 
parental strain levels (Figure 27).  This apparent contradiction with the previous 
study may be explained by differences in calculation method.  While we related 
intracellular replication to bacterial entry, the former study reported total numbers 
of intracellular bacteria at each time point; since the mutant bacteria are not 
internalized as well, there are less initial bacteria present to replicate, lowering 
the final CFU counts.  Additionally, it is possible that other genes present within 
the 42 kbp deletion contribute to virulence.  Deletion of the plasmid-encoded 
T4SS required deletion of almost half of the entire plasmid; in other intracellular 
pathogens with a large plasmid, including Salmonella enterica (527), R. equi 
(202), and Y. pestis (130), the plasmid contributes to intracellular survival and 
virulence.   
Deletion of the complete T4SS-2 cluster resulted in an increase in both 
internalized bacteria and infected cells, but a decrease in intracellular replication, 
when corrected for cytotoxicity.  Deletion of a single gene in the T4SS-2 operon 
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had no effect on bacterial entry or replication, while deletion of the homologous 
gene in T4SS-1 increased bacterial entry and replication, both of which could be 
complemented by restoration of the gene on a complementation plasmid (Figure 
25).  It is possible that subunits of each T4SS are able to cross-complement, 
explaining the lack of phenotype seen for JST184.  L. pneumophila contains two 
separate T4SSs; the dot/icm T4SS is required for intracellular growth in 
macrophages, and is involved in conjugation, while the lvh T4SS is involved in 
plasmid mobilization; elements of the lvh system are able to substitute for 
homologous components of the dot/icm system (432).   
The significant increase in bacterial internalization in the absence of T4SS-2 
suggests some involvement of the secretion system with the inhibition of 
phagocytosis.  Bartonella henselae translocates effector BepG through a VirB/D4 
T4SS to inhibit endocytosis by human endothelial cells (382).  Yersinia spp. 
(144), P. aeruginosa (170), and enteropathogenic E. coli (EPEC) (176) are all 
able to inhibit phagocytosis by macrophages dependent on the action of a T3SS.  
Interestingly, the plant water soaking phenotype linked to T4SS-1 in B. 
cenocepacia is also found in Erwinia spp. and Pantoea stewartii subsp. stewartii, 
where it is caused by T3SS-mediated secretion of effectors DspE/A (197), and 
WtsE/F (184), respectively.   Thus, it is conceivable that an antiphagocytic 
effector delivered by a T3SS in other bacteria may be delivered by T4SS-2 in B. 
cenocepacia.  Of note, B. cenocepacia J2315, which belongs to the ET12 
epidemic clone of B. cenocepacia along with strain K56-2, is internalized by 
macrophages at an increased rate and in increased numbers per cell (411), and 
contains a frameshift mutation in VirD4 of the T4SS-2 cluster (195). 
In flow cytometry assays, neither T4SS deletion affected cell spread, but ∆T4SS-
2 was less cytotoxic.  We determined cytotoxicity by means of 7-AAD, a 
fluorescent compound that binds to DNA but cannot readily cross cell 
membranes, thus technically measuring membrane permeability.  Legionella spp. 
require the dot/icm T4SS to permeabilize macrophage membranes, leading to 
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pyroptosis (522), thus is it possible that inactivation of T4SS-2 in B. cenocepacia 
prevents release of a membrane-permeabilizing effector. 
 
5.2.4 Type VI secretion 
The recently identified T6SS, the most common of the gram-negative large 
specialized secretion systems, plays a diverse role in interbacterial interactions; 
however, it is also linked with host interactions in certain pathogens [reviewed in 
(426)].  In a previous study, three separate transposon mutants in the T6SS 
cluster of B. cenocepacia were attenuated for virulence in a rat model of chronic 
lung infection (207), showing a definite role in pathogenesis.  B. cenocepacia 
upregulates expression of T6SS genes during macrophage infection.  Deletion of 
the T6SS in B. cenocepacia did not alter the number of bacteria internalized by 
macrophages (Figure 23), nor the number of eukaryotic cells infected (Figure 26), 
but significantly increased intracellular survival of the bacteria, a phenotype 
clearly complemented in a single gene deletion model (Figure 25B).  An increase 
in observed intracellular replication could be due to the fact that cytotoxicity was 
significantly decreased in ∆T6SS infected-macrophages.  As with the T2SS, 
maintaining the integrity of the macrophage membrane protects intracellular 
bacteria from the antibiotic-laden culture media, thus leading to an increase in 
viable bacteria at 24 h post-infection.  However, the unchecked spread of the 
mutant at a rate similar to the parental strain suggests either a true increase in 
intracellular replication - with less macrophages dying, more bacteria must be 
released per macrophage to maintain the rate of spread – or a non-membrane 
damaging method of bacterial release.  Comparison with ∆BCAL0340 – 
examined during the transcriptomic study above – lends credence to the former 
hypothesis.   BCAL0340, a putative lipoprotein, is the first gene in the second 
transcriptional unit of the T6SS (24); macrophages infected with ∆BCAL0340 still 
show evidence of an altered actin cytoskeleton (data not shown), while 
macrophages infected with deletions in BCAL0342, BCAL0343, or the entire 
T6SS cluster do not (24, 25).  ∆BCAL0340 does not show decreased 
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macrophage-directed cytotoxicity (Figure 15), but does show increased 
intracellular replication (Figure 11), suggesting that ∆T6SS truly replicates faster 
than the parental strain bacteria within the phagosome.  The ability of the T6SS 
to limit intracellular replication is also seen in Y. pestis, although the 
corresponding promotion of phagocytosis in Y. pestis was not seen in B. 
cenocepacia (386).  In B. pseudomallei, inactivation of T6SS-1 resulted in 
decreased cytotoxicity in macrophages, as well as decreased virulence in a 
hamster model of melioidosis (65).  The role of the T6SS in macrophage-directed 
cytotoxicity has also been demonstrated in A. hydrophila; expression of T6-
essential gene hcp resulted in epithelial cell apoptosis (468).  Thus, there is a 
clear role for the T6SS of B. cenocepacia in interactions with macrophages, 
especially in limiting intracellular replication and promoting host-cell directed 
cytotoxicity. 
 
5.2.5 The contribution of secretion systems as a whole 
B. cenocepacia is somewhat unusual in that it encodes at least one of every 
known gram-negative multi-gene secretion system, including both T3SS and 
T4SS (195).  Among pathogenic Burkholderia spp., however, it lacks the large 
redundancy of secretion systems seen with B. pseudomallei and B. mallei, which 
have three and two T3SSs, and six and four T6SSs, respectively (196, 344).  
Deletion of each secretion system, entailing deletion of large segments of DNA, 
does not affect the growth of the bacterium in rich media; indeed, deletion of all 
secretion systems in a single strain – accounting for a total of 109 kbp – does not 
cause any growth defect (Figure 20).  In gentamicin protection assays, JST112 
behaved as the parental isolate with regards to bacterial entry and intracellular 
replication (Figure 23).  However, flow cytometry revealed a four-fold reduction in 
infection for JST112, suggesting internalization of a greater number of bacteria 
per cell by a decreased number of cells.  Interestingly, though T4SS-2 is absent, 
there is no increase in bacterial internalization, suggesting that bacterial uptake 
by macrophages may be more complex than simple phagocytosis.  In B. 
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cenocepacia J2315, the internalization of more bacteria per cell has been linked 
to the absence of a complete lipopolysaccharide (LPS) O antigen (411), 
demonstrating a role in for surface structures in the interactions between bacteria 
and macrophage.  However, J2315 also infects a greater number of cells, which 
is not seen for JST112.  The means by which B. cenocepacia enters 
macrophages is unknown; it is possible that there is a threshold level of 
stimulation for phagocytosis which is more difficult to reach in the absence of the 
large outer membrane structures unique to specialized secretion systems, thus 
requiring the presence of increased numbers of JST112 for a single event.  
Flow cytometry also showed a decrease in host-directed cytotoxicity by a mutant 
lacking large secretion systems; though JST112 spreads rapidly in an unchecked 
infection, it remains much less cytotoxic than the parental strain (Figure 28).  The 
cause of such bacterial spread – 40-fold in 24 hours – in the absence of 
increased intracellular replication or increased host cell death is source for 
speculation.  Lack of large specialized secretion systems does not preclude all 
secretion from the cell – at the minimum, types I and V remain possibilities (195) 
– but it does prevent expression, or at least translocation, of a vast array of 
effectors.  Effectors of the T2SS, T4SS-2, and T6SS all contribute to host-
directed cytotoxicity (Figure 26).  It is possible that JST112, likely unable to 
secrete effectors to the host cytosol, avoids activating a strong proinflammatory 
response or permeabilizing the cell membrane, and simply resides within the 
phagosome.  In the absence of a functional T6SS, the host cytoskeleton is 
unaffected, allowing normal motility and replication of the macrophage.  Infected 
macrophages typically show multiple BcCVs, especially at later time points post-
infection (Figure 18); the rapid spread of the bacteria could be due to normal 
proliferation of infected macrophages.  Of note, though the ratio of dead to 
infected host cells is lower in a JST112-infection, the total number of dead host 
cells is actually increased due to the rapid spread.  Thus, secretion systems may 
function as an infection-limiting factor in B. cenocepacia, enabling bacterial 
persistence.  Such a strategy is exemplified by Brucella spp., which utilize a 
T4SS to stimulate an inflammatory response carefully balanced between 
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checking uncontrolled intracellular replication and preventing host cell death, thus 
allowing the bacteria to establish a chronic infection within a granuloma (118).  
Similarly, B. cenocepacia-infected macrophages attract other non-infected cells in 
zebrafish embryos, forming cellular aggregates within which local bacterial 
spreading occurs 15 to 20 h post-infection (502).  Aggregate formation and 
kinetics of embryo death differ between B. cenocepacia J2315 and K56-2.   
B. cenocepacia strains K56-2 and J2315 are clonal isolates belonging to the 
highly transmissible lineage known as ET12; J2315, first isolated from a CF 
patient in Scotland, was the index strain for epidemic spread, while the more 
genetically-tractable K56-2 was isolated from a CF patient in Canada (290).  
Though closely related, K56-2 and J2315 have accumulated different genetic 
mutations.  Apart from the aforementioned frameshift mutation in T4SS-2, B. 
cenocepacia J2315 also contains a 110-bp deletion in gspL, an essential 
component of the T2SS, and a frameshift mutation in BCAM2043, located in the 
T3SS cluster (195), putatively inactivating three of the five large, specialized 
secretion systems.  Though there are undoubtedly other genetic differences 
between K56-2 and J2315, it is interesting to link the presence of functional 
secretion systems with pathology.  In our study, absence of the T3SS allowed the 
bacteria to spread more widely, while absence of T4SS-2 was linked with 
increased bacterial uptake, and both the T2SS and T4SS-2 were associated with 
host-directed cytotoxicity.  Thus, in the absence of these three secretion systems, 
one could expect to see increased bacterial uptake, widespread bacterial 
spreading, and slower host killing.  As mentioned previously, J2315 infects a 
greater number of macrophages with a greater number of bacteria than an 
equivalent infection with K56-2 (411).  As an aside, this would tend to suggest a 
role for T4SS-1 in balancing the anti-phagocytic activity of T4SS-2, as this 
increase is not seen in JST112.  In a C. elegans nematode model, though K56-2 
killed rapidly, J2315 was also pathogenic at a slower rate, a phenotype not 
dependent on the LPS O antigen (69).  Differences in virulence may also be seen 
in a zebrafish embryo model, where killing by K56-2 occurred within 48h, but 
J2315 required an additional 24h to induce significant host death; microscopic 
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examination revealed widespread dissemination of J2315 bacterial aggregates 
throughout the vasculature of the embryo prior to death, a phenotype not seen in 
K56-2 infection (502).  Thus, anecdotal evidence would tend to support the role of 
secretion systems in the pathogenicity of B. cenocepacia. 
 
5.3 Proposed future experiments 
There are many interesting avenues to pursue, beginning with further 
investigation into genes upregulated by intracellular B. cenocepacia during 
phagosomal adaptation 4 h p.i..  Transcriptomic analysis of B. cenocepacia and 
further characterization of the BcCV during late stage infection would contribute 
to a greater understanding of the bacteria-macrophage interaction.  The role of 
bacterial secretion systems should be investigated in models more relevant to 
human infection, and an attempt made to identify effectors contributing to 
interactions with eukaryotic cells.   
 
5.3.1 Further investigation of genes regulated by intracellular 
bacteria 
One area for further study is the role of iron in the intracellular life of B. 
cenocepacia.  Intracellular bacteria may limit siderophore-mediated iron 
acquisition, as the receptor for ornibactin is downregulated 10-fold, as is the 
transcriptional activator for the pyochelin receptor; the putative pyochelin 
biosynthetic protein is also repressed.  However, three transport proteins 
predicted to be involved in TonB-dependent ferric iron uptake are upregulated.   
Another aspect of future studies is further characterization of metabolic 
adaptation to the phagosome, including the upregulation of amino acid 
transporters, and the role of cobalamin in the intracellular life of B. cenocepacia.  
Other avenues to pursue include quorum sensing - B. cenocepacia-specific 
regulator cciR is downregulated 46-fold by intracellular bacteria - and changes to 
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the membrane and surface structures; a squalene-hopene cyclase necessary for 
hopanoid biosynthesis is strongly upregulated, as are genes found in the clusters 
of both the Flp type pilus and type IVa pilus, while a number of adhesins, 
including the 22 kDa adhesin encoded by BCAM2143 and several BuHA family 
proteins, are differentially regulated.  Lipase has proven important to infection in 
epithelial cells (336), suggesting that strongly upregulated lipase BCAM0949 may 
play a role in the interactions between B. cenocepacia and macrophages.  Other 
specific genes meriting further characterization include CheYC protein 
BCAM2837 and conserved hypothetical protein BCAM0314, both among the 
most strongly upregulated by intracellular bacteria; BCAM2837 displays a strong 
phenotype in macrophages, but little is known regarding its true function, while 
BCAM0314 is homologous to a putative cell wall-associated hydrolase. 
 
5.3.2 The transcriptional response of macrophage-adapted B. 
cenocepacia  
With the development of gentamicin-sensitive B. cenocepacia MH1K, the 
transcriptional response of B. cenocepacia at later stages of infection can now be 
analyzed with SCOTS and microarrays or next-generation sequencing.  Many of 
the genes upregulated at 4h p.i. are involved in signal transduction and 
transcription, suggesting adaptation is only beginning; as the phagosomal 
environment continues to evolve, B. cenocepacia must continue to adapt.  In L. 
pneumophila, the number of upregulated genes increases with time post-infection 
(148).  Following adaptation to the phagosome, B. cenocepacia is capable of 
replicating, inducing host cell death, and escaping the macrophage.  Thus, 
transcriptome analysis of B. cenocepacia throughout a time-course of infection 
could significantly contribute to a more complete understanding of the interaction 
between B. cenocepacia and murine macrophages. 
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5.3.3 The role of secretion systems in CF infection  
Large, specialized, multigene secretion systems play a clear role in the 
interaction of B. cenocepacia with murine macrophages; however, there are 
many steps between relevance in murine macrophages and relevance to human 
infection.  The panel of secretion system mutants should be examined in more 
relevant cell culture models, including CFTR-/- macrophages and primary cells, 
and in higher organisms, including zebrafish and murine models.  In addition, 
because it is strongly upregulated by intracellular bacteria, a deletion mutant in 
the T1SS should be added to the panel of secretion system mutants.  
Furthermore, analysis of the secretome for each of the mutants may prove useful 
in identifying effectors important in interactions with macrophages. 
The contribution of secretion systems to the dispersal of bacterial elements 
throughout the macrophage could be investigated by B. cenocepacia Ab labelling 
of macrophages infected with JST112; should the dispersed bacterial elements 
be absent in JST112 infection, further experiments with the entire panel of 
secretion system mutants could identify the specific system responsible.  
Identification of the bacterial components would require isolation of macrophage 
membranes during late-stage infection.  If the bacterial component is a protein, it 
could be detected in a Western blot using B. cenocepacia Ab and identified by 
mass spectrometry; likewise, bacterial LPS could be detected by Western blot.  
Effectors translocated in the host cell cytosol by other bacteria have been 
identified by fusing genomic fragments to adenylate cyclase and assaying for an 
increase in host cell cAMP levels (70).  Once identified, putative effectors would 
be screened through the panel of secretion system mutants to determine which 
system is responsible for translocation.  
 
5.3.4 Further characterization of late stage macrophage infection 
by B. cenocepacia  
Preliminary characterization suggests that the BcCV is an acidified 
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phagolysosome 24h p.i., but further studies are necessary.  Immunolabelling with 
compartment-specific markers such as LAMP-1 and cathepsin D, and 
colocalization with Lysosensor dextran would contribute to confirmation; the 
possibility of autophagy should also be investigated.  Because experiments with 
Lysotracker red suggest that intracellular bacteria themselves become acidified, 
measurement of intraphagosomal pH over time would show whether B. 
cenocepacia is able to decrease the pH of the vacuole.   
While we have shown that B. cenocepacia can induce host cell death, the mode 
of cell death is unclear.  Apoptosis could be investigated via flow cytometry 
analysis of infected cells labelled with specific markers.  The ability of B. 
cenocepacia to affect host cell signalling, including caspase activation, should 
also be examined. 
It would also be interesting to isolate and characterize phagosomally-adapted B. 
cenocepacia.  It has been shown that E. coli is capable of transcriptional 
adaptation in anticipation of natural environmental change (329); such bacterial 
“learning” suggests that bacteria which escape the macrophage may be better 
suited to re-infect neighbouring cells.  It would be interesting to investigate the 
infection rate, intracellular trafficking, and replication rate of B. cenocepacia 
isolated from late-stage macrophage infection.   Perhaps B. cenocepacia would 
not need to delay phagosomal maturation, being already adapted to the 
phagosomal environment.  It could be hypothesized that previously intracellular 
B. cenocepacia would display increased infection and intracellular replication, 
and more rapid host cell-directed cytotoxicity. 
 
5.4 Significance and concluding remarks  
Altogether, it appears that there are many elements contributing to the 
intracellular survival and behaviour of B. cenocepacia; if there is a single gene or 
gene cluster that is absolutely essential for intracellular survival, it has yet to be 
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discovered.  B. cenocepacia has an extremely large genome and broad 
metabolic range, potentially explaining the ability of the bacteria to survive in a 
wide variety of niches, including the hostile environment of the phagolysosome.  
Indeed, the intracellular survival of B. cenocepacia in macrophages is associated 
with profound changes in metabolic activity and motility rather than the presence 
of more specific traditional "virulence" genes.  Delay of phagosomal maturation 
provides time for the bacteria to alter gene expression conferring a survival 
advantage for persistence and replication in a phagolysosomal compartment.  
The role of secretion systems in the intracellular behaviour of B. cenocepacia is 
complex.  Large, specialized secretion systems - predominantly the T4SSs - are 
involved in bacterial entry into macrophages, in terms of both numbers of host 
cells infected and numbers of bacteria per host cell.  Secretion systems, 
particularly the T2SS and T6SS, also play a role in intracellular replication, and 
host-directed cytotoxicity, though it is likely that the latter two are intertwined, as 
preservation of the host protects intracellular bacteria.  Together, secretion 
systems function to limit the spread of B. cenocepacia and increase pathogenicity 
during cell culture infection.  
B. cenocepacia is an opportunistic pathogen, not an obligate intracellular 
pathogen, and as such, simply adapts to survive in the niche in which it finds 
itself until it can be released back into the extracellular milieu by dying 
macrophages.  The mechanism by which B. cenocepacia is internalized and 
induces host cell death, whether purposeful or incidental, and the role of the 
varied secretion systems in this interaction, is a subject for further study as it 
relates to the establishment and maintenance of a chronic infection in host cells 
of cystic fibrosis patients. 
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Appendix 1 
1 The role of outer membrane vesicles in the intracellular 
behaviour of B. cenocepacia 
 
1.1 Introduction 
Vesiculation is a nearly ubiquitous process in Gram-negative bacteria. 
Vesiculation may allow bacteria to interact with and alter surrounding prokaryotic 
and eukaryotic cells (11, 16).  Indeed, vesiculation has been referred to as a 
secretion mechanism, allowing delivery of potentially large and complex mixtures 
of proteins and lipids to the extracellular milieu (11).  Although the actual 
mechanism of vesiculation is elusive, it is thought that periplasmic cargo is 
encapsulated within an outer membrane (OM) bleb (20, 23) when the OM bulges 
and pinches off at sites where cross-links between peptidoglycan and the OM are 
decreased (9); vesiculation is not indicative of membrane instability (17), but 
appears to be directed, as specific proteins, lipids, and sugars may be enriched 
or excluded in these vesicles (11).  As such, vesicles have the capacity to act as 
potent virulence factors for pathogenic bacteria, delivering toxins, enzymes, and 
immunomodulatory compounds to a host or neighbouring cell; indeed, vesicles 
from B. cepacia have been found to possess LPS, proteases, lipases, PLC, and 
peptidoglycan hydrolases, all putative virulence factors which could have a role in 
intracellular survival (1).  Vesicles have been observed within the context of 
infection: Borrelia burgdorferi, the causative agent of Lyme disease, produces 
vesicles following invasion of the dermis (3), vesiculating Neisseria meningitidis 
has been identified in the cerebrospinal fluid and blood of meningitis patients 
(21), and, Helicobacter pylori vesicles containing vacuolating cytotoxin have been 
detected in gastric epithelium biopsies (7).  Vesiculation has been suggested as a 
response to stress, which would certainly be present in an intracellular setting.  P. 
aeruginosa alters LPS and increases production of membrane vesicles under 
conditions of oxidative stress (22), and Escherichia coli appears to vesiculate in 
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response to envelope stress (18).  L. pneumophila releases natural membrane 
vesicles which are capable of delaying phagosome-lysosome fusion 
independently of the T4SS (5).  Thus, for pathogenic bacteria, including B. 
cenocepacia, vesicles may be important tools in establishing and maintaining 
infection. 
 
1.2 Materials and Methods 
 
1.2.1 Bacterial strains and growth conditions 
Bacterial strains and plasmids used in this study are listed in Table 8.  Bacteria 
were grown at 37oC in Luria-Bertani (LB; Difco) broth with agitation or on LB 
plates with 1.6% Bacto agar.  For vesicle isolation, large scale broth cultures of 
bacteria were grown in either trypticase soy broth (TSB) or 3-(N-morpholino) 
propanesulfonic acid (MOPS) – minimal salts – tryptose (MMST) medium [3 mM 
KCl, 12 mM (NH4)2SO4, 3.2 mM MgSO4, 0.02 mM FeSO4, 3 mM NaCl, 20 mM
glucose, 0.1% w/v tryptose (Difco)].  Escherichia coli cultures were supplemented 
as required with 20 g/ml tetracycline, 50 g/ml trimethoprim, and 40 g/ml 
kanamycin; B. cenocepacia cultures were supplemented as required with 100 
g/ml tetracycline and 100 g/ml trimethoprim.  Plasmids were conjugated into B. 
cenocepacia by triparental mating at 37
 
oC using E. coli DH5α carrying helper 
plasmid pRK2013 (6).  E. coli donor and helper strains were selected against with 
50 g/ml gentamicin. 
 
1.2.2 Vesicle isolation 
Outer membrane vesicles were isolated as in Allan et al. (1).  Briefly, one litre of 
B. cenocepacia C5424 was grown to an OD600 of 1.0-1.5.  Cells were removed by 
centrifugation at 6000 x g, and the cell-free supernatant was filtered  
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Table 8:  Bacterial strains and plasmids 
Strain or 
plasmid 
Source or 
reference Relevant characteristics 
Escherichia coli 
F-, f80 lacZ DM15 D(lacZYA-argF) U169  endA1 
recA1 hsdR17 (rK- mK+) supE44 thi-1 DgyrA96 relA1 
Laboratory 
stock DH5α 
   
Burkholderia cenocepacia 
J2315 epidemic strain ET12 clone, CF clinical isolate P.A. Sokol 
BCRRCa K56-2 epidemic strain ET12 clone, CF clinical isolate 
BCRRCa C5424 epidemic strain ET12 clone, CF clinical isolate 
   
Plasmid 
RK2 derivative, KanR, mob+, tra+, oricolE1 pRK2013 (6) 
oripBBR1, TetR, mob+, Pdhfr, FLAG epitope pDA17 (8) 
pRF132 pDA17, BCAL2829 HtrA (8) 
oripBBR1, TpR, mob+, Pdhfr, mRFP1 pJRL1 (12) 
   
a B. cepacia complex Research and Referral Repository for Canadian CF Clinics 
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sequentially through 0.45 m and 0.2 m polyethersulfone (PES) membranes.  
OMVs were collected by centrifugation at 150 000 x g for 3h at 5oC, resuspended 
in 50 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) pH 6.8, 
and retained at -20oC.  OMVs were purified through a 30% - 60% sucrose 
gradient in 50 mM HEPES pH 6.8.  Gradients were centrifuged at 183 000 x g for 
18h; no brake was applied to slow the centrifuge.  Fractions were removed and 
protein concentration determined via absorbance at 280 nm.   
OMV were also isolated as in McBroom et al. (17).  Bacteria were pelleted from 
250 mL overnight broth cultures by centrifugation at 10 000 x g for 10 min at 4oC.  
The supernatant was filtered twice through a 0.45 m cellulose ester filter and 
centrifuged at 38 400 x g for 1h at 4oC.  Pelleted vesicles were resuspended in 
Dulbecco’s PBS with 0.2 M NaCl and retained at -20oC. 
 
1.2.3 Outer membrane and periplasmic protein isolation 
Outer membrane proteins were isolated via a modified version of the Sarkosyl 
insolubility protocol of Carlone et al. (4).  Bacterial cells were resuspended in 10 
mM Tris/HCl pH 8.0 and disrupted by sonication until clear.  The lysate was 
pelleted, and the supernatant centrifuged at 31 191 x g  for 30 min at 4oC.  The 
pellet was resuspended in 1.5% w/v Sarkosyl in 20 mM Tris/HCl pH 8.0 and 
incubated at RT for 20 min.  Samples were centrifuged as above, and the OM-
containing pellet resuspended in sterile water.   
Periplasmic proteins were isolated as described previously (10).  Bacterial cells 
were pelleted at 9000 x g for 10 min and resuspended in lysis buffer (20% w/v 
sucrose, 30 mM Tris/HCl pH 8.0, 1 mM EDTA pH 8.0, 3.5 mg/mL lysozyme).  Cell 
suspensions were incubated at 37oC for 3h, and spheroplast formation confirmed 
by light microscopy.  Spheroplast preparations were centrifuged as above, and 
supernatants containing periplasmic proteins were retained at -20oC.  
 
 202
 
1.2.4 Protein analysis 
Protein concentration was determined using the Bradford assay (Bio-Rad).  For a 
slot blot (BioRad), protein adherence to a nitrocellulose membrane was mediated 
by vacuum according to the manufacturer’s instructions.  Both SDS-14% PAGE 
and protein transfer to nitrocellulose membranes were performed as described 
previously (2).  Gels were stained with Coomassie [0.1% (w/v) Coomassie blue, 
10% (v/v) acetic acid, and 50% (v/v) methanol] or with silver.  Silver staining 
required gel fixation [40% (v/v) 95% ethanol, 10% (v/v) acetic acid] and 
sensitization [0.02% (w/v) Na2S2O3.5H2O] prior to staining [0.1% (w/v) AgNO3] 
and developing [0.04% (v/v) CH2O, 2% (w/v) Na2CO3].  Membranes for slot blot 
and Western blot were incubated with our own rabbit-raised B. cenocepacia 
J2315 antibodies or FLAG M2 monoclonal antibodies (Sigma) and AlexaFluor 
IRDye800 CW affinity-purified anti-rabbit IgG (Rockland) or AlexaFluor 680 goat 
anti-mouse IgG  (Molecular Probes) secondary antibodies, respectively; reacting 
bands were fluorescently detected with the Odyssey infrared imaging system 
(Licor Biosciences). 
 
1.2.5 Lipopolysaccharide analysis 
LPS was extracted as described previously (14, 15).  Briefly, bacteria or OMV 
were resuspended in PBS, and boiled for 10 min in lysis buffer [2% sodium 
dodecyl sulfate (SDS), 4% -mercaptoethanol, 10% glycerol, and 1M Tris (pH 
6.8)].  The lysate was treated with proteinase K at 60oC for 12h, and stored at -
20oC.  LPS was separated on a 14% polyacrylamide gel using Tricine-SDS buffer 
and silver-stained as described previously (15).  LPS was quantified using the 
Purpald assay (13). 
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1.2.6 Lipid quantitation 
OMVs were incubated with 3.3 g/mL FM4-64 (Molecular Probes) in PBS at 37oC 
for 10 min.  Following excitation at 506 nm, emission at 750 nm was measured 
with a Cary Eclipse spectrofluorometer (Varian).  Vesicle production was 
calculated as fluorescence units (FU) relative to the CFU of the initial culture.  
 
1.2.7 Electron microscopy 
OMV preparations and B. cenocepacia C5424 grown overnight in TSB were 
negatively stained with 1% uranyl acetate and imaged on a Phillips EM300 
electron microscope; imaging was done in the Transmission Electron Microscope 
(TEM) facility in the Department of Microbiology and Immunology at the 
University of Western Ontario.   
 
1.2.8 Cell culture and infection 
RAW 267.4 macrophages (ATCC) were maintained in DMEM (Wisent) 
supplemented with 10% FBS (Wisent) at 37oC in a 95% humidified atmosphere 
with 5% CO2.  For macrophage infection, cells were seeded in a 6-well plate at 5 
x 105 cells per well and grown 15 h.  Bacterial cultures grown at 37oC for 16 h 
were washed twice and resuspended in DMEM-10% FBS.  Macrophage 
monolayers were washed with PBS (Wisent).  Bacteria were added at a 
multiplicity of infection (MOI) of 50:1 in 2 ml DMEM-10% FBS.  Plates were 
centrifuged 1 min at 300 x g and incubated at 37oC, 95% humidity and 5% CO2. 
 
1.2.9 Gentamicin protection assay 
RAW267.4 macrophages were infected as above with E. coli DH5 at an MOI of 
30.  E. coli was infected alone, with HEPES buffer, or with B. cenocepacia OMV.   
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30 min post-infection, macrophage monolayers were washed three times with 
PBS and DMEM-50 μg/ml gentamicin was added to kill extracellular bacteria.  
Infected monolayers were washed with PBS, and lysed with cold sterile water at 
30, 60, and 90 min p.i..  Surviving bacteria were enumerated by bacterial plate 
count for CFU.   
 
1.2.10 Bead labelling and infection 
Protein A Dynabeads (Invitrogen) were coated with B. cenocepacia J2315 Ab 
according to the manufacturer’s instructions;  40 L of antibody was added to 10 
L of 0.5 M NaPO4 buffer pH 8.1, and incubated with 50 L of Dynabeads for 10 
min.  75 L of B. cenocepacia or 500 L of B. cenocepacia OMV were captured 
by the Ab-coated beads.  Macrophages were infected as above at an MOI of 10 
beads/macrophage.   
 
1.2.11 Immunolabelling and confocal microscopy 
Immunolabelling was performed as in Lamothe et al. (12).  Briefly, coverslip-
grown infected macrophage monolayers were fixed in 4% (v/v) paraformaldehyde 
for 30 min at RT, followed by a 10 min incubation with 100 mM glycine.  Cells 
were permeabilized with 0.1% (v/v) Triton X-100 and blocked with 5% (w/v) skim 
milk powder for 1h at RT.  Cells were sequentially labelled with 1:500 rabbit anti-
B. cenocepacia J2315 and 1:1000 AlexaFluor 488 goat anti-rabbit (Molecular 
Probes) antibodies, each for 1h at RT in 5% milk.  Rat anti-mouse LAMP-1 (ID4B; 
Developmental Studies Hybridoma Bank) was used at a dilution of 1:50, with 
1:1000 secondary antibody AlexaFluor 488 chicken anti-rat (Molecular Probes).  
Coverslips were mounted onto glass slides using fluorescent mounting medium 
(Dako Cytomation).  Images were acquired on a Zeiss LSM 510 laser scanning 
confocal microscope with a 100x oil immersion objective. 
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1.3 Results 
 
1.3.1 Vesicle isolation and characterization 
OMVs were isolated from late-exponential phase rich medium cultures of B. 
cenocepacia using the protocol of Allan et al. (1).  The presence of bacterial 
components in the vesicle fraction was confirmed by a slot blot with B. 
cenocepacia J2315 antibodies (Figure 29), which revealed higher putative vesicle 
production by B. cenocepacia C5424 than by J2315.  B. cenocepacia C5424 is 
effectively labelled with J2315 Ab, but not with K56-2 Ab, and delays phagosomal 
maturation similar to J2315.  Neither the Bradford assay for protein nor the 
purpald assay for LPS were able to accurately quantify OMV production, despite 
the presence of LPS core and several major proteins in OMV preparations 
(Figure 30).   
TEM imaging of B. cenocepacia C5424 showed vesiculation by TSB-grown 
bacteria (Figure 31A); imaging of isolated OMVs (Figure 31B) demonstrated the 
efficacy of vesicle isolation, but also showed significant contamination by flagella 
and pili.  OMV purification through a sucrose gradient showed protein content 
only in the final fractions (Figure 32), of which most contained only a single 45-
kDa protein suggestive of flagellin.  Consequently, the OMV isolation protocol of 
McBroom et al. (17) was adopted, as lower centrifugation speeds would be less 
prone to pelleting contaminating structures.   
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Figure 29.  Bacterial components are detectable in outer membrane vesicle 
fractions. 
Samples were adsorbed to a nitrocellulose membrane via vacuum.  Rows 
contain 50 L (A) or 200 L (B) of indicated sample.  Membranes were 
blotted with anti-B. cenocepacia J2315. 
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Figure 30.  Vesicle fractions contain proteins and lipopolysaccharide. 
 Native or boiled OMV fractions and whole cell lysates were separated on 
a 14% polyacrylamide gel by SDS-PAGE and stained with Coomassie 
blue (A) or transferred to a nitrocellulose membrane and blotted with anti-
B. cenocepacia J2315 (B).  Molecular weight marker (M) masses in kDa.  
LPS extracted from isolated OMV or B. cenocepacia C5424 was 
separated on a 16% Tricine-SDS-PAGE gel and stained with silver nitrate.   
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Figure 31. B. cenocepacia  produces vesicles. 
(A) Negative-stained B. cenocepacia C5424 grown in TSB.  Arrow 
indicates vesicle.  Bar = 500 nm.  (B) Negative-stained OMV preparations 
without sucrose gradient purification.  Contaminating flagella and pili are 
present.  Arrow indicates OMV.  Bar = 100 nm.  
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Figure 32.  OMV purification through sucrose gradient ultracentrifugation. 
Protein concentration in each fraction of the sucrose gradient was 
quantified at a 1 in 5 dilution via absorbance at 280 nm (A).  Later fractions 
were separated on a 14% polyacrylamide gel by SDS-PAGE and stained 
with silver nitrate (B) or transferred to a nitrocellulose membrane and 
blotted with anti-B. cenocepacia J2315 (C). Molecular weight marker (M) 
masses in kDa. 
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1.3.2 Increasing vesiculation in vitro 
Bacteria increase vesiculation under conditions of stress, including oxidative (22) 
and envelope stress (18).  We overexpressed the periplasmic protein HtrA from 
constitutively active plasmid pRF132 in B. cenocepacia C5424.  OMV produced 
by B. cenocepacia C5424 pRF132 are enriched in protein relative to OMV 
produced by wild type bacteria (Figure 33).  While the FLAG-tagged protein is 
present in isolated periplasmic protein, a lesser amount is also present in the OM; 
though this may be due to the high level of overexpression, the FLAG signal in 
isolated OMV cannot be conclusively linked to the packaging of periplasmic 
proteins (Figure 34).  
Nutrient limitation and growth rate have been linked to the regulation of virulence 
factor production in “B. cepacia” (19); previous studies have shown an 
enrichment in OMV-packaging of enzymes during growth in minimal media (1).  
Bacterial growth in minimal medium MMST significantly increased relative 
vesiculation compared to growth in rich medium TSB (Figure 35); the protein 
composition of MMST-OMV was different from TSB-OMV (Figure 36).  TEM 
imaging of MMST-grown C5424 revealed smaller bacteria, many of which were 
associated with OMV (Figure 37); TEM imaging of isolated OMV showed a 
decrease in contaminating protein. 
 
1.3.3 Intramacrophage vesiculation 
An antibody against whole formalin-fixed B. cenocepacia J2315 was raised in 
rabbits; this antibody could be used for effective (Figure 38A), and specific 
(Figure 38B) immunolabelling of B. cenocepacia.  In infected macrophages, the 
B. cenocepacia-specific Ab labels elements unassociated with intact mRFP1-
labelled bacteria; over the course of an infection, these bacterially-derived 
elements increase in number and in distance from intracellular bacteria (Figure 
39).  
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Figure 33.  Overexpression of a periplasmic protein results in a greater 
concentration of protein and LPS in isolated OMV fractions. 
Equivalent volumes of OMV isolated from B. cenocepacia C5424 and B. 
cenocepacia C5424 pRF132 were separated on a 14% polyacrylamide gel 
by SDS-PAGE and stained with silver nitrate (A) or transferred to a 
nitrocellulose membrane and blotted with anti-B. cenocepacia J2315 (B). 
Molecular weight marker (M) sizes are listed in kDa.  LPS prepared from 
equivalent volumes of OMV isolated from B. cenocepacia C5424 and B. 
cenocepacia C5424 pRF132 were separated by 16% Tricine-SDS-PAGE 
and stained with silver nitrate (C). 
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Figure 34.  Periplasmic protein can be detected in isolated OMV. 
Outer membrane (OM), periplasmic protein (P), and isolated OMV (V) 
were separated on a 14% polyacrylamide gel by SDS-PAGE, transferred 
to a nitrocellulose membrane and blotted with anti-B. cenocepacia J2315 
(A) or anti-FLAG (B). Molecular weight marker (M) masses in kDa. 
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Figure 35.  Nutrient stress increases relative vesiculation. 
B. cenocepacia growth is slowed in minimal media MMST when compared 
to growth in rich media TSB, but vesiculation is increased.   (A) Bacterial 
concentration of overnight cultures from which OMV were isolated.  (B) 
Total OMV obtained in an equivalent isolation procedure, as measured in 
fluorescence units. Fluorescence units quantify the lipid content of OMV 
fractions via lipophilic probe FM4-64.  (C) Relative vesiculation, defined as 
fluorescence units in isolated OMV fractions per CFU of culture.  Standard 
error of 2 (TSB) and 4 (MMST) independent experiments is indicated. 
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Figure 36.  OMV isolated from nutrient-stressed bacteria display an altered 
protein profile. 
OMV isolated from E. coli DH5, B. cenocepacia C5424 grown in rich 
media TSB, and B. cenocepacia C5424 grown in minimal media MMST 
were separated on a 14% polyacrylamide gel by SDS-PAGE and stained 
with Coomassie blue.  Molecular weight marker (M) masses in kDa. 
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Figure 37. Growth in minimal media alters the size, shape, and vesiculation 
of B. cenocepacia. 
(A) Negative-stained B. cenocepacia C5424 grown in MMST.  Arrow 
indicates vesicle.  Bar = 500 nm.  (B) Negative-stained OMV preparations 
isolated with slower centrifugation.  Arrow indicates vesicle.  Bar = 100 nm. 
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Figure 38. B. cenocepacia antibodies effectively label the bacteria (A), but 
do not bind to uninfected macrophages (B). 
RAW264.7 macrophages were infected with B. cenocepacia J2315 
expressing mRFP1, immunolabelled with anti-B. cenocepacia J2315, and 
observed with confocal (A) or fluorescence light (B) microscopy.  Arrow 
indicates an uninfected cell.   
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Figure 39. Anti-B. cenocepacia-reacting particles dispersed throughout 
infected macrophages increase in number and in distance from intact 
bacteria over time. 
RAW264.7 macrophages were infected with B. cenocepacia J2315 
expressing mRFP1, immunolabelled with anti-B. cenocepacia J2315, and 
observed with confocal microscopy.  From left to right, panels show 
merged green anti-J2315 and red mRFP1-expressing J2315 fluorescence, 
and fluorescence merged with the DIC image at 30 min (A), 2h (B), 4h (C), 
and 6h (D) post-infection.  Arrows indicate anti-B. cenocepacia-reacting 
particles that are unassociated with intact bacteria. 
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1.3.4 The effect of B. cenocepacia OMV on the intracellular 
trafficking of inert particles 
If the OMV shed by B. cenocepacia are the mechanism by which phagosomal 
maturation is delayed, then the OMV alone should be able to delay delivery of an 
inert particle to the lysosome.  Protein A Dynabeads are magnetic particles to 
which IgG will strongly bind; thus, B. cenocepacia bacteria or OMV can be linked 
to the particle via B. cenocepacia J2315 Ab.  In theory, such a protocol would 
allow magnetic purification of the BcCV.  However, the beads are poorly 
internalized in the absence of bacterial components (Figure 40), immunolabelling 
antibodies bind directly to the beads, antibody binding is inconsistent, and linked 
bacteria can be sheared from the beads (Figure 41).   
 
1.3.5 The effect of B. cenocepacia OMV on the intracellular 
survival of E. coli 
If the OMV shed by B. cenocepacia are the mechanism by which phagosomal 
maturation is delayed, then co-infection of E. coli with B. cenocepacia OMV 
should prolong the intracellular survival of E. coli by delaying delivery to the 
lysosome.  Macrophages were infected with E. coli alone, in the presence of 
buffer, or in the presence of B. cenocepacia OMV.  In the presence of HEPES 
buffer, macrophages took up more E. coli, a phenotype abrogated by the 
presence of B. cenocepacia OMV in HEPES (Figure 42).  However, in 
macrophages infected with E. coli alone or with buffer, the population of 
intracellular bacteria decreased over time to less than 40% of the initial 
population by 90 min p.i..  In contrast, following an initial decrease, in the 
presence of B. cenocepacia OMV, intracellular E. coli began to increase in 
number, suggesting intracellular replication by living bacteria.  Thus, it appears 
that B. cenocepacia OMV are able to affect the intracellular fate of E. coli. 
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Figure 40.  Dynabeads are poorly internalized by macrophages in the 
absence of bacteria. 
RAW264.7 macrophages were infected with Dynabeads alone or in the 
presence of B. cenocepacia J2315.  1 h p.i., a total of 1575 macrophages 
were examined for the presence of internal Dynabeads in a single 
experiment.   
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Figure 41.  Substrate binding to Dynabeads is inconsistent and incomplete. 
RAW264.7 macrophages were infected with Dynabeads coated with B. 
cenocepacia OMV (A) or whole bacteria (B).  4 h p.i., macrophages were 
labeled with anti-LAMP1 (green) and anti-J2315 (red) and observed with 
confocal microscopy.  Arrows in (A) indicate an extracellular bead with 
bound antibody for endosomal marker LAMP1, and an intracellular OMV-
coated bead unlabelled with anti-J2315.  Arrows in (B) indicate intracellular 
bacteria distinct from any bead. 
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Figure 42.  B. cenocepacia OMV affect the intracellular fate of E. coli. 
RAW264.7 macrophages were infected with E. coli DH5 alone, in the 
presence of buffer, or in the presence of B. cenocepacia OMV.  Viable 
intracellular bacteria were quantified 30, 60, and 90 min p.i..  The survival 
index was calculated relative to bacteria present 30 min p.i., set as 100%.  
Data represents the mean of two independent experiments.  Standard 
error bars are indicated.
 
 222
 
1.4 Summary 
B. cenocepacia produces natural outer membrane vesicles than can be pelleted 
from cell-free supernatants.  Strain C5424 appears to produce more OMV than 
J2315.  Biochemical characterization demonstrates LPS and protein components 
in isolated OMV.  Growth in minimal media – nutrient limitation and slowed 
growth rate – greatly increases relative vesiculation, as quantified by lipophilic 
dye, and alters the protein composition of the OMV.  Bacterial components are 
shed into macrophages during infection; further study is necessary to 
characterize both the bacterial elements and the mechanism of dispersal.  
Preliminary experiments show that B. cenocepacia OMV are able to increase the 
intracellular survival of E. coli during co-infection, suggesting that further 
investigation into the relevance of OMV to intracellular trafficking is warranted. 
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 Appendix 2  
2 Selective capture of transcribed sequences for B. 
cenocepacia 
 
2.1 rDNA blocking plasmid isolation 
 Grow E. coli DH5 pJT25 8h in 5 mL LB Ap100 
 Add 25 L of O/N culture to 100 mL LB Ap100 
 Grow to 3-4 x 109 cells/mL (12-16 hours – OD600 = 35) 
 Extract pJT25 with Qiagen midi-plasmid kit (re-use column with 2 batches) 
 Spin 6000 x g 15 min 4oC 
 Resuspend in 4 mL Buffer P1 
 Add 4 mL Buffer P2, mix by vigorous inversion 4-6 times 
 5 min at RT 
 Add 4 mL chilled Buffer P3, mix by immediate vigorous inversion 4-6 times 
 15 min on ice 
 Spin > 20 000 x g for 30 min at 4oC 
 Remove supernatant containing plasmid promptly (to glass bottles) 
 Apply 4 mL buffer QBT to Qiagen-tip 100 column & empty by gravity flow 
 Filter supernatant through glass wool (in pasteur pipet) into column  
 Wash column with 2 x 10 mL Buffer QC 
 Elute DNA with 5 mL Buffer QF 
 It may be stored O/N at 4oC 
 Add 3.5 mL RT isopropanol 
 Mix & centrifuge immediately at 15 000 x g for 30 min at 4oC 
 Carefully decant supernatant 
 Resuspend pellet in 200 L water & transfer to eppendorf 
 Add 20 L 3M Na acetate pH 5.2 
 Add 1 mL 100% EtOH 
 Leave at -20oC for > 45 min (O/N) 
 Spin 10-15 min 13.2 krpm 
 Wash pellet in 1 mL of RT 70% ethanol 
 Spin 1 min 
 Air dry pellet 5-10 min 
 Resuspend plasmid in appropriate volume of 10mM EPPS – 1mM EDTA 
(EE) 
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 Quantify with NanoDrop spectrophotometer 
 
2.2 Chromosomal library preparation 
 Grow B. cenocepacia K56-2 to mid-log phase (OD600 0.4-0.6) 
 Extract DNA 
 Pellet 1.5 mL of O/N culture  
 Resuspend pellet in 560 L TE buffer, 30 L 10% SDS, 10 L Proteinase 
K (20 mg/mL) 
 Incubate at 37oC at least 1 h (until mix is clear) 
 Add 300 L chloroform:isoamyl alcohol (24:1) 
 Mix well & spin 10 min at 13.2 krpm 
 Transfer ~ 400 L of upper phase to new tube 
 Add 0.1 volume (= 40 L) 3M sodium acetate & 2.5 volumes (=1.2 mL) 
100% EtOH 
 Mix & spin 15 min at 13.2 krpm 
 Discard supernatant & wash twice with 500 L 70% EtOH 
 Dry pellet at 45oC (~ 10 min) 
 Resuspend in 50 L water by vortexing vigorously 
 Add 1 L RnaseA (10 mg/mL) 
 Incubate at 37oC 30 min 
 Check A260  (NanoDrop) 
 Aliquot 15 L with 0.5 – 1.0 g/mL DNA into clear 0.6 mL thin-walled PCR 
tube 
 photobiotinylate 
 Add 15 L of 1g/mL photobiotin acetate in sterile distilled water 
 Incubate on ice 2-3 cm below 250W incandescent bulb for 30 min 
 Switch ice buckets & rotate tube every 5 minutes 
 Add 15 L fresh photobiotin acetate solution 
 photoactivate on ice an additional 30 min 
 Switch ice buckets & rotate tube every 5 minutes 
 Dilute to 50 L with water 
 Add 50 L 0.1x TE buffer [pH 9.0] (10 mM Tris-1mM EDTA) 
 Butanol extract DNA (removes unbound biotin  – repeat 2x or as required) 
 Add 100 L isobutanol & mix well 
 Centrifuge 2 min 
 Remove & discard organic (upper) layer 
 Evaporate any residual isobutanol 
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 Add 1/10 volume 3M sodium acetate pH 5.2 
 Add 1 L glycogen 
 Precipitate with 2 volumes 100% EtOH >3h 
 Spin at 4oC 15-30 min 
 Resuspend DNA in EE 
 For each chromosomal library, include 0.3 g of biotinylated chromosome and 
5 g of pJT25 (1 chromosome: 17 rDNA) – typical SCOTS-CE requires 30 
aliquots 
 Use microtip and sonicate in minimal volume  
 Sonicate 150 g pJT25 with 2-2s pulses at 10% amplitude 
 Add 9 g biotinylated chromosome 
 Sonicate 2s at 10% amplitude 
 Check fragments on gel, determine final volume & quantitate 
-    Divide into 30 aliquots of 4 L containing 5.4 g of DNA 
 
 
2.3 RNA extraction 
 Prepare RNA from 2-6 well plates per condition 
 Resuspend & collect bacteria from non-macrophage-exposed condition 
 Lyse macrophages in 1mL cold water / well 
 Spin 8 min at 8000 rpm in a 50mL Falcon tube 
 Resuspend in 100 L lysozyme (1 mg/mL in TE buffer) 
 5 min at room temperature (RT) 
 Add 1 mL TRIzol  
 Vortex until homogeneous (~ 1 min) 
 5 min on ice 
 Add 200 L chloroform 
 Mix ~ 1 min 
 5 min on ice 
 Spin 15 min at 4oC & 12 000xg 
 Recover ~ 600 L RNA-containing supernatant 
 Add 500 L isopropanol & mix 
 30-40 min on ice 
 Spin 10 min at 4oC & 12 000xg 
 Discard supernatant 
 Wash with 500 L cold 75% EtOH 
 Vortex 
 Spin 5 min at 4oC & 7500xg 
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 Discard EtOH 
 respin ~ 30 s & draw out residual EtOH 
 air-dry pellet 
 5-10 min at  45oC 
 Resuspend gently in 10 L RNase-free water 
 5 min at RT 
 add 5 L DNase 
 60 min at 37oC 
 15 min at 75oC 
 check DNA removal by PCR with RNA as template: 
21.2 L water 
8 L Q solution 
4 L 5x PCR buffer 
0.8 L dNTPs 
0.8 L / primer (3550+3551:  cblB, 3743+3744:  -actin) 
0.8 L Taq polymerase 
- divide into 3 x 9 L aliquots 
- add 1 L of template (two RNA samples + water control) 
3 min at 95 oC 
28 cycles of: 
 45s at 95oC 
 30s at 55oC 
 30s at 72oC 
5 min at 72oC 
check by agarose gel 
 quantify clean RNA with NanoDrop 
 
2.4 cDNA synthesis 
 
2.4.1 First strand cDNA synthesis 
 heat RNA & primer 75oC 5 min  
1 μL random primer (I-3025; NME-3017) 
x μL DNase-trasted RNA (5 μg) 
(11-x) μL RNase-free water 
 set up RT reactions: 
 8 μL RT buffer 
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 1 μL RNase inhibitor 
 4 μL dNTPs 
 1 μL DMSO 
 1 μL Q Solution 
 divide into 2 x 7.5 μL 
 add RNA mixture 
 0.75 μL RT enzyme  
 15 min at 25oC 
 40 min at 55oC 
 5 min at 85oC 
 immediately on ice 
 
2.4.2 Second strand cDNA synthesis 
 to 20 uL RT rxn add (for 50 uL Klenow rxn): 
 5 uL 10x Klenow buffer (random priming) 
 1.25 uL dNTP 
 4 uL Klenow fragment 
 19.75 uL water 
 45 min at 37oC 
 clean with PCR product purification kit 
 elute in 62 μL water 
 
2.4.3 cDNA amplification 
 100 uL cDNA PCR: 
 4 μL primer (I-3032; NME-3033)  
 2 μL dNTP 
 10 μL 10x buffer 
 20 μL Q solution 
 2 μL Taq 
 62 uL template 
 95oC for 5 min 
 25 cycles of: 
 95oC for 30 s 
 49oC for 90 s 
 72oC for 50 s 
 72oC for 5 min 
 4oC for 10 min 
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 purify cDNA & elute in 42 μL EE 
 quantify with NanoDrop  
 divide into 10 x 4 μL aliquots of 750 ng/μL 
 
2.5 Selective capture of transcribed sequences 
 heat 1 chromosomal DNA aliquot (5.3 μg in 4 μL) to 98oC (boiling) under 
mineral oil for 3 min 
 add 1 μL 1M NaCl 
 incubate at 68oC 30 min 
 boil cDNA (3 μg) 3 min in 4 μL hybridization buffer (10 mM EPPS – 1 mM 
EDTA) 
 add 1 μL 1M NaCl 
 incubate at 68oC 30 min (if desiring to enrich for low abundance 
transcripts) 
 mix chromosomal DNA with cDNA 
 continue hybridization at 68oC for 20-24 h with oil overlay 
 wash Dynabeads-streptavidin (10 mg/mL) 
 shake vial to resuspend beads 
 transfer 60 μg (6 μL) of beads to eppendorf 
 place on magnet 1-2 min 
 remove supernatant with pipette while tube remains on magnet 
 remove tube from magnet 
 resuspend in equal volume capture buffer 
 repeat wash 
 resuspend in 1 mL capture buffer 
 add cDNA to capture buffer with beads 
 incubate at 43oC 30 min 
 place tube on magnet 1-2 min 
 remove supernatant with pipette 
 3 washes in wash buffer (20mM NaCl-0.5% SDS) 
 > 5 minutes at 65oC 
 elute with 100 μL elution buffer (0.25M NaOH-0.1M NaCl) 
 15 minutes at 65oC 
 place tube on magnet 1-2 min 
 remove supernatant to fresh eppendorf with pipette 
 neutralize with 20 μL neutralization buffer (1M Tris pH 7.4) 
 ethanol precipitate in the presence of 10 μg (0.5 μL) glycogen 
 PCR amplify with linker primers 
 resuspend pellet in 124 μL water  
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 8 μL primer (I-3032; NME-3033)  
 4 μL dNTP 
 20 μL 10x buffer 
 40 μL Q solution 
 4 μL Taq 
 divide into 2 x 100 μL PCR reactions 
o 95 C for 5 min 
 25 cycles of: 
o 95 C for 30 s 
o 49 C for 90 s 
o 72 C for 50 s 
o 72 C for 5 min 
 4oC for 10 min 
 clean PCRs  
 elute both together in hybridization buffer 
 10 parallel first round captures of each cDNA mixture  
 combine amplified cDNAs for second round 
 at least 3 rounds of SCOTS with cDNA mixtures from each condition 
 
Hybridization Buffer:    10 mM EPPS – 1 mM EDTA  
Capture Buffer:  1 M NaCl – 5 mM EPPS – 0.5 mM EDTA 
Wash Buffer:   20 mM NaCl – 0.5% SDS 
Elution Buffer:  0.25 M NaOH – 0.1 M NaCl 
Neutralization Buffer: 1 M Tris pH 7.4 
 
2.6 Competitive enrichment 
 prehybridize chromosomal DNA with both rDNA & SCOTS-treated NME 
cDNA  
 use 10 μg NME-cDNA / chromosomal aliquot 
o 24 hour hybridization with 0.5 μg I-cDNA at 68 C 
 recover by binding to streptavidin-coated beads as above 
 PCR amplify with I-3032 linker primer  
 Repeat twice for a total of 3 rounds of competitive enrichment 
 
2.7 Screening 
 prepare 50 μL pUC19 using Qiagen MiniPrep kit 
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 digest vector & cDNA with XbaI 
 10 μL vector / cDNA 
 1.5 μL Buffer H 
 1.5 μL XbaI 
 2 μL water 
 incubate at 37oC O/N 
 clean digested cDNA with MinElute kit 
 elute in 15 μL water 
 treat vector with alkaline phosphatase 
 35 μL digested pUC19 
 4 μL 10x AP buffer 
 1 μL Antarctic alkaline phosphatase 
 incubate at 37oC at least 1 h 
 clean vector with Qiagen kit  
 ligate O/N 
 15 μL vector/cDNA 
 2 μL 10x ligation buffer 
 1 μL T4 DNA ligase 
 2 μL water 
 incubate at 16oC O/N 
 transform plasmid into E. coli DH5 
 heat shock or electroporation 
 screen colonies using linker primers (I-3032) or vector primers (3035+3037) 
 with vector primers, negative results will have ~100 bp product 
 with linker primers, multiple inserts of different sizes will be obvious 
 screen clones using parallel Southern blot hybridization with DIG-labelled 
cDNA libraries 
 dilute PCRs 1/20 to run on gel 
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